



HU000027525T2

(19) **HU**(11) Lajstromszám: **E 027 525**(13) **T2****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala**EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA

- (21) Magyar ügyszám: **E 09 811805**
- (22) A bejelentés napja: **2009. 08. 25.**
- (96) Az európai bejelentés bejelentési száma:
EP 20090811805
- (97) Az európai bejelentés közzétételi adatai:
EP 2350129 A2 **2010. 03. 11.**
- (97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2350129 B1 **2015. 06. 10.**
- (51) Int. Cl.: **C07K 14/47** (2006.01)
C07K 14/52 (2006.01)
C07K 147/05 (2006.01)
C07K 147/15 (2006.01)
C12N 15/62 (2006.01)
- (86) A nemzetközi (PCT) bejelentési szám: **PCT/US 09/004825**
- (87) A nemzetközi közzétételi szám: **WO 10027423**

(30) Elsőbbségi adatok: 91709 P 2008. 08. 25. US 91694 P 2008. 08. 25. US 211697 P 2009. 04. 02. US 91705 P 2008. 08. 25. US	(73) Jogosult(ak): Amplimmune, Inc., Gaithersburg, MD 20878 (US)
(72) Feltalálók(k): LANGERMANN, Solomon, Baltimore, MD 21215 (US) LIU, Linda, Clarsville, MD 21029 (US)	(74) Képvisező: dr. Kompagne Hajnalka, DANUBIA Szabadalmi és Jogi Iroda Kft., Budapest

(54) **PD-1-Antagonista készítmények és alkalmazásuk**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 350 129 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
10.06.2015 Bulletin 2015/24

(51) Int Cl.:
C07K 14/47^(2006.01) C07K 14/705^(2006.01)
C07K 14/52^(2006.01) C07K 14/715^(2006.01)
C12N 15/62^(2006.01)

(21) Application number: **09811805.2**

(86) International application number:
PCT/US2009/004825

(22) Date of filing: **25.08.2009**

(87) International publication number:
WO 2010/027423 (11.03.2010 Gazette 2010/10)

(54) **COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE**

PD1-ANTAGONISTENZUSAMMENSETZUNGEN UND VERFAHREN ZU IHRER VERWENDUNG
COMPOSITIONS D'ANTAGONISTES DE PD-1 ET METHODES D'UTILISATION ASSOCIEES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Designated Extension States:
AL BA RS

WO-A2-03/020259 US-A1- 2002 091 246
US-A1- 2006 159 685 US-A1- 2006 292 593
US-A1- 2007 231 344

(30) Priority: **25.08.2008 US 91709 P**
25.08.2008 US 91694 P
02.04.2009 US 211697 P
25.08.2008 US 91705 P

- **TSENG SU-YI ET AL: "B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, UNITED STATES, vol. 193, no. 7, 2 April 2001 (2001-04-02), pages 839-845, XP002189416, ISSN: 0022-1007**
- **OZKAYNAK E ET AL: "Programmed Death-1 Targeting Can Promote Allograft Survival", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 169, 1 January 2002 (2002-01-01), pages 6546-6553, XP002980100, ISSN: 0022-1767**
- **GREENWALD R J ET AL: "Negative co-receptors on lymphocytes", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 14, no. 3, 1 June 2002 (2002-06-01), pages 391-396, XP004350492, ISSN: 0952-7915**
- **YOUNGNAK P ET AL: "Differential binding properties of B7-H1 and B7-DC to programmed death-1", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 307, no. 3, 1 August 2003 (2003-08-01), pages 672-677, XP004441481, ISSN: 0006-291X, DOI: 10.1016/S0006-291X(03)01257-9**

(43) Date of publication of application:
03.08.2011 Bulletin 2011/31

(60) Divisional application:
15163742.8

(73) Proprietor: **Amplimmune, Inc.**
Gaithersburg, MD 20878 (US)

(72) Inventors:

- **LANGERMANN, Solomon**
Baltimore, MD 21215 (US)
- **LIU, Linda**
Clarsville, MD 21029 (US)

(74) Representative: **Potter Clarkson LLP**
The Belgrave Centre
Talbot Street
Nottingham, NG1 5GG (GB)

(56) References cited:
WO-A1-93/08120 WO-A2-01/94413

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 350 129 B1

- EMENS LEISHA A ET AL: "Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 10 DEC 2009, vol. 27, no. 35, 10 December 2009 (2009-12-10), pages 5911-5918, ISSN: 1527-7755
- WADA SATOSHI ET AL: "Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.", CANCER RESEARCH 15 MAY 2009, vol. 69, no. 10, 15 May 2009 (2009-05-15), pages 4309-4318, ISSN: 1538-7445

Description**FIELD OF THE INVENTION**

5 **[0001]** The present invention relates to therapeutic compositions containing a compound that prevents inhibitory signal transduction on T cells in combination with potentiating agents and the use of said components together or separately for the induction of T cell responses valuable in disease therapy.

BACKGROUND OF THE INVENTION

10

[0002] The response of T lymphocytes to disease states, such as infection and chronic diseases like cancer, is complicated and involves intercellular interactions and the production of soluble mediators (called cytokines or lymphokines). Activation of T cells normally depends on an antigen-specific signal following contact of the T cell receptor (TCR) with an antigenic peptide presented via the major histocompatibility complex (MHC) while the extent of this reaction is controlled by positive and negative antigen-independent signals emanating from a variety of co-stimulatory molecules. The latter are commonly members of the CD28/B7 family. Conversely, Programmed Death-1 (PD-1) is a member of the CD28 family of receptors that delivers a negative immune response when induced on T cells. Contact between PD-1 and one of its ligands (B7-H1 or B7-DC) induces an inhibitory response that decreases T cell multiplication and/or the strength and/or duration of a T cell response.

20 **[0003]** Thus, the T lymphocyte response is regulated by various factors, including cell surface molecules that act as receptors, where the latter include both the TCR complex as well as other surface molecules.

[0004] In sum, an antigen specific T cell response is mediated by two signals: 1) engagement of the TCR with antigenic peptide presented in the context of HC (signal 1), and 2) a second antigen-independent signal delivered by contact between different receptor/ligand pairs (signal 2). This "second signal" is critical in determining the type of T cell response (activation vs tolerance) as well as the strength and duration of that response, and is regulated by both positive and negative signals from costimulatory molecules, such as the B7 family of proteins.

30 **[0005]** The most extensively characterized T cell costimulatory pathway is B7-CD28, in which B7-1 (CD80) and B7-2 (CD86) each can engage the stimulatory CD28 receptor and the inhibitory CTLA-4 (CD152) receptor. In conjunction with signaling through the T cell receptor, CD28 ligation increases antigen-specific proliferation of T cells, enhances production of cytokines, stimulates differentiation and effector function, and promotes survival of T cells (Lenschow, et al., *Annu. Rev. Immunol.*, 14:233-258 (1996); Chambers and Allison, *Curr. Opin. Immunol.*, 9:396-404 (1997); and Rathmell and Thompson, *Annu. Rev. Immunol.*, 17:781-828 (1999)). In contrast, signaling through CTLA-4 is thought to deliver a negative signal that inhibits T cell proliferation, IL-2 production, and cell cycle progression (Krummel and Allison, *J. Exp. Med.*, 183:2533-2540 (1996); and Walunas, et al., *J. Exp. Med.*, 183:2541-2550 (1996)). Other members of the B7 family of costimulatory molecules include B7-H1 (Dong, et al., *Nature Med.*, 5:1365-1369 (1999); and Freeman, et al., *J. Exp. Med.*, 192:1-9 (2000)), B7-DC (Tseng, et al., *J. Exp. Med.*, 193:839-846 (2001); and Latchman, et al., *Nature Immunol.*, 2:261-268 (2001)), B7-H2 (Wang, et al., *Blood*, 96:2808-2813 (2000); Swallow, et al., *Immunity*, 11:423-432 (1999); and Yoshinaga, et al., *Nature*, 402:827-832 (1999)), B7-H3 (Chapoval, et al., *Nature Immunol.*, 2:269-274 (2001)) and B7-H4 (Choi, et al., *J. Immunol.*, 171:4650-4654 (2003); Sica, et al., *Immunity*, 18:849-861 (2003); Prasad, et al., *Immunity*, 18:863-873 (2003); and Zang, et al., *Proc. Natl. Acad. Sci. U.S.A.*, 100:10388-10392 (2003)). B7-H5 (described in WO 2006/012232) is a newly discovered member of the B7 family.

45 **[0006]** B7 family molecules have a membrane proximal IgC (constant) domain and a membrane distal IgV (variable) domain. The CD28-like family of receptors for these ligands share a common extracellular IgV-like domain. Interactions of receptor-ligand pairs are mediated predominantly through residues in the IgV domains of the ligands and receptors (Schwartz, et al., *Nature Immunol.*, 3:427-434 (2002)). In general, IgV domains are described as having two sheets that each contains a layer of β -strands (Williams and Barclay, *Annu. Rev. Immunol.*, 6:381-405 (1988)). The front and back sheets of CTLA-4 contain strands A'GFC'C and ABEDC, respectively (Ostrov, et al., *Science*, 290:816-819 (2000)), whereas the front and back sheets of the B7 IgV domains are composed of strands AGFCC'C" and BED, respectively (Schwartz, et al., *Nature*, 410:604-608 (2001); Stamper, et al., *Nature*, 410:608-611 (2001); and Ikemizu, et al., *Immunity*, 12:51-60 (2000)). Crystallographic analysis revealed that the CTLA-4/B7 binding interface is dominated by the interaction of the CDR3-analogous loop from CTLA-4, composed of a MYPPPY motif, with a surface on B7 formed predominately by the G, F, C, C' and C" strands (Schwartz, et al., *Nature*, 410:604-608 (2001); and Stamper, et al., *Nature*, 410:608-611 (2001)). Data from amino acid homologies, mutation, and computer modeling provide support for the concept that this motif also is a major B7-binding site for CD28 (Bajorath, et al., *J. Mol. Graph. Model.*, 15:135-139 (1997)). Although the MYPPPY motif is not conserved in ICOS, the receptor for B7-H2, studies have indicated that a related motif having the sequence FDPPPF and located at the analogous position is a major determinant for binding of ICOS to B7-H2 (Wand, et al., *J. Exp. Med.*, 195:1033-1041 (2002)).

55 **[0007]** B7-DC (also called PD-L2 or CD273) is a relatively new member of the B7 family, and has an amino acid

sequence that is about 34% identical to B7-H1 (also called PD-L1). Human and mouse B7-DC orthologues share about 70% amino acid identity. While B7-H1 and B7-DC transcripts are found in various tissues (Dong, et al., *Nature Med.*, 5:1365-1369 (1999); Latchman, et al., *Nature Immunol.*, 2:261-268 (2001); and Tamura, *Blood*, 97:1809-1816 (2001)), the expression profiles of the proteins are quite distinct. B7-H1 is broadly expressed on a wide variety of tissue and cell types, while B7-DC expression is predominantly restricted to activated dendritic cells (DC) and macrophages.

[0008] It has been shown that both B7-H1 and B7-DC bind to PD-1 (Freeman, et al., *J. Exp. Med.*, 192:1027-1034 (2000)), a distant member of the CD28 family with an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain (Ishida, et al., *EMBO J.*, 11:3887-3895 (1992)). PD-1, a member of the CD28 family of receptors, is inducibly expressed on activated T cells, B cells, natural killer (NK) cells, monocytes, DC, and macrophages (Keir, et al. *Curr. Opin. Immunol.* 19:309-314 (2007)).

[0009] The primary result of PD-1 ligation by its ligands is to inhibit signaling downstream of the T cell Receptor (TCR). Therefore, signal transduction via PD-1 usually provides a suppressive or inhibitory signal to the T cell that results in decreased T cell proliferation or other reduction in T cell activation. B7-H1 is the predominant PD-1 ligand causing inhibitory signal transduction in T cells. The present disclosures solve the problem of undesired T cell inhibition by providing agents that bind to PD-1 and thus prevent inhibitory signal transduction, or else bind to ligands of PD-1 such as B7-H1, thereby preventing the ligand from binding to PD-1 to deliver an inhibitory signal. In either case, T cell responses, such as T cell proliferation or activation, are stimulated.

[0010] B7-H1 is the predominant PD-1 ligand, likely due to its broader distribution and higher expression levels. PD-1 inhibition occurs only when PD-1 and TCR are ligated in close proximity to each other, in the context of the immune synapse. PD-1 and its ligands have been the topic of several review articles.

[0011] B7-H1 is also over expressed in many cancers (including breast cancer, colon cancer, esophageal cancer, gastric cancer, glioma, leukemia, lung cancer, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, renal cell carcinoma, and urothelial cancer), and has been linked to poor prognosis. B7-H1 is expressed by many tumor cell lines, especially following stimulation with interferon gamma (IFN- γ), and is also upregulated on tumor infiltrating myeloid derived suppressor cells (MDSC). For example, PD-1 is up-regulated on tumor specific CD8 T cells and is associated with functional impairment, anergy, exhaustion, and apoptosis. PD-1 upregulation has also been associated with dysfunctional and/or suppressive phenotypes on additional cell types, such as regulatory T cells (Treg) and natural killer T (NKT) cells.

[0012] The present disclosures make use of such molecular functions by providing treatment regimens for treating diseases through increased T cell activity, especially cancer and infectious diseases.

BRIEF SUMMARY OF THE INVENTION

[0013] The invention is as defined in the accompanying claims. In one aspect, the present disclosures relate to a method of increasing T cell responses, for example, to an antigen, in a mammal in need of such increase, comprising administering to said mammal a compound that reduces inhibitory signal transduction in immune cells, especially T cells, and a potentiating agent, wherein said treatment regimen is effective to increase the T cell response of said mammal.

[0014] Compounds useful in the treatment regimen of the disclosures include those that bind to and block PD-1 receptors on T cells without triggering inhibitory signal transduction, compounds that bind to PD-1 ligands to prevent their binding to PD-1, compounds that do both and compounds that prevent expression of genes that encode either PD-1 or natural ligands of PD-1. Such compounds are referred to herein as "PD-1 antagonists." Compounds that bind to natural ligands of PD-1 include PD-1 itself, as well as active fragments of PD-1, and in the case of the B7-H1 ligand, B7.1 proteins and fragments. Such antagonists include proteins, antibodies, anti-sense molecules and small organics. In a preferred embodiment, said T cell response is greater than that produced by either of said PD-1 antagonist fusion protein or said potentiating agent when either is administered without the other.

[0015] In another embodiment, compounds useful in the methods of the disclosures are those that bind to T cell surface molecules such as CTLA4 to prevent the inhibitory signals triggered by binding of natural ligands thereof or that bind to said natural ligands. Such antagonists include proteins, antibodies, anti-sense molecules and small organics.

[0016] In a general embodiment, compounds useful in treatment regimens and compositions of the present disclosures include those that bind to PD-1 without triggering, inducing, increasing, facilitating and/or permitting co-ligation of PD-1 with TCR.

[0017] Preferred compounds of the disclosures that prevent inhibitory signal transduction through PD-1 and thus act as PD-1 antagonists include, but are not limited to, B7-DC polypeptides, especially soluble portions of these, including active fragments of these, variants and homologs of these, as well as fusion proteins incorporating any of the foregoing, that bind to PD-1 without triggering inhibitory signal transduction. In preferred embodiments, B7-DC comprises the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4. Preferred such compounds are those incorporating the soluble domain of B7-DC (i.e., without transmembrane sequence). Suitable fragments of B7-DC polypeptides include fragments containing the IgV and/or IgC domains or fragments containing only the IgV domain, with the latter being a preferred embodiment,

with amino acids 20-121 of SEQ ID NO: 1 being a preferred example of an IgV domain.

[0018] Preferred PD-1 antagonists of the disclosures also include, but are not limited to, active fragments of natural ligands of PD-1, such as B7-H1 polypeptides (disclosed in U.S. Patent No. 6,803,192, incorporated by reference herein in its entirety), especially soluble portions of these, including variants and homologs of these, as well as fusion proteins incorporating any of the foregoing, that bind to PD-1 without triggering inhibitory signal transduction.

[0019] Preferred compounds of the disclosures also include, but are not limited to, compounds, including active fragments, variants and homologs, that bind to natural ligands of PD-1, such as fragments of B7-1 that bind to B7-H1, as well as fusion proteins incorporating any of the foregoing, that bind to ligands of PD-1 to prevent the latter from binding to PD-1 to trigger inhibitory signal transduction.

[0020] In another embodiment of the disclosures, the compositions and methods of use thereof, include a combination of a PD-1 receptor antagonist that binds to and blocks the PD-1 receptor, and a separate PD-1 receptor antagonist that binds to and blocks PD-1 receptor ligands. Another embodiment of the present invention provides PD-1 receptor antagonists that bind to the PD-1 receptor without triggering inhibitory signal transduction through the PD-1 receptor and also have the ability to bind and antagonize PD-1 receptor ligands, such as B7-H1, that would otherwise trigger inhibitory signal transduction through the PD-1 receptor. Other contemplated PD-1 receptor antagonists include bi-specific antibodies that can bind both the PD-1 receptor and PD-1 receptor ligands.

[0021] Preferred embodiments of compounds useful in the present disclosures also include antibodies that bind to PD-1 or CTLA4, thereby reducing, or abolishing, inhibitory signal transduction mediated by these sources.

[0022] Preferred compounds for use in the methods of the disclosures also include, but are not limited to, active fragments of ligands of CTLA4 (such as B7-1 and B7-2) that bind to CTLA4 to reduce subsequent inhibitory signals yet do not bind to CD28 or otherwise inhibit positive signal transduction by CD28.

[0023] Preferred compounds of the disclosures that prevent inhibitory signal transduction through PD-1 and thus act as PD-1 antagonists include, but are not limited to, B7-DC antagonists, especially soluble portions of these, including active fragments of these, variants and homologs of these, as well as fusion proteins incorporating any of the foregoing, that bind to B7-DC.

[0024] In one embodiment of the disclosures, B7-DC polypeptides, fragments or variants thereof are coupled to other polypeptides to form fusion proteins that antagonize the PD-1 receptor by binding to the PD-1 receptor without causing inhibitory signal transduction through PD-1, thereby reducing, or interfering with, ligand binding to PD-1, particularly B7-H1 binding, and thereby interfering with inhibitory signal transduction through the PD-1 receptor. Examples of fusion proteins of the invention are polypeptides comprising the amino acid sequence of SEQ ID NO: 9, 10, 12 or 13, as well as homologs thereof. In one preferred embodiment, all or a portion of the extracellular domain (ECD) of B7-DC is part of a fusion protein wherein it is linked to a second polypeptide containing an Fc portion of an immunoglobulin. A preferred example of this is B7-DC-Ig, especially where this structure is part of a homodimer wherein two B7-DC-Ig molecules are linked to each other, such as by a disulfide linkage.

[0025] In specific embodiments of the disclosures, fragments useful in the compounds of the invention consist of at least 10, 15, 25, 50, 75, 100, 150, 200 or more contiguous amino acids of a polypeptide having the desired antagonist activity. Such fragments are also commonly part of fusion proteins for use in the invention.

[0026] In another aspect, the present disclosures relate to a method of increasing T cell responses in a mammal in need thereof, comprising administering to said mammal an effective treatment regimen comprising an anti-PD-1 antibody and a potentiating agent, wherein said treatment regimen is effective to increase the T cell response of said mammal.

[0027] In another aspect, the present disclosures relate to a method of increasing T cell responses in a mammal in need thereof, comprising administering to said mammal an effective treatment regimen comprising an immunomodulator, and a potentiating agent, wherein said treatment regimen is effective to increase the T cell response of said mammal. Such immunomodulators include molecules that antagonize other CD28 family receptors (such as CTLA4) that inhibit T cell responses. A preferred embodiment uses an anti-CTLA4 antibody and a potentiating agent. Additional immunomodulators include: molecules that agonize CD28 family receptors (such as CD28 and ICOS) that activate T cell responses; molecules that antagonize B7 family ligands (such as B7-H1, B7-DC, B7-H4) that inhibit T cell responses; and molecules that agonize B7 family ligands (such as B7.1 and B7.2) that activate T cell responses.

[0028] In additional embodiments of any of the methods of the invention, the treatment regimen of a PD-1 antagonist fusion protein and a potentiating agent further comprises at least one additional therapeutic agent. Additional therapeutic agents contemplated include immunomodulatory agents. Exemplary immunomodulating agents for such methods include anti-PD-1 and anti-CTLA4 antibodies.

[0029] In one embodiment of the invention, the potentiating agent is selected from cyclophosphamide and analogs of cyclophosphamide, Sunitinib (Sutent), anti-TGF β and Imatinib (Gleevec), anthracyclines, oxaliplatin, doxorubicin. Other potentiating agents disclosed but not claimed include: (a) a mitosis inhibitor, such as paclitaxel, an aromatase inhibitor, such as letrozole, an A2a adenosine receptor (A2AR) antagonist, an angiogenesis inhibitor) TLR4 antagonists, and IL-18 antagonists. Some of these agents reduce the number of Tregs (i.e., regulatory T lymphocytes or T-regs) within the tumor microenvironment.

[0030] In another embodiment, the compositions of the invention specifically contemplate use of any suitable adjuvant as part of said method and/or composition.

[0031] In accordance with the invention, T cells can be contacted with PD-1 receptor antagonist fusion protein and/or compositions thereof containing a potentiating agent *in vitro*, *ex vivo* or *in vivo*. Contacting T cells using PD-1 receptor antagonist fusion proteins and/or compositions thereof containing a potentiating agent can occur before, during or after activation of the T cell.

[0032] In a specific embodiment, a fusion protein that prevents or reduces inhibitory signal transduction through PD-1 and the potentiating agent are administered at different times, such as where the potentiating agent is administered prior to administering the PD-1 antagonist. Such administration may be in conjunction with an additional therapeutic agent.

[0033] In specific embodiments a composition for use in a method of the invention, the treatment regimen includes administration of the potentiating agent at least 1 hour, or at least 2 hours, or at least 3 hours, or at least 5 hours, or at least 10 hours, or at least 15 hours, or at least 20 hours, or at least 24 hours, or at least 30 hours before administering the fusion protein. Also disclosed is the administration of the potentiating agent at one of the immediately aforementioned times or even longer before administering any or all of the PD-1 antagonist, the anti-PD-1 antibody, the anti-CTLA4 antibody, and/or additional therapeutic agents. Administration of the potentiating agent may also occur after administering any or all of the PD-1 antagonist, the anti-PD-1 antibody, the anti-CTLA4 antibody and/or additional therapeutic agents, such as no more than 1 hour, 2 hours, 3 hours, 5 hours, 10 hours, 15 hours, 20 hours, 24 hours, or even up to 30 hours after administering a PD-1 antagonist, or may occur in conjunction with administering the PD-1 antagonist.

[0034] The increased T cell response achieved as a result of the compositions of the invention is sufficient to treat a disease, including one or more of cancer, viral infection, bacterial infection and parasitic infection. Where the disease is cancer, such cancer is any one or more of bladder, brain, breast, cervical, colo-rectal, esophageal, kidney, liver, lung, nasopharyngeal, pancreatic, prostate, skin, stomach, uterine, ovarian, testicular, or hematologic cancer.

[0035] In another aspect, the present disclosure includes compositions of the antagonists used in the methods of the invention, in a pharmaceutically acceptable carrier and wherein said PD-1 binding molecule and said potentiating agent are each present in an amount effective to produce increased T cell stimulation.

[0036] In one preferred embodiment, the invention includes medical kits comprising containers holding one or more of the agents for use in the invention together with pharmaceutical carriers for dilution thereof and instructions for administration. In addition, it is disclosed that both of said PD-1 receptor antagonist and potentiating agent may be present as components in a single container, in a pharmaceutically acceptable carrier, when said components are to be administered at the same time.

BRIEF DESCRIPTION OF THE DRAWINGS

[0037]

Figure 1 shows that B7-DC-Ig binds to PD-1. Labeled B7-DC-Ig was incubated at various concentrations with a CHO cell line constitutively expressing PD-1 or parent CHO cells that do not express PD-1. Binding was analyzed by flow cytometry. The median fluorescence intensity (MFI) of B7-DC-Ig (y-axis) is shown as a function of the concentration of probe (x-axis). B7-DC-Ig binds to CHO.PD-1 cells (solid circle) but not untransfected CHO cells (gray triangle).

Figure 2 shows that B7-DC-Ig competes with B7-H1 for binding to PD-1. Unlabeled B7-DC-Ig at various concentrations was first incubated with a CHO cell line constitutively expressing PD-1 before adding labeled B7-H1-Ig to the cell mixture. The median fluorescence intensity (MFI) of B7-H1-Ig (y-axis) is shown as a function of the concentration of unlabeled B7-DC-Ig competitor (x-axis) added. As the concentration of unlabeled B7-DC-Ig is increased the amount of labeled B7-H1-Ig bound to CHO cells decreases, demonstrating that B7-DC-Ig competes with B7-H1 for binding to PD-1.

Figure 3 shows the results of experiments wherein the combination of cyclophosphamide (CTX or Cytoxan®) and dimeric murine B7-DC-Ig resulted in eradication of established CT26 tumors (colon carcinoma) in mice. Graph A shows tumor volume (mm³) versus days post tumor challenge in mice treated with 100 mg/kg of CTX on Day 10 while Graph B shows tumor volume (mm³) versus days post tumor challenge in mice treated with CTX on Day 10 followed a day later by the first B7-DC-Ig administration. Each line in each graph represents one mouse. Black arrow stands for B7-DC-Ig administration. Graph C shows average tumor volume.

Figure 4 shows the results of experiments wherein the combination of CTX and dimeric murine B7-DC-Ig eradicated established CT26 tumors (colon carcinoma) in mice and protected against re-challenge with CT26. Mice that were treated with CTX and B7-DC-Ig and found to be free of tumor growth on day 44 following tumor inoculation were

EP 2 350 129 B1

rechallenged with tumors. The mice were later rechallenged again on on Day 70. None of the mice displayed tumor growth by day 100.

5 Figure 5 shows CTX and B7-DC-Ig treatment resulted in generation of tumor specific memory CTL. Mice eradicated established CT26 subcutaneous tumors post CTX and B7-DC-Ig treatment were re-challenged with CT26 cells. Seven days later, splenocytes were isolated and pulsed with either ovalbumin, an irrelevant peptide, or AH1, a CT26 specific peptide. Cells were stained with anti-CD8 antibody first followed by intracellular staining with anti-IFN γ antibody prior to FACS analysis.

10 Figure 6 shows the effects of different doses of B7-DC-Ig in combination with CTX on the eradication of established CT26 tumors in mice. Balb/C mice at age of 9 to 11 weeks were implanted subcutaneously with 1E05 CT26 cells. On Day 9, mice were injected IP with 100 mg/kg of CTX. Twenty four hours later, on Day 10, mice were treated with 30, 100, or 300 ug of B7-DC-Ig followed by 2 injections every week up to total 8 treatments. Tumor growth was measured two times per week.

15 Figure 7 shows the results of experiments wherein the combination of CTX and anti-PD-1 antibody resulted in eradication of established CT26 tumors (colon carcinoma) in mice. Graph A shows tumor volume (mm³) versus days post tumor challenge in untreated mice (i.e., mice treated with vehicle alone), Graph B shows tumor volume (mm³) versus days post tumor challenge in mice treated with anti-PD-1 alone starting on Day 11 at 300 μ g per injection, 3 times per week, up to 12 injections and Graph C shows tumor volume (mm³) versus days post tumor challenge in mice treated with CTX on Day 11 and the first anti-PD-1 administration on Day 12 at 300 μ g per injection, 3 times per week, up to 12 injections. Each line in each graph represents one mouse. Black arrow stands for anti-PD-1 administration.

25 Figure 8 shows the results of experiments wherein the combination of CTX and anti-CTLA4 antibody resulted in eradication of established CT26 tumors (colon carcinoma) in mice. Here, Graph A shows tumor volume (mm³) versus days post tumor challenge in mice treated with 100 mg/kg of CTX on Day 11 while Graph B shows tumor volume (mm³) versus days post tumor challenge in mice treated with CTX on Day 11 and anti-CTLA4 on Day 12 at 100 μ g per injection, 2 times per week, up to 8 injections. Each line in each graph represents one mouse. Black arrow stands for anti-CTLA-4 administration.

30 Figure 9 shows the results of experiments wherein Balb/C mice at age of 9 to 11 weeks of age were implanted with 1 X 10⁵ CT26 cells subcutaneously. On Day 9, mice were injected with 100 mg/kg of CTX, IP. Twenty four hours later, on Day 10, mice were treated with 100 ug of B7-DC-Ig. There were 5 groups: naïve mice that did not receive any tumor cells, vehicle injected, CTX alone, CTX + B7-DC-Ig or B7-DC-Ig alone. Two naïve mice and 4 mice from other groups were removed from the study on Day 11 (2 days post CTX) and Day 16 (7 days post CTX) for T cell analysis. Left panel shows on Day 11, 2 days post CTX injection, Treg in the spleen of the mice with CTX treatment was significantly lower than the one in the mice with tumor implantation and injected with vehicle. Right panel shows that on Day 16, 7 days post CTX and 6 days post B7-DC-Ig treatment, B7-DC-Ig significantly lowered the CD4+ T cells expressing high PD-1. This was observed in both the B7-DC-Ig treated and CTX + B7-DC-Ig treated mice. Mice implanted with tumor cells intended to have more PD-1+/CD4+ T cells in the draining LN compared with naïve mice.

35 Figure 10 shows the results of experiments wherein the combination of CTX and B7-DC-Ig resulted in increased survival in mice with tail vein injection of a mouse prostate tumor cell line. SP-1 cells were isolated from mouse lungs that were metastasized from TRAMP prostate tumor cell injection. B10.D2 mice were first injected with 3x10⁵ SP-1 cells via tail vein injection. On Day 5, 12 and 19, mice were injected with 50 mg/kg of CTX where was indicated. On Day 6, 13 and 20, mice were administered with 5 mg/kg of B7-DC-Ig where it was indicated. Here, "NT" refers to "not treated".

40 Figure 11. Balb/C mice at age of 11-13 weeks were given isolated hepatic metastases using a hemispleen injection technique. The spleens of anesthetized mice were divided into two halves and the halves were clipped. CT26 cells (1E05) were injected into one hemispleen, and after 30 seconds, that hemispleen was resected and the splenic draining vein was clipped. On Day 10, mice received 1 injection of CTX at 50 mg/kg, IP. Twenty four hours later, on Day 11, mice were treated with recombinant Listeria carrying AH1 peptide, an immunodominant epitope of CT26, at 0.1 x LD₅₀ (1 x10⁷ CFU), then on Day 14 and 17. Mice were also treated with B7-DC-Ig on Day 11 and then on Day 18. Mouse overall survival was monitored.

DEFINITIONS

[0038] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. In particular, the following terms and phrases have the following meaning.

[0039] The term "inhibitory signal transduction" is intended to mean any signal transduction having the effect of abolishing, or otherwise reducing, T cell responses against an antigen, whether by reducing T cell proliferation or by any other inhibitory mechanism, whereby the extent or duration of an immunogenic T cell response is decreased. Such inhibitory signal transduction may be due to PD-1 binding to a natural ligand, such as binding of PD-1 by B7-H1 or some other member of this class of ligands, B7-DC, or may be due to binding of CTLA4 to ligands, such as B7-1 or B7-2. In general, compounds of the disclosures reduce such inhibitory signal transduction and include, but are not limited to, PD-1 antagonists and CTLA4 antagonists.

[0040] The term "PD-1 antagonist" means any molecule that attenuates inhibitory signal transduction mediated by PD-1, found on the surface of T cells, B cells, natural killer (NK) cells, monocytes, DC, and macrophages. Such an antagonist includes a molecule that disrupts any inhibitory signal generated by a PD-1 molecule on a T cell. In specific examples of the disclosures, a PD-1 antagonist is a molecule that inhibits, reduces, abolishes or otherwise reduces inhibitory signal transduction through the PD-1 receptor signaling pathway. Such decrease may result where: (i) the PD-1 antagonist of the invention binds to a PD-1 receptor without triggering signal transduction, to reduce or block inhibitory signal transduction; (ii) the PD-1 antagonist binds to a ligand (e.g. an agonist) of the PD-1 receptor, preventing its binding thereto (for example, where said agonist is B7-H1); (iii) the PD-1 antagonist binds to, or otherwise inhibits the activity of, a molecule that is part of a regulatory chain that, when not inhibited, has the result of stimulating or otherwise facilitating PD-1 inhibitory signal transduction; or (iv) the PD-1 antagonist inhibits expression of a PD-1 receptor or expression ligand thereof, especially by reducing or abolishing expression of one or more genes encoding PD-1 or one or more of its natural ligands. Thus, a PD-1 antagonist of the disclosures is a molecule that effects a decrease in PD-1 inhibitory signal transduction, thereby increasing T cell response to one or more antigens.

[0041] As used herein, the term "CTLA4 antagonist" means a compound that reduces CTLA4-mediated inhibition of T cell reactions. For example, in an T cell, CTLA4 delivers an inhibitory impulse upon binding of B7 ligands, such B7-1 and B7-2. A CTLA4 antagonist is one that disrupts binding of said ligands to CTLA4 on activated T cells. In one embodiment of the disclosures, the antagonist is an anti-CTLA4 antibody that binds CTLA4 to prevent ligand binding.

[0042] As used herein, the term "active fragment" refers to a portion of a natural polypeptide, or a polypeptide with high sequence homology (for example, at least 80%, 85%, 90%, 95%, 98%, or 99% amino acid sequence identity) to a natural polypeptide and that exhibits PD-1 antagonist activity, for example, by binding PD-1 or by binding to a ligand of PD-1. In preferred embodiments, such a fragment would consist of the extracellular domain (ECD) of a B7-DC protein that binds to PD-1, such as SEQ ID NO: 3, preferably amino acids 20 to 221 thereof. In the case of PD-1 polypeptide, an active fragment would be a portion of said polypeptide comprising a binding domain that binds to a natural ligand of PD-1 to prevent stimulation of PD-1 mediated inhibitory signal transduction by said ligand. Active fragments may be identified by their ability to compete with the molecule they are derived from for binding to a natural binding site. For example, active fragments will compete with wild-type B7-DC for binding to PD-1.

[0043] With respect to an antibody, the term "active fragment" means an antigen binding portion of an antibody that is less than an entire immunoglobulin. Such fragments include Fab and F(ab₂)' fragments, capable of reacting with and binding to any of the polypeptides disclosed herein as being receptors or ligands. These Fab and F(ab₂)' fragments lack the Fc portion of an intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al., J. Nuc. Med. 24:316-325 (1983)). Also included are Fv fragments (Hochman, J. et al. (1973) Biochemistry 12:1130-1135; Sharon, J. et al. (1976) Biochemistry 15:1591-1594). These various fragments are produced using conventional techniques such as protease cleavage or chemical cleavage (see, e.g., Rousseaux et al., Meth. Enzymol., 121:663-69 (1986)).

[0044] As used herein, the term "soluble portion" of a PD-1 antagonist means that portion of the full length polypeptide that does not include any part of the transmembrane portion or segment. For example, with respect to B7-DC, a soluble portion would include the extracellular portion (with or without the N-terminal signal sequence) but would not include any part of the transmembrane portion (or, at least, not enough to reduce solubility). Thus, the ECD of human B7-DC is shown as SEQ ID NO: 3 and consists of both the IgV-like and IgC-like domains of the full length molecule (i.e., amino acids 20-221 of the full length sequence (SEQ ID NO: 1)).

[0045] As used herein, a "co-stimulatory polypeptide" is a polypeptide that, upon interaction with a cell-surface molecule on T cells, modulates the activity of the T cell. Thus, the response of the T cell can be an effector (e.g., CTL or antibody-producing B cell) response, a helper response providing help for one or more effector (e.g., CTL or antibody-producing B cell) responses, or a suppressive response.

[0046] As used herein, the term "treatment regimen" refers to a treatment of a disease or a method for achieving a desired physiological change, such as increased or decreased response of the immune system to an antigen or immu-

nogen, such as an increase or decrease in the number or activity of one or more cells, or cell types, that are involved in such response, wherein said treatment or method comprises administering to an animal, such as a mammal, especially a human being, a sufficient amount of two or more chemical agents or components of said regimen to effectively treat a disease or to produce said physiological change, wherein said chemical agents or components are administered together, such as part of the same composition, or administered separately and independently at the same time or at different times (i.e., administration of each agent or component is separated by a finite period of time from one or more of the agents or components) and where administration of said one or more agents or components achieves a result greater than that of any of said agents or components when administered alone or in isolation.

[0047] As used herein the term "isolated" is meant to describe a compound of interest (e.g., either a polynucleotide or a polypeptide) that is in an environment different from that in which the compound naturally occurs e.g. separated from its natural milieu such as by concentrating a peptide to a concentration at which it is not found in nature. "Isolated" is meant to include compounds that are within samples that are substantially enriched for the compound of interest and/or in which the compound of interest is partially or substantially purified.

[0048] As used herein, the term "polypeptide" refers to a chain of amino acids of any length, regardless of modification (e.g., phosphorylation or glycosylation). A polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.

[0049] As used herein, a "variant" polypeptide contains at least one amino acid sequence alteration as compared to the amino acid sequence of the corresponding wild-type polypeptide.

[0050] As used herein, an "amino acid sequence alteration" can be, for example, a substitution, a deletion, or an insertion of one or more amino acids.

[0051] As used herein, the terms "portion," "segment," and "fragment," when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. A "fragment" of a polypeptide thus refers to any subset of the polypeptide that is a shorter polypeptide of the full length protein. Generally, fragments will be five or more amino acids in length.

[0052] A derivative, analog or homolog, of a polypeptide (or fragment thereof) of the invention may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

[0053] As used herein, "valency" refers to the number of binding sites available per molecule.

[0054] In accordance with the present disclosures, the term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

$$\text{Percent Identity} = 100 [1 - (C/R)]$$

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid. If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.

[0055] As used herein, the term "conservative amino acid substitution" means a substitution wherein the substituted amino acid has similar structural or chemical properties, and "non-conservative" amino acid substitutions are those in

which the charge, hydrophobicity, or bulk of the substituted amino acid is significantly altered. Non-conservative substitutions will differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Examples of conservative amino acid substitutions include those in which the substitution is within one of the five following groups: 1) small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro, Gly); 2) polar, negatively charged residues and their amides (Asp, Asn, Glu, Gin); polar, positively charged residues (His, Arg, Lys); large aliphatic, nonpolar residues (Met, Leu, Ile, Val, Cys); and large aromatic residues (Phe, Tyr, Trp). Examples of non-conservative amino acid substitutions are those where 1) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl, or alanyl; 2) a cysteine or proline is substituted for (or by) any other residue; 3) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or 4) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) a residue that does not have a side chain, e.g., glycine.

[0056] The terms "individual", "host", "subject", and "patient" are used interchangeably herein, and refer to a mammal, including, but not limited to, primates, for example, human beings, as well as rodents, such as mice and rats, and other laboratory animals.

[0057] As used herein the term "effective amount" or "therapeutically effective amount" means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms of a disease state being treated or to otherwise provide a desired pharmacologic and/or physiologic effect, especially enhancing T cell response to a selected antigen. The precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being administered.

[0058] As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0059] The term "antibody" is meant to include both intact molecules as well as fragments thereof that include the antigen-binding site. Whole antibody structure is often given as H₂L₂ and refers to the fact that antibodies commonly comprise 2 light (L) amino acid chains and 2 heavy (H) amino acid chains. Both chains have regions capable of interacting with a structurally complementary antigenic target. The regions interacting with the target are referred to as "variable" or "V" regions and are characterized by differences in amino acid sequence from antibodies of different antigenic specificity. The variable regions of either H or L chains contains the amino acid sequences capable of specifically binding to antigenic targets. Within these sequences are smaller sequences dubbed "hypervariable" because of their extreme variability between antibodies of differing specificity. Such hypervariable regions are also referred to as "complementarity determining regions" or "CDR" regions. These CDR regions account for the basic specificity of the antibody for a particular antigenic determinant structure. The CDRs represent non-contiguous stretches of amino acids within the variable regions but, regardless of species, the positional locations of these critical amino acid sequences within the variable heavy and light chain regions have been found to have similar locations within the amino acid sequences of the variable chains. The variable heavy and light chains of all antibodies each have 3 CDR regions, each non-contiguous with the others (termed L1, L2, L3, H1, H2, H3) for the respective light (L) and heavy (H) chains. The accepted CDR regions have been described by Kabat et al, J. Biol. Chem. 252:6609-6616 (1977). The antibodies disclosed according to the invention may also be wholly synthetic, wherein the polypeptide chains of the antibodies are synthesized and, possibly, optimized for binding to the polypeptides disclosed herein as being receptors. Such antibodies may be chimeric or humanized antibodies and may be fully tetrameric in structure, or may be dimeric and comprise only a single heavy and a single light chain.

DETAILED DESCRIPTION OF THE INVENTION

[0060] The present disclosures provide a treatment regimen, or combination therapy, for treating disease in mammals comprising a compound that reduces or abolishes inhibitory signal transduction in T cells, preferably human T cells, administered in conjunction with a potentiating agent to increase an immune response.

[0061] The methods of the disclosures also relate to the use of broad spectrum immunomodulators and compositions of these. In general, the increased T cell response resulting from these methods is greater than any increased T cell response resulting from administering the same dose of either of said PD-1 antagonist or said potentiating agent alone.

[0062] The disclosed compositions and regimens are useful to stimulate or enhance immune responses involving T cells. Thus, the compositions of the invention are most useful in treating a disease condition that would benefit from an increase in T cell activity and where the increased T cell response is necessary or sufficient to treat said disease, even though the disease is not specifically caused or aggravated by a reduced T cell response. In a preferred embodiment, the type of disease to be treated or prevented is a malignant tumor or a chronic infectious disease caused by a bacterium,

virus, protozoan, helminth, or other intracellular microbial pathogen that is attacked, i.e., by cytotoxic T lymphocytes. Activation of T cells using the disclosed compositions is also advantageous to treat or prevent conditions characterized by immunosuppression.

[0063] In accordance with the present disclosures, the T cell response can be regulated by molecules that bind to receptors on the T cell surface and molecules that bind to ligands of such receptors. In the case of PD-1, molecules that bind PD-1 to reduce its inhibitory effect and/or molecules that bind one or more PD-1 ligands to reduce their ability to bind PD-1 have the effect of reducing the ability of PD-1 to inhibit T cell response, thereby increasing this response and the immunological effects thereof.

A. PD-1 RECEPTOR ANTAGONISTS

[0064] Compositions containing antagonists of PD-1 receptors are provided and include compounds or agents that either bind to and block a ligand of PD-1 to interfere with or inhibit the binding of the ligand to the PD-1 receptor, or bind directly to and block the PD-1 receptor without inducing inhibitory signal transduction through the PD-1 receptor. In another embodiment of the disclosures, the PD-1 receptor antagonist binds directly to the PD-1 receptor without triggering inhibitory signal transduction and also binds to a ligand of the PD-1 receptor to reduce or inhibit the ligand from triggering signal transduction through the PD-1 receptor. By reducing the number and/or amount of ligands that bind to PD-1 receptor and trigger the transduction of an inhibitory signal, fewer cells are attenuated by the negative signal delivered by PD-1 signal transduction and a more robust immune response can be achieved.

[0065] In accordance with the present disclosures, PD-1 signaling requires binding to a PD-1 ligand (such as B7-H1 or B7-DC) in close proximity to a peptide antigen presented by major histocompatibility complex (MHC) (see, for example, Freeman Proc. Natl. Acad. Sci. U. S. A 105:10275-10276 (2008)). Therefore, proteins, antibodies or small molecules that prevent co-ligation of PD-1 and TCR on the T cell membrane are useful PD-1 antagonists contemplated by the disclosures.

[0066] Exemplary PD-1 receptor antagonists include, but are not limited to B7-DC polypeptides, including homologs and variants of these, as well as active fragments of any of the foregoing, and fusion proteins that incorporate any of these. In a preferred embodiment, the fusion protein comprises the soluble portion of B7-DC coupled to the Fc portion of an antibody, such as human IgG, and does not incorporate all or part of the transmembrane portion of human B7-DC. The PD-1 receptor antagonists can also be small molecule antagonists or antibodies that reduce or interfere with PD-1 receptor signal transduction by binding to ligands of PD-1 or to PD-1 itself, especially where co-ligation of PD-1 with TCR does not follow such binding, thereby not triggering inhibitory signal transduction through the PD-1 receptor.

[0067] The PD-1 receptor antagonists provided herein are generally useful *in vivo* and *ex vivo* as immune response-stimulating therapeutics. In general, the disclosed antagonist compositions are useful for treating a subject having or being predisposed to any disease or disorder to which the subject's immune system mounts an immune response.

1. B7-DC Polypeptides

[0068] In certain disclosures, B7-DC proteins can be used as PD-1 receptor antagonists. B7-DC is a natural ligand of PD-1 and binds to PD-1 with higher affinity than B7-H1, and can thus inhibit B7-H1:PD-1 interactions. Suitable B7-DC polypeptides, including variants, homologs and fragments thereof, can be obtained from the following full length human B7-DC polypeptides with (SEQ ID NO:1) or without (SEQ ID NO:2) the endogenous signal peptide.

MIFLLMLSL ELQLHQIAAL FTVTVPKELY IIEHGSNVTL ECNFDTGSHV NLGAITASLQ	60
KVENDTSPHR ERATLLEEQL PLGKASFHIP QVQVRDEGQY QCIIYGVAV DYKYLTCLKV	120
ASYRKINTHI LKVPETDEVE LTCQATGYPL AEVSWPNVSV PANTSHSRTP EGLYQVTSVL	180
RLKPPPGRNF SCVFNWTHVR ELTLASIDLQ SQMEPRTHPT WLLHIFIPFC IIAFIFIATV	240
IALRQLCQK LYSSKDTTKR PVTTTKREVN SAI	273

(SEQ ID NO:1)

LFTVTVPKEL YIIEHGSNVT LECNFDTGSH VNLGAI TASL QKVENDTSPH RERATLLEEQ 60
 LPLGKASFHI PQVQVRDEGQ YQCIIYGYVA WDKYLTLTKV KASYRKINTH ILKVPETDEV 120
 ELTCQATGYP LAEVSWPVNS VPANTSHSRT PEGLYQVTSV LRLKPPGRN FSCVFWNTHV 180
 5 RELTLASIDL QSQMEPRTHP TWLLHIFIPF CIIAFIFIAT VIALRKQLCQ KLYSSKDTTK 240
 RPVTTTKREV NSAI 254
 (SEQ ID NO:2)

10 **[0069]** The B7 family of molecules, including B7-DC, are expressed at the cell surface with a membrane proximal constant IgC domain and a membrane distal IgV domain. Receptors for these ligands share a common extracellular IgV-like domain. Interactions of receptor-ligand pairs are mediated predominantly through residues in the IgV domains of the ligands and receptors. In general, IgV domains are described as having two sheets that each contains a layer of β -strands. These β -strands are referred to as A', B, C, C', C", D, E, F and G. The structure of such polypeptides has
 15 been described in the literature (See Molnar et al., Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2, PNAS, Vol. 105, pp. 10483-10488 (29 July 2008)).

[0070] B7-DC, a transmembrane protein, in its monomeric form, comprises IgV and IgC domains that make up the extracellular portion of the molecule (the extracellular domain, or ECD), with the IgV-like domain being responsible, in whole or in part, for PD-1 binding as well as other functions recited in the compositions of the disclosures. For the human
 20 protein, the IgV domain is characterized in that it possesses a disulfide bond linking the B and F strands (referred to above), which appears to be characteristic of many IgV domains and possesses a similar three-dimensional structure with the IgV domains of both B7-1 and B7-2 (see Molnar et al.(2008), *supra*).

[0071] In one embodiment of the disclosures the B7-DC variant polypeptides contain amino acid alterations (i.e., substitutions, deletions or insertions) within one or more of these β -strands in any possible combination. In another
 25 embodiment of the disclosures, B7-DC variants contain one or more amino acid alterations (i.e., substitutions, deletions or insertions) within the A', C, C', C", D, E, F or G β -strands. In a preferred embodiment B7-DC variants contain one or more amino acid alterations in the G β -strand. In another embodiment of the disclosures, variant B7-DC polypeptide fragments include the IgC and IgV domains of B7-DC. In another embodiment of the disclosures, variant B7-DC polypeptide fragments include the IgV domain of B7-DC.

30 **[0072]** Human and mouse B7-DC proteins contain a short intracytoplasmic domain, a single transmembrane domain and an extracellular domain. The extracellular domain contains two Ig domains; a membrane proximal IgC domain and a membrane distal IgV domain. Useful fragments of variant B7-DC polypeptides include soluble fragments. Soluble B7-DC fragments are fragments of B7-DC that may be shed, secreted or otherwise extracted from the producing cells. In one embodiment, variant B7-DC polypeptide fragments of the fusion protein include the entire extracellular domain of
 35 B7-DC. The extracellular domain of B7-DC includes amino acids from about 20 to about amino acid 221 of murine or human B7-DC or active fragments thereof. In another embodiment, variant B7-DC polypeptide fragments include the IgC and IgV domains of B7-DC. In another embodiment, variant B7-DC polypeptide fragments include the IgV domain of B7-DC.

[0073] PD-1 signaling is thought to require binding to a PD-1 ligand (typically B7-H1) in close proximity to a peptide
 40 antigen presented by major histocompatibility complex (MHC) (Freeman Proc. Natl. Acad. Sci. U. S. A 105:10275-10276 (2008)). Therefore, proteins, antibodies or small molecules that prevent co-ligation of PD-1 and TCR on the T cell membrane are useful PD-1 antagonists contemplated by this invention.

[0074] The PD-1 antagonist of the disclosures useful in the methods and compositions of the invention include fragments of the B7-DC protein incorporating the ECD. Alternatively, the fragments of B7-DC include part of the extracellular
 45 domain that comprise the an IgV or IgV-like domain, preferably amino acids 20-221, more preferably 20-121, that are sufficient to bind to the PD-1 receptor to interfere with, or prevent, or otherwise reduce inhibitory signal transduction through the PD-1 receptor. In a preferred embodiment of the invention the B7-DC fragment of the fusion protein competes with B7-H1 for binding to PD-1 receptors.

[0075] In one embodiment, variant B7-DC polypeptide fragments of the fusion protein may contain a region of the
 50 polypeptide that is important for binding to PD-1. These polypeptide fragments may be useful to compete for binding to PD-1 and to prevent native B7-DC from binding to PD-1. By competing for binding to PD-1, these fragments may be useful to enhance an immune response, as inhibiting interactions of B7-H1 and B7-DC with PD-1 inhibits the suppression of immune responses that would otherwise occur. A polypeptide fragment of mouse or human B7-DC that could competitively bind to PD-1 can contain, for example, amino acids 101-108 or 110-114. The binding of wild-type B7-DC to PD-1 typically is inhibited by at least 50 percent, 60 percent, 70 percent, 75 percent, 80 percent, 90 percent, 95 percent,
 55 or more than 95 percent as compared to the level of binding of wild-type B7-DC to PD-1 in the absence of a fragment of said wild-type B7-DC. Exemplary B7-DC fragments useful in the methods and/or compositions of the invention include, but are in no way limited to, the following B7-DC extracellular domains:

EP 2 350 129 B1

Human B7-DC extracellular domain (ECD):

5 LFTVTVPKEL YIIEHGSNVT LECNFDGTGSH VNLGAITASL QKVENDTSPH RERATLLEEQ 60
LPLGKASFHI PQVQVRDEGQ YQCIIIYGVA WDYKYLTCLKV KASYRKINTH ILKVPETDEV 120
ELTCQATGYP LAEVSWPNVV VPANTSHSRT PEGLYQVTSV LRLKPPPGRN FSCVFNTHV 180
RELTLASIDL QSQMEPRTHP TW 202
(SEQ ID NO:3)

10 and murine B7-DC ECD:

15 LFTVTAPKEV YTVDVGSSVS LECDFDRREC TELEGIASL QKVENDTSLQ SERATLLEEQ 60
LPLGKALFHI PSVQVRDSGQ YRCLVICGAA WDYKYLTCLKV KASYRMIDTR ILEVPGTGEV 120
QLTCQARGYP LAEVSQNVV VPANTSHIRT PEGLYQVTSV LRLKPQPSRN FSCMFWNAHM 180
KELTSIIDP LSRMEPKVPR TW 202
(SEQ ID NO:4)

20 Cynomolgus monkey B7-DC ECD:

25 LFTVTVPKEL YIIEHGSNVT LECNFDGTGSH VNLGAITASL QKVENDTSPH RERATLLEEQ 60
LPLGKASFHI PQVQVRDEGQ YQCIIIYGVA WDYKYLTCLKV KASYRKINTH ILKVPETDEV 120
ELTCQATGYP LAEVSWPNVV VPANTSHSRT PEGLYQVTSV LRLKPPPGRN FSCVFNTHV 180
RELTLASIDL QSQMEPRTHP TW 202
(Seq ID NO: 15)

30 **[0076]** Numerous other primate sequences useful in the methods and compositions of the invention are provided in Onlamoon et al., Immunology, Vol. 124, pp. 277-293 (2008).

35 **[0077]** A PD-1 antagonist useful in the compositions and methods of the disclosures also includes a fusion protein (as described below) that comprises first and second polypeptide portions, wherein said fusion protein, or at least the first polypeptide portion thereof, possesses PD-1 antagonist activity, especially where said fusion protein binds to and blocks PD-1 or binds to and blocks a ligand of PD-1. The first polypeptide portion of such fusion protein can comprise, or consist of, any of the PD-1 antagonistic polypeptides, or PD-1 binding fragments thereof, otherwise recited herein for use as PD-1 antagonists in the methods of the disclosures. In a preferred embodiment of such a fusion protein, the recited first polypeptide portion is N-terminal to the recited second polypeptide portion. In a separate embodiment of the disclosures, the recited first polypeptide portion is linked to the recited second polypeptide portion by an oligopeptide in addition to the amino acids composing the recited first and second polypeptide portions, where said linking amino acids do not substantially decrease the PD-1 antagonist activity of said fusion protein.

40 **[0078]** In a preferred dimeric fusion protein, the dimer results from the covalent bonding of Cys residues in the CH regions of two of the Ig heavy chains that are the same Cys residues that are disulfide linked in dimerized normal Ig heavy chains.

45 **[0079]** A large number of polypeptide sequences that are routinely used as fusion protein binding partners are well known in the art. Examples of useful polypeptide binding partners include, but are not limited to, green fluorescent protein (GFP), glutathione S-transferase (GST), polyhistidine, myc, hemagglutinin, Flag™ tag (Kodak, New Haven, CT), maltose E binding protein and protein A.

50 **[0080]** Still another embodiment provides a tetramer construct having a BirA substrate fused to the extracellular domain of a variant B7-DC polypeptide. Methods for making tetramer constructs are known in the art (see Pertovas, et al., J. Exp. Med., 203:2281 (2006)).

55 **[0081]** Exemplary murine B7-DC fusion proteins contain amino acids 20-221 of murine B7-DC fused to amino acids 237-469 of murine IgG2a (CAA49868). In one non-limiting example, human B7-DC fusion proteins contain amino acids 20-221 of human B7-DC fused to amino acids 245-476 of human IgG1 (AAA02914). The signal peptides for B7-DC fusion proteins include the endogenous signal peptides or any other signal peptide that facilitates secretion of the fusion protein from a host. In another embodiment of the disclosures, the first polypeptide would include only the IgV domain. Other embodiments may comprise the hinge and Fc domain of an IgG antibody, such IgG1, with none of the variable

region present. Other embodiments include use of the hinge and Fc region of IgG2 or IgG4, especially having an N297Q or other mutation that reduces effector function.

[0082] In accordance with the methods and compositions of the disclosures, the polypeptide useful as a PD-1 antagonist, or the first polypeptide portion of a fusion protein useful as a PD-1 antagonist, comprises an amino acid sequence that has at least 60%, or at least 65%, or at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%, identity to amino acids 1-221 of SEQ ID NO: 1, preferably amino acids 20-221 of SEQ ID NO: 1, or amino acids 26-221 of SEQ ID NO: 1, or amino acids 1-202 of SEQ ID NO: 3 or 4, more preferably amino acids 20-121 of SEQ ID NO: 1 or amino acids 1-102 of SEQ ID NO: 3 or 4.

[0083] In one embodiment of the disclosures, a polypeptide useful as a PD-1 antagonist, or the first polypeptide portion of a fusion protein useful as a PD-1 antagonist, consists of amino acids 1-221 of SEQ ID NO: 1, or consists of amino acids 20-221 of SEQ ID NO: 1, or consists of amino acids 26-221 of SEQ ID NO: 1, or consists of amino acids 1-202 of SEQ ID NO: 3 or 4. In one embodiment (SEQ ID NO: 2), it does not comprise amino acids 1-19 of SEQ ID NO: 1.

[0084] In other specific examples, a PD-1 antagonist polypeptide, or first polypeptide portion of a PD-1 antagonist fusion protein, comprises the amino acid sequence 20-121 of SEQ ID NO: 1, preferably where it comprises the amino acid sequence WDYKY at residues 110-114 thereof, or where it comprises amino acids 1-102 of SEQ ID NO: 3, preferably where it comprises the amino acid sequence WDYKY at residues 91-95 thereof.

[0085] In a preferred embodiment, such percent identities are achieved by reliance on conservative amino acid substitutions as defined elsewhere herein.

[0086] In one such embodiment, the PD-1 antagonist polypeptide, or first polypeptide portion of a PD-1 antagonist fusion protein, does not comprise amino acids 1-19 of SEQ ID NO: 1, or does not comprise any portion of a transmembrane domain, especially not the entire such domain, or does not comprise any portion of the intracellular (or soluble) domain, especially not the entire such domain, of a PD-1 ligand or other PD-1 antagonist protein. In a preferred embodiment, such antagonist, or first polypeptide portion, comprises only the extracellular domain (ECD) of SEQ ID NO:1 and is thus comprised only of a soluble portion of the polypeptide of said sequence, or a fragment of said soluble portion.

[0087] In other such embodiments of the disclosures, the PD-1 antagonist polypeptide, or first polypeptide portion of a PD-1 antagonist fusion protein, comprises the IgV domain, or IgV-like domain, or PD-1 binding fragment thereof, of a PD-1 ligand, or consists of the IgV domain, or IgV-like domain, or PD-1 binding fragment thereof, of a PD-1 ligand. In specific examples, such PD-1 ligand is a wild-type B7-DC or B7-H1 molecule, preferably mouse or primate, preferably human, wild-type B7-DC or B7-H1 molecule.

[0088] In other such embodiments of the disclosures, the PD-1 antagonist polypeptide, or first polypeptide portion of a PD-1 antagonist fusion protein, a PD-1 binding fragment of the IgV domain, or IgV-like domain, of a PD-1 ligand, especially where IgV domain, or IgV-like domain, consists of amino acids 20 - 121 of SEQ ID NO: 1 or amino acids 1 - 102 of SEQ ID NO: 3.

[0089] A PD-1 antagonist of the invention also includes a PD-1 binding fragment of amino acids 20-121 of SEQ ID NO: 1 (human full length), or as disclosed herein but not claimed amino acids 1-102 of SEQ ID NO: 3 (extracellular domain or ECD).

[0090] In specific embodiments thereof, the polypeptide or PD-1 binding fragment also incorporates amino acids WDYKY at residues 110-114 of SEQ ID NO: 1 or WDYKY at residues 91-95 of SEQ ID NO: 3. By way of non-limiting examples disclosed herein but not claimed, such a PD-1 binding fragment comprises at least 10, or at least 20, or at least 30, or at least 40, or at least 50, or at least 60, or at least 70, or at least 75, or at least 80, or at least 85, or at least 90, or at least 95, or at least 100 contiguous amino acids of the sequence of amino acids 20-121 of SEQ ID NO: 1, wherein a preferred embodiment of each such PD-1 binding fragment would comprise as a sub-fragment the amino acids WDYKY found at residues 110-114 of SEQ ID NO: 1 or WDYKY at residues 91-95 of SEQ ID NO: 3.

[0091] Other preferred polypeptides and PD-1 binding fragments specifically contemplated by the invention include the polypeptide sequence of amino acids 20-121 of SEQ ID NO: 1 (human full length) and PD-1 binding fragments thereof, wherein, in such polypeptide or PD-1 binding fragment, a cysteine is present at residues 42 and/or 102, with a cysteine at both positions being preferred, and/or wherein a phenylalanine is present at residue 21, and/or wherein a glutamic acid is present at residue 28, and/or wherein a threonine, and/or wherein a glutamine is present at residue 60, and/or wherein a glutamic acid is present at residue 101, and/or wherein isoleucine is present at residue 103, and/or wherein an isoleucine is present at residue 105, and/or wherein a glycine is present at residue 107, and/or wherein valine is present at residue 108, and/or wherein a tryptophan is present at residue 110, and/or wherein aspartic acid is present at residue 111, and/or wherein a tyrosine is present at residue 112, and/or wherein a lysine is present at residue 113, and/or wherein a tyrosine is present at residue 114, provided that, in the case of PD-1 binding fragments, said fragment is large enough to include such amino acid positions.

[0092] Additional preferred polypeptides and PD-1 binding fragments specifically contemplated by the disclosures include the polypeptide sequence of amino acids 1-102 of SEQ ID NO: 3 (human ECD) or SEQ ID NO: 4 (murine ECD) and PD-1 binding fragments thereof, wherein, in such polypeptide or PD-1 binding fragment, a cysteine is present at residues 23 and/or 83, with a cysteine at both positions being preferred, and/or wherein a phenylalanine is present at

residue 2, and/or wherein a glutamic acid is present at residue 9, and/or wherein a threonine or arginine is present at residue 37, with threonine preferred, and/or wherein a glutamine is present at residue 41, and/or wherein arginine is present at residue 82, and/or wherein a leucine is present at residue 84, and/or wherein an isoleucine is present at residue 86, and/or wherein a glycine is present at residue 88, and/or wherein an alanine is present at residue 89, and/or wherein a tryptophan is present at residue 91, and/or wherein an aspartic acid is present at residue 92, and/or wherein a tyrosine is present at residue 93, and/or wherein a lysine is present at residue 94, and/or wherein a tyrosine is present at residue 95, provided that, in the case of PD-1 binding fragments, said fragment is large enough to include such amino acid positions.

[0093] In additional embodiments, any of the above polypeptides may also incorporate portions or fragments, for example, from 1 to 10 contiguous amino acids, drawn from the signal, transmembrane or C-terminal domains of the B7-DC or B7-H1 polypeptide, such as that of mouse or primate, preferably human.

[0094] Such polypeptides and/or PD-1 binding fragments can also be present in any of the fusion proteins of the invention, for example, where such polypeptide or PD-1 binding fragment represents the "first polypeptide" of such fusion protein.

[0095] In specific examples, the molecule, combined with a potentiating agent for use in a treatment regimen of the invention, comprises a PD-1 binding fragment of amino acids 20-221 of SEQ ID NO: 1. In one such embodiment, the fragment is from amino acids 20 - 121 of SEQ ID NO: 1, preferably where the fragment contains amino acids 110-114 of SEQ ID NO: 1. In some embodiments, more than one such fragment is present (as described elsewhere herein) and the molecule comprises at least 2, 3, 4, 5 or more fragments of a B7-DC protein, especially where the fragment is part of, or contains part of, amino acids 20-221 of SEQ ID NO: 1. In a preferred embodiment thereof, at least one said fragment is from amino acids 20 - 121 of SEQ ID NO: 1, more preferably wherein at least one said fragment includes amino acids 110-114 of SEQ ID NO: 1 (i.e., the sequence WDYKY (SEQ ID NO: 14)). In preferred embodiments of the disclosures, the PD-1 binding fragment comprises at least 10, or at least 25, or at least 50, or at least 75, or at least 100 contiguous amino acids in length.

[0096] The endogenous human signal peptide has the following sequence MIFLLMLSL ELQLHQIAA (SEQ ID NO:5) and represents the first 19 amino acids of SEQ ID NO: 1. In certain embodiments of the disclosures, the polypeptide fragments of B7-DC can include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 contiguous amino acids of the endogenous or heterologous signal peptide (which can be used to produce a recombinant B7-DC polypeptide by expression in and secretion from a transformed cell). It will also be appreciated that a useful B7-DC polypeptide can include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 contiguous amino acids of the transmembrane domain of B7-DC, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 contiguous amino acids of the cytoplasmic domain, or combinations thereof provided the B7-DC fragment retains the ability to antagonize the PD-1 receptor.

[0097] The phenotypes of PD-1^{-/-} mice provide direct evidence for PD-1 being a negative regulator of immune responses in vivo. In the absence of PD-1, mice on the C57BL/6 background slowly develop a lupus-like glomerulonephritis and progressive arthritis (Nishimura, et al., *Immunity*, 11:141-151 (1999)). PD-1^{-/-} mice on the BALB/c background rapidly develop a fatal autoimmune dilated cardiomyopathy (Nishimura, et al., *Science*. 291:319-322 (2001)). However, substantial evidence indicates that B7-DC can function to costimulate activate T cell responses. In the presence of suboptimal TCR signals, B7-DC causes increased proliferation and production of cytokines in vitro (Tseng, et al., *J. Exp. Med.* 193:839-846 (2001)). On the other hand, in vitro studies indicate a negative regulatory role for B7-DC in T cell responses. These seemingly contradictory data are best interpreted by expression of additional receptors for B7-DC on T cells other than PD-1.

[0098] Therefore, B7-DC proteins, variants, fragments and fusions thereof, may have the advantage of directly enhancing T cell responses by binding to an unknown receptor that activates the T cell, in addition to enhancing T cell responses by preventing the PD-1 mediated inhibitory signal transduction.

2. B7-H1 Polypeptides

[0099] In another embodiment of the disclosures, the compound for use in combination with a potentiating agent in the treatment regimen of the invention, is, or comprises, a fragment of a mammalian B7-H1, preferably from mouse or primate, preferably human, wherein said fragment binds to and blocks PD-1 but does not result in inhibitory signal transduction through PD-1 and said fragment is at least 10, or at least 20, or at least 30, or at least 40, or at least 50, or at least 60, or at least 70, or at least 80, or at least 90, or at least 100 contiguous amino acids in length. In other embodiments of the disclosures, the fragment can be of variable length so long as it has the function of binding to PD-1 but does not produce inhibitory signal transduction that results in reduced T cell proliferation. Such B7-H1 fragments also find use as part of the first polypeptide portion of fusion proteins of the disclosures.

[0100] B7-H1 sequences are as follows:

Human B7-H1 Polypeptide (SEQ ID NO. 16):

EP 2 350 129 B1

MRIFAVFIFM TYWHLLNAFT VTPKDLVYV EYGSNMTIEC KFPVEKQLDL AALIVYWEME 60
 DKNIIQFVHG EEDLKVQHS YRQRARLLKD QLSLGNAALQ ITDVKLQDAG VYRCMISYGG 120
 ADYKRITVKV NAPYNKINQR ILVVDPTSE HELTCQAEY PKAEVIWTSS DHQVLSGKTT 180
 5 TTNSKREEKL FNVSTLRIN TTTNEIFYCT FRRLDPEENH TAEVPELPA LAHPPNERTH 240
 LVILGAILLC LGVALTFIFR LRGKRMMDVK KCGIQDTNSK KQSDTHLEET 290

Murine B7-H1 (SEQ ID NO: 17)

10 MRIFAGIIFT ACCHLLRAFT ITAPKDLVYV EYGSNVTMEC RFPVERELDL LALVVYWEKE 60
 DEQVIQFVAG EEDLKPQHSN FRGRASLPKD QLLKGNAALQ ITDVKLQDAG VYCCIISYGG 120
 15 ADYKRITLKV NAPYRKINQR ISVDPATSEH ELICQAEQYP EAEVIWTNSD HQPVSGKRSV 280
 TTSRTEGMLL NVTSSLRVNA TANDVFYCTF WRSQPQNHT AELIPELPA THPPQNRTHW 240
 VLLGSILLFL IVVSTVLLFL RKQVRMLDVE KCGVEDTSSK NRNDTQFEET 290

20 Macaca mulatta PD-L1 (SEQ ID NO: 18)

MRIFAVFIFT IYWHLLNAFT VTPKDLVYV EYGSNMTIEC RFPVEKQLGL 60
 TSLIVYWEME DKNIIQFVHG EEDLKVQHSN YRQRAQLLKD QLSLGNAALR 120
 25 ITDVKLQDAG VYRCMISYGG ADYKRITVKV NAPYNKINQR ILVVDPTSE 180
 HELTCQAEY PKAEVIWTSS DHQVLSGKTT TTNSKREEKL LNVSTLRIN 240
 TTANEIFYCI FRRLGPEENH TAEVPELPA LALPPNERTH LVILGAIFFL 300
 30 LGVALTFIFY LRGKRMMDMK KSGIRVTNSK KQRDTQLEET 340

[0101] B7-H1-ig proteins are described in WO/2001/014557 (pub. 1 March 2001) and in WO/2002/079499 (pub. 10 October 2002).

35 3. PD-1 and Other Polypeptides

[0102] Other useful polypeptides of the disclosures include those that bind to the ligands of the PD-1 receptor. These include the PD-1 receptor protein, or soluble fragments thereof, which can bind to the PD-1 ligands, such as B7-H1 or B7-DC, and prevent binding to the endogenous PD-1 receptor, thereby preventing inhibitory signal transduction. B7-H1 has also been shown to bind the protein B7.1 (Butte et al., Immunity, Vol. 27, pp. 111-122, (2007)). Such fragments also include the soluble ECD portion of the PD-1 protein that includes mutations, such as the A99L mutation, that increases binding to the natural ligands (Molnar et al., Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2, PNAS, Vol. 105, pp. 10483-10488 (29 July 2008)), B7-1 or soluble fragments thereof, which can bind to the B7-H1 ligand and prevent binding to the endogenous PD-1 receptor, thereby preventing inhibitory signal transduction, are also useful.

[0103] PD-1 polypeptides useful in the methods of the disclosures are as follows:

Human PD-1 (SEQ ID NO: 19)

50 MQIPQAPWPV VWAFLQLGWR PGWFLDSPDR PWNPTFFPA LLVVTEGDNA TFTCSFSNTS 60
 ESFVLNMYRM SPSNQTDKLA AFPEDRSQPG QDCRFRTQL PNGRDFHMSV VRARRNDSGT 120
 YLCGAISLAP KAQIKESLRA ELRVTERRAE VPTAHPSPSP RPAGQFQTLV VGVVGGLLGS 180
 55 LVLLVWVLAV ICSRAARGTI GARRTGQPLK EDPSAVPVFS VDYGELDFQW REKTPEPPVP 240
 CVPEQTEYAT IVFPSGMGTS SPARRGSADG PRSAQPLRPE DGHCSWPL 288

Cynomolgus monkey PD-1 (SEQ ID NO: 20)

	MQIQAPWPV VWAFLQLGWR PGWFLESPDR PWNAPTFSPA LLLVTEGDNA TFTCSFSNAS	60
	ESFVLNWRM SPSNQTDKLA AFPEDRSQPG QDCRFVTRL PNGRDFHMSV VRARRNDSGT	120
	YLCGAISLAP KAQIKESLRA ELRVTERRAE VPTAHPSPSP RPAGQFQTLV VGVVGGLLGS	180
5	LVLLVWVLAV ICSRAARGTI GARRTGQPLK EDPSAVPVFS VDYGELDFQW REKTPEPPVP	240
	CVPEQTEYAT IVFPSMGTS SPARRGSADG PRSAQPLRPE DGHCSWPL	288

[0104] In accordance with the disclosures, because B7-1 and fragments thereof can also bind to B7-H1 and send inhibitory transduction to T cells through B7-H1, blocking of this interaction can also reduce inhibitory signal transduction that occurs through B7-H1. Compounds for use in the disclosures include those molecules that block this type of interaction. Such molecules have been disclosed in Butte et al (2007), *supra*, and include anti-B7-H1 antibodies with dual-specificity that block either the B7-H1 :B7-1 and B7-H1:PD-1 interaction as well as antibodies exhibiting mono-specificity that block the PD-L1:B7-1 interaction. Compounds that block this interaction by blocking B7-1 are also useful, and include anti-B7-1 antibodies.

4. Variant polypeptides

[0105] Polypeptides useful in the disclosures, as described, include those that are mutated to contain one or more amino acid substitutions, deletions, or insertions. Methods for mutagenesis are known in the art. The mutated or variant polypeptides inhibit or reduce inhibitory signal transduction through PD-1 receptors by binding to ligands of PD-1. Alternatively, the variants (e.g. B7-DC polypeptides) can bind to the PD-1 receptor and inhibit, reduce, or block inhibitory signal transduction through the PD-1 receptor. The variant polypeptides may be of any species of origin. In one embodiment of the disclosures, the variant polypeptide is from a mammalian species. In a preferred embodiment, the variant polypeptide is of murine or primate, preferably human, origin.

[0106] In one embodiment the variant polypeptide is a B7-DC polypeptide that has the same binding affinity to PD-1 as wildtype or non-variant B7-DC but does not have or has less than 10% ability to trigger inhibitory signal transduction through the PD-1 receptor relative to a non-mutated B7-DC polypeptide. In other embodiments, the variant B7-DC polypeptide has 10%, 20%, 30%, 40%, 50%, or 60% more binding affinity to PD-1 than wildtype B7-DC without triggering PD-1 inhibitory signaling transduction.

[0107] A variant polypeptide (e.g. a variant B7-DC polypeptide) includes those having any combination of amino acid substitutions, deletions or insertions so long as the PD-1 antagonizing activity is not substantially reduced versus the wild type. However, where there is such a reduction, this should be by no more than half that of the wild type so that said variant has at least 50% of the PD-1 antagonist activity of the wild type protein, preferably at least 60%, more preferably at least 80%, most preferably at least 90% or 95%, with at least 100% being especially preferred. Increases in such activity resulting from said variant is even more desirable. In one embodiment, isolated B7-DC variant polypeptides have amino acid alterations such that their amino acid sequence shares at least 60, 70, 80, 85, 90, 95, 97, 98, 99, 99.5 or 100% identity with an amino acid sequence of a wild type B7-DC polypeptide, especially that from a mammal, preferably wild type murine or wild type primate, preferably human, B7-DC polypeptide.

[0108] Polypeptide sequence identity can be calculated using the definition of % identity provided hereinabove.

[0109] Amino acid substitutions in polypeptides may be "conservative" or "non-conservative".

[0110] B7 family molecules, including B7-DC, are expressed at the cell surface with a membrane proximal constant IgC domain and a membrane distal IgV domain. Receptors for these ligands share a common extracellular IgV-like domain. Interactions of receptor-ligand pairs are mediated predominantly through residues in the IgV domains of the ligands and receptors. In general, IgV domains are described as having two sheets that each contains a layer of β -strands. These β -strands are referred to as A', B, C, C', C", D, E, F and G. In one embodiment of the disclosures the B7-DC variant polypeptides contain amino acid alterations (i.e., substitutions, deletions or insertions) within one or more of these β -strands in any possible combination. In another embodiment of the disclosures, B7-DC variants contain one or more amino acid alterations (i.e., substitutions, deletions or insertions) within the A', C, C', C", D, E, F or G β -strands. In one embodiment of the disclosures, B7-DC variants contain one or more amino acid alterations in the G β -strand.

[0111] With respect to murine or primate, preferably human, B7-DC, a variant B7-DC polypeptide can contain, without limitation, substitutions, deletions or insertions at positions that do not substantially reduce binding to PD-1 relative to non-mutated B7-DC.

[0112] It is understood, however, that substitutions at the recited amino acid positions can be made using any amino acid or amino acid analog. For example, the substitutions at the recited positions can be made with any of the naturally-occurring amino acids (e.g., alanine, aspartic acid, asparagine, arginine, cysteine, glycine, glutamic acid, glutamine, histidine, leucine, valine, isoleucine, lysine, methionine, proline, threonine, serine, phenylalanine, tryptophan, or tyrosine).

[0113] While the substitutions described herein are with respect to mouse and primate, especially human, B7-DC, it

is noted that one of ordinary skill in the art could readily make equivalent alterations in the corresponding polypeptides from other species (e.g., rat, hamster, guinea pig, gerbil, rabbit, dog, cat, horse, pig, sheep, cow or non-human primate).

[0114] Preferred fragments include all or part of the extracellular domain of B7-DC effective to bind to PD-1.

[0115] In one embodiment of the disclosures, variant B7-DC polypeptide fragments are those that retain the ability to bind to PD-1 without triggering PD-1 inhibitory signal transduction. One embodiment of the disclosures provides a variant B7-DC polypeptide that is a fragment of full-length B7-DC and typically has at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 98 percent, 99 percent, 100 percent, or even more than 100 percent of the PD-1 antagonist activity of the full-length variant B7-DC polypeptide.

[0116] Useful fragments of variant B7-DC polypeptides include soluble fragments. Soluble B7-DC fragments are fragments of B7-DC that may be shed, secreted or otherwise extracted from the producing cells. In one embodiment, variant B7-DC polypeptide fragments include the entire extracellular domain of B7-DC. The extracellular domain of B7-DC includes amino acids from about 20 to about amino acid 221 of murine or primate, preferably human, B7-DC. In another embodiment of the disclosures, variant B7-DC polypeptide fragments include the IgC and IgV domains of B7-DC. In another embodiment, variant B7-DC polypeptide fragments include the IgV domain of B7-DC.

[0117] In one embodiment of the disclosures, variant B7-DC polypeptide fragments contain a region of the polypeptide that is important for binding affinity for PD-1. These polypeptide fragments are useful to bind to and block the PD-1 receptor to prevent native ligands from binding to PD-1 receptor, thereby enhancing an immune response. Inhibiting interactions of native B7-H1 or B7-DC with PD-1 inhibits the suppression of immune responses that would otherwise occur. A polypeptide fragment of mouse or primate, preferably human, B7-DC that binds to PD-1 contains, by way of non-limiting example, amino acids 101-105, or 111-113. The binding of B7-H1 to PD-1 receptor typically is inhibited by at least 50 percent, or by at least 60 percent, or by at least 70 percent, or by at least 75 percent, or by at least 80 percent, or by at least 90 percent, or by at least 95 percent, or more compared to the level of binding of B7-H1 to PD-1 in the absence of the fragment.

[0118] Human PD-1 mutant A99L binds B7-DC and B7-H1 with higher affinity than unmutated human PD-1 (Lazar Molnar et al PNAS 105 p. 10483-10488 (2008)). In one embodiment of the disclosures, the compound acting to reduce inhibitory signal transduction is a soluble protein, such as the ECD of PD-1 incorporating this mutation.

5. Modified Polypeptides

[0119] Polypeptides useful in the disclosures, as described, including variants, homologs and fragments thereof, can be modified by chemical moieties found associated with polypeptides in the normal cellular environment, for example, by phosphorylation, methylation, amidation, sulfation, acylation, glycosylation, sumoylation and ubiquitylation of the polypeptide.

[0120] Such polypeptides may also be modified by chemical moieties that are not normally part of polypeptides in a cellular environment. Such modifications can be introduced into the molecule by reacting targeted amino acid residues of the polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. Another useful modification is cyclization of the protein. Such modifications also include introduction of a label capable of providing a detectable signal, either directly or indirectly, including, but not limited to, radioisotopes and fluorescent compounds.

[0121] Examples of chemical derivatives of the polypeptides include lysinyl and amino terminal residues derivatized with succinic or other carboxylic acid anhydrides. Derivatization with a cyclic carboxylic anhydride has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing amino-containing residues include imidoesters such as methyl picolinimide; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate. Carboxyl side groups, aspartyl or glutamyl, may be selectively modified by reaction with carbodiimides (R-N=C=N--R') such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl)carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues can be converted to asparaginyl and glutaminyl residues by reaction with ammonia. Polypeptides of the invention can also include one or more D-amino acids that are substituted for one or more L-amino acids.

[0122] In other embodiments of the disclosures, the potentiating agent, such as CTX, may be itself part of the compound that reduces inhibitory signal transduction, such as where the potentiating agent is chemically linked to a PD-1 antagonist of the disclosures.

6. Fusion Proteins

[0123] Fusion polypeptides having a first fusion partner, or polypeptide portion, comprising all or a part of a PD-1 antagonist protein, a B7-DC polypeptide for example, (including variants, homologs and fragments thereof) fused (i) directly to a second polypeptide or, (ii) optionally, fused to a linker peptide sequence that is fused to the second polypeptide are also provided. The presence of the fusion partner can alter, for example, the solubility, affinity and/or valency of the

PD-1 antagonist polypeptide. The disclosed fusion proteins include any combination of amino acid alteration (i.e., substitution, deletion or insertion), fragment, and/or modification of a PD-1 antagonist polypeptide as described above. In one embodiment, B7-DC fusion proteins include the extracellular domain of a B7-DC protein as the first binding partner. In another embodiment of the disclosures, such B7-DC fusion proteins include the IgV and IgC domain of a B7-DC protein as the first binding partner. In another embodiment of the disclosures, variant B7-DC fusion proteins include the IgV domain of a B7-DC protein as the first binding partner.

[0124] Representative first fusion partners include primate, preferably human, or murine B7-DC polypeptide, fragments thereof, and variants thereof disclosed hereinabove. Preferred fragments include the extracellular domain of B7-DC. As recited, the extracellular domain can include 1-10 contiguous amino acids of a signal peptide, B7-DC transmembrane domain, or both.

[0125] In one embodiment of the disclosures, the compositions and/or products and/or methods of the invention utilize PD-1 receptor antagonist, especially polypeptides, including variants, homologs and fragments thereof, that are coupled to other polypeptides to form fusion proteins that antagonize the PD-1 receptor by binding a PD-1 ligand, such as B7-H1, thereby inhibiting the ligand from interacting with PD-1. In another embodiment of the disclosures, PD-1 receptor antagonist polypeptides, or variants thereof, are coupled to other polypeptides to form fusion proteins that antagonize the PD-1 receptor by binding to and blocking the PD-1 receptor and inhibit or reduce inhibitory signal transduction through PD-1.

[0126] The second polypeptide binding partner, or second polypeptide portion, may be N-terminal or C-terminal relative to the PD-1 antagonist polypeptide. In a preferred embodiment of the disclosures, the second polypeptide is C-terminal to the PD-1 antagonist polypeptide.

[0127] In a preferred embodiment, the fusion protein contemplated for use in and compositions and/or products of the invention comprises at least a portion of an antibody. With the advent of methods of molecular biology and recombinant technology, it is now possible to produce antibody molecules by recombinant means and thereby generate gene sequences that code for specific amino acid sequences found in the polypeptide structure of the antibodies. Such antibodies can be produced by either cloning the gene sequences encoding the polypeptide chains of said antibodies or by direct synthesis of said polypeptide chains, with *in vitro* assembly of the synthesized chains to form active tetrameric (H₂L₂) structures with affinity for specific epitopes and antigenic determinants. This has permitted the ready production of antibodies having sequences characteristic of neutralizing antibodies from different species and sources.

[0128] Regardless of the source of the antibodies, or how they are recombinantly constructed, or how they are synthesized, *in vitro* or *in vivo*, using transgenic animals, such as cows, goats and sheep, using large cell cultures of laboratory or commercial size, in bioreactors or by direct chemical synthesis employing no living organisms at any stage of the process, all antibodies have a similar overall 3 dimensional structure. This structure is often given as H₂L₂ and refers to the fact that antibodies commonly comprise 2 light (L) amino acid chains and 2 heavy (H) amino acid chains. Both chains have regions capable of interacting with a structurally complementary antigenic target. The regions interacting with the target are referred to as "variable" or "V" regions and are characterized by differences in amino acid sequence from antibodies of different antigenic specificity.

[0129] In preferred embodiments of the disclosures, the PD-1 receptor antagonist polypeptides, including fragments, mutants and other variants, have a first fusion partner having all or a part of a B7-DC protein or variant thereof fused (i) directly to a second polypeptide or, (ii) optionally, fused to a linker peptide sequence that is fused to the second polypeptide. The presence of the fusion partner can alter the solubility, affinity and/or valency of the B7-DC polypeptide. In more preferred embodiments, B7-DC polypeptides are fused to one or more domains of an Ig heavy chain constant region, more preferably an amino acid sequence corresponding to the hinge, C_H2 and C_H3 regions of a human immunoglobulin C_γ1 chain or to the hinge, C_H2 and C_H3 regions of a murine immunoglobulin C_γ2a chain. In a preferred embodiment, the constant region preferably includes a mutation (for example N297Q) to eliminate or reduce Fc receptor binding.

[0130] The hinge, C_H2 and C_H3 regions of a human immunoglobulin C_γ1 chain has the following amino acid sequence:

EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKE	60
NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT	120
ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTFP	180
PVLDSGDSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK	232

(SEQ ID NO:6).

[0131] The hinge, C_H2 and C_H3 regions of a murine immunoglobulin C_γ2a chain has the following amino acid sequence:

EP 2 350 129 B1

EPRGPTIKPC PCKCPAPNL LGGPSVFIFP PKIKDVLMI LSPIVTCVVV DVSEDDPDVQ 60
 ISWFVNNVEV HTAQTQTHRE DYNSTLRVVS ALPIQHODWM SGKEFKCKVN NKDLPAPIER 120
 TISKPKGSVR APQVYVLP PP EEEMTKKQVT LTCMVTDFMP EDIYVEWTNN GKTELNYKNT 180
 5 EPVLSDSGSY FMYSKLRVEK KNWVERNSYS CSVVHEGLHN HHTTKSFSRT PGK 233

(SEQ ID NO:7)

[0132] Exemplary murine B7-DC fusion proteins contain amino acids 20-221 of murine B7-DC fused to amino acids 237-469 of murine IgG2a (CAA49868). Human B7-DC fusion proteins can contain amino acids 20-221 of human B7-DC fused to amino acids 245-476 of human IgG1 (AAA02914). The signal peptides for B7-DC fusion proteins can be the endogenous signal peptides or any other signal peptide that facilitates secretion of the fusion protein from a host.

[0133] A representative murine B7-DC-Ig fusion protein is encoded by the nucleic acid sequence of SEQ ID NO:8.

[0134] It will be appreciated that the disclosed nucleic acid sequences can be codon-optimized to increase levels of expression for synthesizing the fusion proteins useful in the methods and compositions of the present invention. Methods for codon optimization are known in the art.

[0135] The murine B7-DC-Ig fusion protein encoded by SEQ ID NO:8 has the following amino acid sequence:

MLLLLPIILNL SLQLHPVAAL FVTAPKEVY TVDVGSSVSL ECFDRRECT ELEGIRASLQ 60
 KVENDTSLQS ERATLLEEQL PLGKALFHIP SVQVRDSGQY RCLVICGAAW DYKYLTVKVK 120
 ASYMRIDTRI LEVPGTGEVQ LTCQARGYPL AEVSWQNVSV PANTSHIRTP EGLYQVTSVL 180
 RLKPQPSRNF SCMFWNAHMK ELTSAIIDPL SRMEPKVPRT WEPRGPTIKP CPPCKCPAPN 240
 25 LLGGPSVFIF PPKIKDVLMI SLSPIVTCVV VDVSEDDPDV QISWFVNNVE VHHTAQTQTHR 300
 EDYNSTLRVV SALPIQHODW MSGKEFKCKV NNKDLPAPIE RTISKPKGSV RAPQVYVLP 360
 PEEEMTKKQV TLTTCMVTDFM PEDIYVEWTN NGKTELNYKN TEPVLSDSGS YFMYSKLRVE 420
 KKNWVERNSY SCSVVHEGLH NHHTTKSFSR TPGK 454

(SEQ ID NO:9)

[0136] SEQ ID NO:10 provides the amino acid sequence for murine B7-DC-Ig fusion protein without the signal sequence.

LFTVTAPKEV YTVDVGSSVS LECDFDRREC TELEGIRASL QKVENDTSLQ SERATLLEEQ 60
 LPLGKALFHI PSVQVRDSGQ YRCLVICGAA WDKYLTVKVK KASYMRIDTR ILEVPGTGEV 120
 QLTTCQARGYP LAEVSQNVSV VPANTSHIRT PEGLYQVTSV LRLKPQPSRN FSCMFWNAHM 180
 40 KELTSAIIDP LSRMEPKVPR TWEPRGPTIK PCPPCKCPAP NLLGGPSVFI FPPKIKDVLMI 240
 ISLSPIVTCV VDVSEDDPD VQISWFVNNV EVHTAQTQTH REDYNSTLRV VSALPIQHOD 300
 WMSGKEFKCK VNNKDLPAPI ERTISKPKGS VRAPQVYVLP PPEEMTKKQ VTLTCMVTDF 360
 MPEDIYVEWT NNGKTELNYK NTEPVLSDSG SYFMYSKLRV EKKNWVERNS YSCSVVHEGL 420
 45 HNHHTTKSFS RTPGK 435

(SEQ ID NO:10)

[0137] In one embodiment human B7-DC-Ig is encoded by the nucleic acid sequence of SEQ ID NO:11, encoding the amino acid sequence for human B7-DC-Ig:

EP 2 350 129 B1

MIFLLLMLSL ELQLHQIAAL FTVTVPKELY IIEHGSNVT ECFDGTGSHV NLGAITASLQ 60
 KVENDTSPHR ERATLLEEQL PLGKASFHIP QVQVRDEGQY QCIIYGVAV DYKYLTLKVK 120
 ASYRKINTHI LKVPETDEVE LTCQATGYPL AEVSWPNVSV PANTSHSRTP EGLYQVTSVL 180
 5 RLKPPPGRNF SCVFWNTHVR ELTLASIDLQ SQMEPRTHPT WEPKSCDKTH TCPPCPAPEL 240
 LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
 QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS 360
 RDELTKNOVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSGDSF FLYSKLTVDK 420
 10 SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 453
 (SEQ ID NO:12)

[0138] The present invention specifically contemplates embodiments where the mature fusion protein useful in the methods and compositions of the invention have the signal sequence removed. In a preferred embodiment, the signal sequence is completely removed.

[0139] SEQ ID NO:13 provides the amino acid sequence for human B7-DC-Ig without the signal sequence.

LFTVTVPKEL YIIEHGSNVT LECNFDGTGSH VNLGAITASL QKVENDTSPH RERATLLEEQ 60
 LPLGKASFHI PQVQVRDEGQ YQCIIYGVA WDYKYLTLKV KASYRKINTH ILKVPETDEV 120
 ELTCQATGYPL LAEVSWPNVSV VPANTSHSRTP PEGLYQVTSV LRLKPPPGRN FSCVFWNTHV 180
 RELTLASIDL QSQMEPRTHPT TWEPKSCDKT HTCPCCPAPE LLGGPSVFLF PKPKDTLMI 240
 25 SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW 300
 LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SRDELTKNOV SLTCLVKGFY 360
 PSDIAVEWES NGQPENNYKT TPPVLDSGDS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH 420
 NHYTQKSLSL SPGK 434
 30 (SEQ ID NO:13).

[0140] The present disclosures specifically contemplates embodiments where the disclosed B7-DC-Ig fusion proteins used in the methods and compositions disclosed herein have at least about 80%, 85%, 90%, 99% or 100% sequence identity to SEQ ID NO: 9, 10, 12, or 13.

[0141] In another embodiment of the disclosures, the fusion polypeptide may have bi-specific function whereby the first fusion partner binds to a ligand of PD-1, such as B7-H1, and the second fusion partner binds to the PD-1 receptor without triggering inhibitory signal transduction through the PD-1 receptor.

[0142] While a polypeptide useful in the invention may be monomeric or dimeric, the fusion proteins themselves may be present in a monomeric or an oligomeric form, preferably as a dimer. In specific embodiments, the fusion proteins useful as PD-1 antagonists in the compositions of the invention may assemble spontaneously into oligomeric, especially dimeric, forms or may be chemically linked to form such oligomers by means well known in the art. For example, a fusion protein useful in practicing the invention may itself comprise a portion of a B7-DC polypeptide fused to a portion of an antibody and these may be further assembled into a dimer. In one such example, a polypeptide for use in the invention is fused as a single amino acid chain to the Fc region of an antibody (such as where this construct is expressed from a single recombinant polynucleotide), after which two such fusion products are linked to each other to form a homodimer, such as by a disulfide linkage between the respective Fc regions.

[0143] Such dimeric products may be homodimers (where both monomeric fusion proteins are identical) or may be heterodimers (where two different fusion proteins are linked to each other). The individual monomers of such dimers may be linked by any means known in the art, such as by covalent linkage (e.g., a disulfide bond) or by noncovalent linkage (such as an ionic interaction). The B7-DC-Ig used in the examples of the invention were present in the form of a homodimer having 2 copies of SEQ ID NO: 10 linked together by a disulfide linkage. In addition, the heterodimers of the invention include bispecific proteins and fusion proteins wherein one monomeric portion binds to PD-1 and the other binds to a natural ligand of PD-1. Such heterodimers are formed by coupling of polypeptides and fusion proteins fully described elsewhere herein.

[0144] In another useful embodiment of the invention, the PD-1 antagonist fusion protein is a heterodimer, such as where two fusion proteins are linked together but they are not of identical amino acid sequence. In a specific example, each monomer may comprise an Fc portion of an antibody linked to an active fragment of a B7-DC polypeptide where

these active fragments are from different portions of the B7-DC polypeptide or where a fusion protein comprising an Fc portion of an antibody fused to a full length native B7-DC polypeptide is linked (for example, cross-linked) to a fusion protein comprising an Fc portion of an antibody and an active fragment of a full length native B7-DC polypeptide. In each such case, the portion of the antibody used in forming each monomeric fusion protein may be different between the two monomeric units. Any such dimeric combination is specifically contemplated by the methods and compositions of the invention.

[0145] In a preferred dimeric fusion protein, the dimer results from the covalent bonding of Cys residue in the CH regions of two of the Ig heavy chains that are the same Cys residues that are disulfide linked in dimerized normal Ig heavy chains.

[0146] Still another embodiment provides a tetramer construct having a BirA substrate fused to the extracellular domain of a variant B7-DC polypeptide. Methods for making tetramer constructs are known in the art (see Pertovas, et al., J. Exp. Med., 203:2281 (2006)).

7. Anti-PD-1 and Other Antibodies

[0147] Other PD-1 antagonists contemplated by the methods of the disclosures include antibodies that bind to PD-1 or ligands of PD-1, and other antibodies.

[0148] In one aspect, the present disclosures relate to a method of increasing a T cell response in a mammal in need thereof, comprising administering to said mammal an effective treatment regimen comprising an anti-PD-1 antibody and a potentiating agent, wherein said treatment regimen is effective to increase the T cell response of said mammal to said antigen.

[0149] Anti-PD-1 antibodies useful in the treatment regimens(s) of the disclosures include, but are not limited to, those described in the following publications:

- PCT/IL03/00425 (Hardy et al., WO/2003/099196)
- PCT/JP2006/309606 (Korman et al., WO/2006/121168)
- PCT/US2008/008925 (Li et al., WO/2009/014708)
- PCT/JP03/08420 (Honjo et al., WO/2004/004771)
- PCT/JP04/00549 (Honjo et al., WO/2004/072286)
- PCT/IB2003/006304 (Collins et al., WO/2004/056875)
- PCT/US2007/088851 (Ahmed et al., WO/2008/083174)
- PCT/US2006/026046 (Korman et al., WO/2007/005874)
- PCT/US2008/084923 (Terrett et al., WO/2009/073533)
- Berger et al., Clin. Cancer Res., Vol. 14, pp. 30443051 (2008).

[0150] A specific example of an anti-PD-1 antibody useful in the methods of the disclosures is MDX-1106 (see Kosak, US 20070166281 (pub. 19 July 2007) at par. 42), a human anti-PD-1 antibody, preferably administered at a dose of 3 mg/kg.

[0151] In another aspect, the present disclosures relate to a method of increasing a T cell response in a mammal in need thereof, comprising administering to said mammal an effective treatment regimen comprising an anti-PD-1 ligand antibody, an anti-B7-H1 antibody for example, and a potentiating agent, wherein said treatment regimen is effective to increase the T cell response of said mammal to said antigen.

[0152] Anti-B7-H1 antibodies useful in the treatment regimens(s) of the disclosures include, but are not limited to, those described in the following publications:

- PCT/US06/022423 (WO/2006/133396, pub. 14 December 2006)
- PCT/US07/088851 (WO/2008/083174, pub. 10 July 2008)
- US 2006/0110383 (pub. 25 May 2006)

[0153] A specific example of an anti-B7-H1 antibody useful in the methods of the disclosures is MDX-1105 (WO/2007/005874, published 11 January 2007), a human anti-B7-H1 antibody. For anti-B7-DC antibodies see 7,411,051, 7,052,694, 7,390,888, 20060099203

[0154] Another embodiment of the disclosures includes a bi-specific antibody that comprises an antibody that binds to the PD-1 receptor bridged to an antibody that binds to a ligand of PD-1, such as B7-H1. In a preferred embodiment of the disclosures, the PD-1 binding portion reduces or inhibits signal transduction through the PD-1 receptor.

[0155] The antibody for use in the disclosures need not be an anti-PD-1 or anti-PD-1 ligand antibody but may be another antibody useful in mediating the effects of T cells in an immune response. In this aspect, the present disclosures relate to a method of increasing a T cell response to an antigen in a mammal in need thereof, comprising administering

to said mammal an effective treatment regimen comprising an anti-CTLA4 antibody and a potentiating agent, wherein said treatment regimen is effective to increase the T cell response of said mammal to said antigen. An example of an anti-CTLA4 antibody contemplated for use in the methods of the disclosures include an antibody as described in PCT/US2006/043690 (Fischkoff et al., WO/2007/056539).

5 **[0156]** Specific examples of an anti-CTLA4 antibody useful in the methods of the disclosures are Ipilimumab, also known as MDX-010 or MDX-101, a human anti-CTLA4 antibody, preferably administered at a dose of 10 mg/kg, and Tremelimumab a human anti-CTLA4 antibody, preferably administered at a dose of 15 mg/kg.

8. Small Molecule PD-1 Antagonists

10 **[0157]** The PD-1 receptor antagonists can also be small molecule antagonists. The term "small molecule" refers to small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons, preferably between 100 and 2000, more preferably between about 100 and about 1250, more preferably between about 100 and about 1000, more preferably between about 100 and about 750, more preferably between about 200 and about 500 daltons. The small molecules often include cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more functional groups. The small molecule antagonists reduce or interfere with PD-1 receptor signal transduction by binding to ligands of PD-1 such as B7-H1 and B7-DC and preventing the ligand from interacting with PD-1 or by binding directly to and blocking the PD-1 receptor without triggering signal transduction through the PD-1 receptor.

15 **[0158]** In one embodiment of the disclosures, such a small molecule may be administered in combination with another PD-1 antagonist or CTLA4 antagonist, such as an antibody specific for PD-1 or one of its ligands or an antibody specific for CTLA4 or one of its ligands. Thus, such small molecules may be administered as compounds in one or more of the methods of the disclosures or may be administered in combination with other compounds useful in the methods of the disclosures. For example, a series of small organic compounds have been shown to bind to the B7-1 ligand to prevent binding to CTLA4 (see Erbe et al., J. Biol. Chem., Vol. 277, pp. 7363-7368 (2002)). Such small organics could be administered alone or together with an anti-CTLA4 antibody, in combination with CTX administration, to reduce inhibitory signal transduction of T cells.

20 **[0159]** In one embodiment of the disclosures, PD-1 antagonists or CTLA4 antagonists contemplated for use in the methods of the invention include anti-sense nucleic acids, both DNA and RNA, as well as siRNA molecules. Such anti-sense molecules prevent-expression of PD-1 on T cells as well as production of T cell ligands, such as B7-H1, PD-L1 and PD-L2. For example, siRNA (for example, of about 21 nucleotides in length, which is specific for the gene encoding PD-1, or encoding a PD-1 ligand, and which oligonucleotides can be readily purchased commercially) complexed with carriers, such as polyethyleneimine (see Cubillos-Ruiz et al., J. Clin. Invest. 119(8): 2231-2244 (2009)), are readily taken up by cells that express PD-1 as well as ligands of PD-1 and reduce expression of these receptors and ligands to achieve a decrease in inhibitory signal transduction in T cells, thereby activating T cells.

B. POTENTIATING AGENTS

30 **[0160]** In accordance with the disclosures, the activity of the PD-1 antagonist is increased, preferably synergistically, by the presence of a potentiating agent. The potentiating agent acts to increase the efficacy of the PD-1 receptor antagonist, possibly by more than one mechanism, although the precise mechanism of action is not essential to the broad practice of the present invention.

35 **[0161]** In the preferred embodiment, the potentiating agent is cyclophosphamide. Cyclophosphamide (CTX, Cytoxan[®], or Neosar[®]) is an oxazaphosphorine drug and analogs include ifosfamide (IFO, Ifex), perfosfamide, trophosphamide (trofosfamide; Ixoten), and pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof (US patent application 20070202077). Ifosfamide (MITOXANA[®]) is a structural analog of cyclophosphamide and its mechanism of action is considered to be identical or substantially similar to that of cyclophosphamide. Perfosfamide (4-hydroperoxy-cyclophosphamide) and trophosphamide are also alkylating agents, which are structurally related to cyclophosphamide. For example, perfosfamide alkylates DNA, thereby inhibiting DNA replication and RNA and protein synthesis. New oxazaphosphorines derivatives have been designed and evaluated with an attempt to improve the selectivity and response with reduced host toxicity (Liang J, Huang M, Duan W, Yu XQ, Zhou S. Design of new oxazaphosphorine anticancer drugs. Curr Pharm Des. 2007;13(9):963-78. Review). These include mafosfamide (NSC 345842), glufosfamide (D19575, beta-D-glucosylisophosphoramidate mustard), S-(-)-bromofosfamide (CBM-11), NSC 612567 (aldophosphamide perhydrothiazine) and NSC 613060 (aldophosphamide thiazolidine). Mafosfamide is an oxazaphosphorine analog that is a chemically stable 4-thioethane sulfonic acid salt of 4-hydroxy-CPA. Glufosfamide is IFO derivative in which the isophosphoramidate mustard, the alkylating metabolite of IFO, is glycosidically linked to a beta-D-glucose molecule. Additional cyclophosphamide analogs are described in US patent 5,190,929 entitled "Cyclophosphamide analogs useful as anti-tumor agents".

[0162] In other embodiments of the disclosures, the potentiating agent is an agent that reduces activity and/or number of regulatory T lymphocytes (T-regs), preferably, as claimed, Sunitinib (SUTENT®), anti-TGF β or Imatinib (GLEEVAC®). The recited treatment regimen may also include administering an adjuvant.

[0163] Useful potentiating agents also include mitosis inhibitors, such as paclitaxol, aromatase inhibitors (e.g. Letrozole) and angiogenesis inhibitors (VEGF inhibitors e.g. Avastin, VEGF-Trap) (see, for example, Li et al., Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006 Nov 15;12(22)6808-16.), TLR4 antagonists, and IL-18 antagonists, or as claimed herein anthracyclines, oxaliplatin, doxorubicin .

C. PHARMACEUTICAL COMPOSITIONS

[0164] In one aspect, the disclosures relate to a therapeutic composition, comprising a molecule that prevents inhibitory signal transduction through PD-1, or a CTLA4 antagonist, and a potentiating agent in a pharmaceutically acceptable carrier. The components of said composition are present in an amount effective to increase a T cell response in a mammal. In specific embodiments of the disclosures, the potentiating agent is cyclophosphamide or an analog of cyclophosphamide, examples of such analogs having been recited above.

[0165] In other specific examples, the potentiating agent is an agent that reduces activity of regulatory T lymphocytes (T-regs), preferably where the activity is reduced due to a decrease in the number of said T-regs. In preferred non-limiting embodiments, the agent is Sunitinib (SUTENT®), anti-TGF β or Imatinib (GLEEVAC®).

[0166] The potentiating agent useful in formulating compositions of the disclosures also include mitosis inhibitors, such as paclitaxol, aromatase inhibitors (e.g. Letrozole), angiogenesis inhibitors (VEGF inhibitors e.g. Avastin, VEGF-Trap), anthracyclines, oxaliplatin, doxorubicin, TLR4 antagonists, and IL-18 antagonists.

[0167] A therapeutic composition of the invention also optionally comprises at least one additional agent that may be one or more of an anti-PD-1 antibody, an anti-CTLA4 antibody, a mitosis inhibitor, an aromatase inhibitor, an A2a adenosine receptor (A2AR) antagonist, or an angiogenesis inhibitor.

[0168] Any of the therapeutic compositions of the invention may also contain one or more adjuvants as described herein.

[0169] A PD-1 antagonist useful as a component of a therapeutic composition of the disclosures include any of the PD-1 antagonists recited herein for use in any of the methods of the disclosures. For example, such PD-1 antagonist includes any of the fusion proteins recited herein. Such antagonist can also be any of the polypeptides or PD-1 binding fragments recited herein for use as the first polypeptide portion of any of the fusion proteins described for use in any of the methods of the disclosures. Such antagonist can further be an antibody, such as any of the known anti-PD-1, -B7-DC or -B7-H1 antibodies mentioned herein.

[0170] A therapeutic composition of the disclosures also includes, in addition to or in place of the aforementioned PD-1 antagonist, an anti-CTLA4 antibody. Such a composition would therefore contain such an anti-CTLA4 antibody and a potentiating agent of the kind already described herein.

[0171] A therapeutic composition of the disclosures finds use in any of the methods of the disclosures herein. Such composition, while intended for use as an active treatment of a disease condition, may also find use as prophylactic compositions to prevent any of the diseases recited herein.

[0172] In one aspect, the present disclosures contemplate a therapeutic composition comprising a PD-1 antagonist and a potentiating agent in a pharmaceutically acceptable carrier, wherein the PD-1 antagonist and the potentiating agent are together present in an amount effective to increase a T cell response in a mammal.

[0173] Therapeutic compositions within the scope of the disclosures include compositions comprising any and all combinations of the PD-1 antagonists and/or antibodies disclosed herein with any of the recited potentiating agents. By way of non-limiting examples, a therapeutic composition of the disclosures includes a composition comprising an effective amount of one or more PD-1 antagonists, such as a combination of any or all of the full length polypeptides enumerated herein as specific SEQ ID NOs. or homologs thereof together with one or more fragments of any of said polypeptides, including where any or all of these are fused to other proteins, such as being fused to one or more immunoglobulins recited herein, or not so fused, and comprising one or more potentiating agents, such as cyclophosphamide alone, or cyclophosphamide plus one or more analogs thereof, of just one or more analogs of cyclophosphamide, or the potentiating agent may consist of cyclophosphamide and an agent that reduces T reg number in a mammal receiving the composition, or may consist of a cyclophosphamide analog plus an agent that reduces T reg number or the potentiating agent may consist only of one or more agents that reduce T reg number or other Treg activity. All such combinations are contemplated by the disclosures so long as the composition comprises at least one PD-1 antagonist and/or antibody mediating T cell activity and at least one potentiating agent.

[0174] The compositions of the invention may also include additional active agents. In preferred embodiments of any of the compositions of the invention, the pharmaceutical or therapeutic composition further comprises at least one additional agent selected from the group consisting of an anti-PD-1 antibody, an anti-CTLA4 antibody, a mitosis inhibitor, such as paclitaxel, an aromatase inhibitor, such as letrozole, an A2AR antagonist, an angiogenesis inhibitor, anthracy-

clines, oxaliplatin, doxorubicin, TLR4 antagonists, and IL-18 antagonists.

[0175] The PD-1 antagonist and/or potentiating agent may be administered by any suitable means. In a preferred embodiment, the PD-1 antagonist and/or potentiating agent is administered in an aqueous solution, by parenteral injection. The formulation may also be in the form of a suspension or emulsion. In general, pharmaceutical compositions are provided including effective amounts of a peptide or polypeptide, and optionally include pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents sterile water, buffered saline of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; and optionally, additives such as detergents and solubilizing agents (e.g., TWEEN 20, TWEEN 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), and preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. The formulations may be lyophilized and redissolved/resuspended immediately before use. The formulation may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.

[0176] Pharmaceutical compositions of the invention may be administered by parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection), transdermal (either passively or using iontophoresis or electroporation), or transmucosal (nasal, vaginal, rectal, or sublingual) routes of administration. The methods of administering the compositions of the invention do not preclude administering the PD-1 antagonist and the potentiating agent by separate and different routes (e.g. topically).

[0177] The PD-1 antagonist and the potentiating agent may be administered at the same time, or at different times, with the potentiating agent being administered before or after the PD-1 antagonist. In one embodiment of the disclosures, a potentiating agent is administered both before and after the PD-1 antagonist. In one such embodiment, the same potentiating agent is administered before and after the PD-1 antagonist. In another embodiment, the potentiating agent administered before the PD-1 antagonist.

[0178] As used herein the term "effective amount" or "therapeutically effective amount" means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms of the disorder being treated or to otherwise provide a desired pharmacologic and/or physiologic effect. The precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being effected. Therapeutically effective amounts of PD-1 receptor antagonists and/or antibodies together with a potentiating agents cause an immune response to be activated or sustained.

[0179] The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment desired. Generally dosage levels of 0.001 to 50 mg/kg of body weight daily are administered to mammals. Preferably, said dose is 1 to 50 mg/kg, more preferably 1 to 40 mg/kg, or even 1 to 30 mg/kg, with a dose of 2 to 20 mg/kg being also a preferred dose. Examples of other dosages include 2 to 15 mg/kg, or 2 to 10 mg/kg or even 3 to 5 mg/kg, with a dose of about 4 mg/kg being a specific example.

[0180] For treatment regimens using a potentiating agent and an antibody, such as an anti-PD-1 antibody or an anti-CTLA4 antibody, dosages are commonly in the range of 0.1 to 100 mg/kg, with shorter ranges of 1 to 50 mg/kg preferred and ranges of 10 to 20 mg/kg being more preferred. An appropriate dose for a human subject is between 5 and 15 mg/kg, with 10 mg/kg of antibody (for example, human anti-PD-1 antibody, like MDX-1106) most preferred (plus a suitable dose of cyclophosphamide or other potentiating agent given up to about 24 hours before the antibody).

[0181] In general, by way of example only, dosage forms based on body weight for any of the signal transduction antagonists useful in the methods of the invention include doses in the range of 5-300 mg/kg, or 5-290 mg/kg, or 5-280 mg/kg, or 5-270 mg/kg, or 5-260 mg/kg, or 5-250 mg/kg, or 5-240 mg/kg, or 5-230 mg/kg, or 5-220 mg/kg, or 5-210 mg/kg, or 20 to 180 mg/kg, or 30 to 170 mg/kg, or 40 to 160 mg/kg, or 50 to 150 mg/kg, or 60 to 140 mg/kg, or 70 to 130 mg/kg, or 80 to 120 mg/kg, or 90 to 110 mg/kg, or 95 to 105 mg/kg, with doses of 3 mg/kg, 5 mg/kg, 7 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 50 mg/kg and 100 mg/kg being specific examples of preferred doses. Such doses may, of course, be repeated. The dose will, of course, be correlated with the identity of the mammal receiving said dose. Doses in the above-recited mg/kg ranges are convenient for mammals, including rodents, such as mice and rats, and primates, especially humans, with doses of about 5 mg/kg, about 10 mg/kg and about 15 mg/kg being especially preferred for treating humans.

[0182] In accordance with the treatment regimen of the invention, the potentiating agent, for example cyclophosphamide, is administered in non-toxic doses that vary depending on the animal. In specific embodiments, the potentiating agent is administered by any suitable means of administration, including parenteral or oral, the former including system administration, such as intravenous. For example, a potentiating agent like cyclophosphamide is normally administered orally. Such administration may be at any convenient dosage, depending on the potentiating agent. The dosage in each case may be based on body weight or may be administered as a unit dosage.

[0183] While CTX itself is nontoxic, some of its metabolites are cytotoxic alkylating agents that induce DNA crosslinking and, at higher doses, strand breaks. Many cells are resistant to CTX because they express high levels of the detoxifying

enzyme aldehyde dehydrogenase (ALDH). CTX targets proliferating lymphocytes, as lymphocytes (but not hematopoietic stem cells) express only low levels of ALDH, and cycling cells are most sensitive to DNA alkylation agents.

[0184] Low doses of CTX (< 200 mg/kg) can have immune stimulatory effects, including stimulation of anti-tumor immune responses in humans and mouse models of cancer (Brode & Cooke Crit Rev. Immunol. 28:109-126 (2008)).

5 These low doses are sub-therapeutic and do not have a direct anti-tumor activity. In contrast, high doses of CTX inhibit the anti-tumor response. Several mechanisms may explain the role of CTX in potentiation of anti-tumor immune response: (a) depletion of CD4+CD25+FoxP3+ Treg (and specifically proliferating Treg, which may be especially suppressive), (b) depletion of B lymphocytes; (c) induction of nitric oxide (NO), resulting in suppression of tumor cell growth; (d) mobilization and expansion of CD11b+Gr-1+ MDSC. These primary effects have numerous secondary effects; for example following
10 Treg depletion macrophages produce more IFN- γ and less IL-10. CTX has also been shown to induce type I IFN expression and promote homeostatic proliferation of lymphocytes.

[0185] Treg depletion is most often cited as the mechanism by which CTX potentiates the anti-tumor immune response. This conclusion is based in part by the results of adoptive transfer experiments. In the AB1-HA tumor model, CTX treatment at Day 9 gives a 75% cure rate. Transfer of purified Treg at Day 12 almost completely inhibited the CTX
15 response (van der Most et al. Cancer Immunol. Immunother. 58:1219-1228 (2009)). A similar result was observed in the HHD2 tumor model: adoptive transfer of CD4+CD25+ Treg after CTX pretreatment eliminated therapeutic response to vaccine (Taieb, J. J. Immunol. 176:2722-2729 (2006)).

[0186] Numerous human clinical trials have demonstrated that low dose CTX is a safe, well-tolerated, and effective agent for promoting anti-tumor immune responses (Bas, & Mastrangelo Cancer Immunol. Immunother. 47:1-12 (1998)).

20 **[0187]** The optimal dose for CTX to potentiate an anti-tumor immune response, is one that lowers overall T cell counts by lowering Treg levels below the normal range but is subtherapeutic (see Machiels et al. Cancer Res. 61:3689-3697 (2001)).

[0188] In human clinical trials where CTX has been used as an immunopotentiating agent, a dose of 300 mg/m² has usually been used. For an average male (6 ft, 170 pound (78 kg) with a body surface area of 1.98 m²), 300 mg/m² is 8
25 mg/kg, or 624 mg of total protein. In mouse models of cancer, efficacy has been seen at doses ranging from 15 - 150 mg/kg, which relates to 0.45 - 4.5 mg of total protein in a 30g mouse (Machiels et al. Cancer Res. 61:3689-3697 (2001), Hengst et al Cancer Res. 41:2163-2167 (1981), Hengst Cancer Res. 40:2135-2141 (1980)).

[0189] For larger mammals, such as a primate, preferably human, patient, such mg/m² doses may be used but unit doses administered over a finite time interval may be preferred. Such unit doses may be administered on a daily basis
30 for a finite time period, such as up to 3 days, or up to 5 days, or up to 7 days, or up to 10 days, or up to 15 days or up to 20 days or up to 25 days, are all specifically contemplated by the invention. The same regimen may be applied for the other potentiating agents recited herein.

[0190] All such administrations disclosed herein but not claimed may occur before or after administration of a PD-1 binding molecule of the invention. Alternatively, administration of one or more doses of a PD-1 binding molecule of the
35 invention may be temporally staggered with the administration of potentiating agent to form a uniform or non-uniform course of treatment whereby one or more doses of potentiating agent are administered, followed by one or more doses of a PD-1 binding compound, followed by one or more doses of potentiating agent, all according to whatever schedule is selected or desired by the researcher or clinician administering said agents.

[0191] In other specific embodiments, the treatment regimen includes multiple administrations of one or more PD-1 antagonists. In some embodiments, such multiple administrations of PD-1 antagonists are in conjunction with multiple
40 administrations of the same or different potentiating agents.

[0192] As in other embodiments of the invention, here the potentiating agent is administered at least 1, 2, 3, 5, 10, 15, 20, 24 or 30 hours prior to administering of the PD-1-antagonist.

[0193] The pharmaceutical compositions useful herein also contain a pharmaceutically acceptable carrier, including any suitable diluent or excipient, which includes any pharmaceutical agent that does not itself induce the production of
45 antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Pharmaceutically acceptable carriers include, but are not limited to, liquids such as water, saline, glycerol and ethanol, and the like, including carriers useful in forming sprays for nasal and other respiratory tract delivery or for delivery to the ophthalmic system. A thorough discussion of pharmaceutically acceptable carriers, diluents, and other excipients is presented in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. current edition).

50 **[0194]** Vaccine compositions (as discussed below) may further incorporate additional substances to stabilize pH, or to function as adjuvants, wetting agents, or emulsifying agents, which can serve to improve the effectiveness of the vaccine.

[0195] Vaccines are generally formulated for parenteral administration and are injected either subcutaneously or
55 intramuscularly. Such vaccines can also be formulated as suppositories or for oral administration, using methods known in the art, or for administration through nasal or respiratory routes.

D. METHODS OF MANUFACTURE

[0196] Isolated PD-1 antagonist polypeptides, including variants, homologs and fragments thereof, either wild-type or mutated, and fusion proteins comprising any of these, all contemplated for use in the invention, can be obtained by, for example, chemical synthesis or by recombinant production in a host cell. To recombinantly produce a costimulatory polypeptide, a nucleic acid containing a nucleotide sequence encoding the polypeptide can be used to transform, transduce, or transfect a bacterial or eukaryotic host cell (e.g., an insect, yeast, or mammalian cell). It will be appreciated that the nucleotide sequences can be codon-optimized to increase levels of protein expression in a particular kind of host cell. Methods for codon optimization are well known in the art. In general, nucleic acid constructs include a regulatory sequence operably linked to a nucleotide sequence encoding a costimulatory polypeptide. Regulatory sequences (also referred to herein as expression control sequences) typically do not encode a gene product, but instead affect the expression of the nucleic acid sequences to which they are operably linked. The signal peptides used to secrete proteins from a cell can be the endogenous signal peptides or any other signal peptide that facilitates secretion of the fusion protein from a host.

[0197] For general molecular biology procedures useful in practicing the present disclosures, a number of standard references are available that contain procedures well known in the art of molecular biology and genetic engineering and which procedures need not be further described herein. Useful references include Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, N.Y., (1989), Wu et al, *Methods in Gene Biotechnology* (CRC Press, New York, NY, 1997), and *Recombinant Gene Expression Protocols*, in *Methods in Molecular Biology*, Vol. 62, (Tuan, ed., Humana Press, Totowa, NJ, 1997).

E. DISEASE TREATMENT

[0198] Diseases to be treated or prevented by administering a therapeutic combination provided by the present disclosures include a malignant tumor or a chronic infectious disease caused by a bacterium, virus, protozoan, helminth, or other microbial pathogen that enters intracellularly. Such diseases are often combatted through attack by cytotoxic T lymphocytes. Because the present invention provides combination therapies useful in enhancing T cell responses, through increased T cell activity, increased T cell proliferation and reduced T cell inhibitory signals, the combination therapies of the invention have unique advantage in treating (or even preventing) such diseases.

[0199] In one embodiment, because viral infections are cleared primarily by T-cells, an increase in T-cell activity is therapeutically useful in enhancing clearance of an infective viral agent from a human. Thus, the disclosed compounds of the invention, with PD-1 receptor antagonist activity, together with a potentiating agent work in combination for the treatment of local or systemic viral infections. Infections that are to be treated by the compounds of the invention include, but are not limited to, immunodeficiency (e.g., HIV), papilloma (e.g., HPV), herpes (e.g., HSV), encephalitis, influenza (e.g., human influenza virus A), hepatitis (e.g. HCV, HBV), and common cold (e.g., human rhinovirus) viral infections. Pharmaceutical formulations of PD-1 receptor antagonists compositions can also be administered to treat systemic viral diseases, including, but not limited to, AIDS, influenza, the common cold, or encephalitis.

[0200] Non-viral infections treatable by the compounds of the invention include, but are not limited to, infections cause by microorganisms including, but not limited to, *Actinomyces*, *Anabaena*, *Bacillus*, *Bacteroides*, *Bdellovibrio*, *Bordetella*, *Borrelia*, *Campylobacter*, *Caulobacter*, *Chlamydia*, *Chlorobium*, *Chromatium*, *Clostridium*, *Corynebacterium*, *Cytophaga*, *Deinococcus*, *Escherichia*, *Francisella*, *Halobacterium*, *Heliobacter*, *Haemophilus*, *Hemophilus influenza type B (HIB)*, *Hyphomicrobium*, *Legionella*, *Leptspirois*, *Listeria*, *Meningococcus A, B and C*, *Methanobacterium*, *Micrococcus*, *Mycobacterium*, *Mycoplasma*, *Myxococcus*, *Neisseria*, *Nitrobacter*, *Oscillatoria*, *Prochloron*, *Proteus*, *Pseudomonas*, *Phodospirillum*, *Rickettsia*, *Salmonella*, *Shigella*, *Spirillum*, *Spirochaeta*, *Staphylococcus*, *Streptococcus*, *Streptomyces*, *Sulfolobus*, *Thermoplasma*, *Thiobacillus*, *Treponema*, *Vibrio*, *Yersinia*, *Cryptococcus neoformans*, *Histoplasma sp. (such as Histoplasma capsulatum)*, *Candida albicans*, *Candida tropicalis*, *Nocardia asteroides*, *Rickettsia rickettsii*, *Rickettsia typhi*, *Leishmania*, *Mycoplasma pneumoniae*, *Chlamydial psittaci*, *Chlamydial trachomatis*, *Plasmodium sp. (such as Plasmodium falciparum)*, *Trypanosoma brucei*, *Entamoeba histolytica*, *Toxoplasma gondii*, *Trichomonas vaginalis* and *Schistosoma mansoni*.

[0201] In one embodiment, the present invention provides compositions for inducing or enhancing an immune response in a human host for treating cancer by increasing a T cell response. The types of cancer that may be treated with the provided compositions and methods include, but are not limited to, the following: bladder, brain, breast, cervical, colorectal, esophageal, kidney, liver, lung, nasopharyngeal, pancreatic, prostate, skin, stomach, uterine, ovarian testicular, and hematologic cancer.

[0202] Malignant tumors which may be treated are classified herein according to the embryonic origin of the tissue from which the tumor is derived. Carcinomas are tumors arising from endodermal or ectodermal tissues such as skin or the epithelial lining of internal organs and glands. Sarcomas, which arise less frequently, are derived from mesodermal connective tissues such as bone, fat, and cartilage. The leukemias and lymphomas are malignant tumors of hematopoietic

cells of the bone marrow. Leukemias proliferate as single cells, whereas lymphomas tend to grow as tumor masses. Malignant tumors may show up at numerous organs or tissues of the body to establish a cancer.

[0203] As a demonstration of the value of the treatment regimens of the disclosures, the murine analog of B7-DC-Ig (in which the mouse B7-DC ECD, which shares 72% sequence identity with the human protein, is fused to the Fc domain of mouse IgG_{2a}) tested in syngeneic mouse tumor models for colon cancer, mastocytoma, and other tumor types incorporating a cyclophosphamide (CTX) pre-treatment as described herein.

[0204] The results showed that treatment with a single subtherapeutic dose of CTX, which acts as an immunopotentiating agent, followed by murine B7-DC-Ig eradicates established CT26 colon carcinoma tumors in upto 80% of the animals. Further, in CT26 colon carcinoma tumor re-challenge studies, no tumor re-growth was detected in mice that had previously eradicated tumor following CTX + murine B7-DC-Ig treatment. These mice were also shown to have an increased tumor-specific CTL population relative to naïve mice.

[0205] In one embodiment, the present disclosures contemplate use of a compound that reduces inhibitory signal transduction in a T cell, as described elsewhere herein, in the manufacture of a medicament for increasing a T cell response by combination therapy wherein said compound is administered in conjunction with a potentiating agent. Further, the compound that reduces inhibitory signal transduction in a T cell and said potentiating agent are provided as separate medicaments for administration at different times, preferably where the potentiating agent is administered prior to the compound that reduces inhibitory signal transduction, for example, up to 24 hours prior to the inhibitory compound (or other time intervals recited herein). Preferably, the compound and potentiating agent are for use in the treatment of an infectious disease or cancer, including diseases caused by any of the infectious agents or cancers recited elsewhere herein.

[0206] In a preferred embodiment, a compound useful in these compositions is a recombinant protein composed of the ECD of human B7-DC fused to the Fc domain of human IgG₁, referred to herein as B7-DC-Ig.

[0207] In one embodiment, the present invention relates to a medical kit for administering a compound that reduces inhibitory signal transduction in a T cell, as disclosed herein, in combination with a potentiating agent, said kit comprising:

- (a) a dosage supply of a compound that reduces inhibitory signal transduction in a T cell,
- (b) a supply of a potentiating agent;
- (c) a supply of pharmaceutically acceptable carrier; and
- (d) printed instructions for administering the compound in a use as described above.

F. COMBINATION THERAPIES

[0208] Vaccines require strong T cell response to eliminate cancer cells and infected cells or infectious agents. PD-1 receptor antagonists described herein can be administered as a component of a vaccine, along with a potentiating agent, to provide a costimulatory signal to T cells. Vaccines disclosed herein include antigens, a PD-1 receptor antagonist and optionally adjuvants and targeting molecules.

[0209] The antigens against which the T cell response is enhanced by the composition of the invention includes peptides, proteins, polysaccharides, saccharides, lipids, nucleic acids, or combinations thereof. The antigens, in the case of disease, are present due to the disease process.

[0210] The disclosed PD-1 receptor antagonists fusion protein compositions may be administered in conjunction with prophylactic vaccines, which confer resistance in a subject to subsequent exposure to infectious agents, or in conjunction with therapeutic vaccines, which can be used to initiate or enhance a subject's immune response to a pre-existing antigen, such as a tumor antigen in a subject with cancer, or a viral antigen in a subject infected with a virus.

[0211] The desired outcome of a prophylactic, therapeutic or de-sensitized immune response may vary according to the disease, based on principles well known in the art. For example, an immune response against an infectious agent may completely prevent colonization and replication of an infectious agent, affecting "sterile immunity" and the absence of any disease symptoms. However, a vaccine against infectious agents may be considered effective if it reduces the number, severity or duration of symptoms; if it reduces the number of individuals in a population with symptoms; or reduces the transmission of an infectious agent. Similarly, immune responses against cancer, allergens or infectious agents may completely treat a disease, may alleviate symptoms, or may be one facet in an overall therapeutic intervention against a disease. For example, the stimulation of an immune response against a cancer may be coupled with surgical, chemotherapeutic, radiologic, hormonal and other immunologic approaches in order to affect treatment.

[0212] The products of the invention do not preclude use of an adjuvant in addition to the potentiating agent. Such adjuvant may be administered, for example, along with the PD-1 antagonist. The adjuvants useful in the compositions and methods of the invention include, but are not limited to, one or more of the following: oil emulsions (e.g., Freund's adjuvant); saponin formulations; virosomes and viral-like particles; bacterial and microbial derivatives; immunostimulatory oligonucleotides; ADP-ribosylating toxins and detoxified derivatives; alum; BCG; mineral-containing compositions (e.g., mineral salts, such as aluminium salts and calcium salts, hydroxides, phosphates, sulfates, etc.); bioadhesives and/or

mucoadhesives; microparticles; liposomes; polyoxyethylene ether and polyoxyethylene ester formulations; muramyl peptides; polyphosphazene; imidazoquinolone compounds; and surface active substances (e.g. lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Useful adjuvants also include immunomodulators such as cytokines, interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g.,

5

interferon- γ), macrophage colony stimulating factor, and tumor necrosis factor.
[0213] Nothing herein precludes the disclosed PD-1 receptor antagonist, including any of the polypeptides, fragments, variants, homologs and fusion proteins disclosed herein, from being administered to a subject in need thereof in combination with one or more additional therapeutic agents (in addition to the potentiating agent). The additional therapeutic agents are selected based on the condition, disorder or disease to be treated. For example, PD-1 receptor antagonists

10

can be co-administered with one or more additional agents that function to enhance or promote an immune response, and which are considered herein as active agents.

[0214] Such agents include, but are not limited to, amsacrine, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, crisantaspase, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxycarbamide, idarubicin, ifosfamide, irinotecan, leucovorin, liposomal doxorubicin, liposomal daunorubicin, lomustine, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, pentostatin, procarbazine, raltitrexed, satraplatin, streptozocin, tegafur-uracil, temozolomide, teniposide, thiotepa, tioguanine, topotecan, treosulfan, vinblastine, vincristine, vindesine, vinorelbine, or a combination thereof. Representative proapoptotic agents include, but are not limited to fludarabinetaurosporine, cycloheximide, actinomycin D, lactosylceramide, 15d-PGJ(2) and combinations thereof.

15

20

[0215] The therapies provided by the methods and compositions of the present invention may also be used in conjunction with other types of therapies, such as radiation treatments, surgery, and the like.

G. ASSAYS FOR ANTAGONIST ACTIVITY

25

[0216] The present disclosures recites a number specific structures useful in practicing the methods of the disclosures. Other compounds possessing antagonist activity and being useful in the methods of the disclosures may also be identified by reference to well known assay procedures for identifying chemical structures that bind to PD-1, CTLA4, and ligands of any of these and that also possess the ability to reduce inhibitory signal transduction in T cells. Some such assays are binding assays useful in determining if a selected chemical structure binds to receptors; these are well known in the art and need not be discussed in detail herein (see, for example, U.S. 2008/0274490, (pub. 6 November 2008) and U.S. 7,105,328 (issued 12 September 2006), each showing assays for PD-1 signaling modulators using T cells) the disclosures. Other assays are used to determine the effects of agents of the invention, such as active fragments, to activate T cells by increasing proliferation and/or production of cytokines. Such assays are also well known in the art. For example, increased proliferation of cells can be demonstrated by increased ^3H -thymidine incorporation (due to increased DNA synthesis needed for cellular multiplication) or ELISA and/or RIA for detecting increased production of cytokines by T cells in culture.

30

35

[0217] In one such experiment, PD-1 binding activity of human B7-DC-Ig was assessed by ELISA. 96-well ELISA plates were coated with 100 μL 0.75 $\mu\text{g}/\text{mL}$ recombinant human PD-1/Fc (R&D Systems) diluted in BupH Carbonate/Bicarbonate pH 9.4 buffer (Pierce) for 2 hours and then blocked with BSA solution (Jackson ImmunoResearch) for 90-120 minutes. Serially diluted human B7-DC-Ig (wild type, as well as D111S mutein, and K113S mutants that were selected for reduced binding to PD-1) as well as human IgG1 isotype control were allowed to bind for 90 minutes. Bound B7-DC-Ig was detected using 100 μL of 0.5 $\mu\text{g}/\text{mL}$ biotin conjugated anti-human B7-DC clone MIH18 (eBioscience) followed by 1:1000 diluted HRP-Streptavidin (BD Bioscience) and TMB substrate (BioFX). Absorbance at 450 nm was read using a plate reader (Molecular Devices) and data were analyzed in SoftMax using a 4-parameter logistic fit. The data showed that human B7-DC-Ig (wildtype) bound to PD-1 but the K113S and D111S mutants do not bind to PD-1.

40

45

[0218] In carrying out the procedures of the present disclosures it is of course to be understood that reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein.

50

[0219] The disclosures are described in more detail in the following non-limiting examples. It is to be understood that these methods and examples in no way limit the disclosures to the embodiments described herein and that other embodiments and uses will no doubt suggest themselves to those skilled in the art.

55

Examples

Example 1

5 **BT-DC-Ig binds to PD01 expressing CHO cells**

[0220] B7-DC-Ig was first conjugated with allophycocyanin (APC) and then incubated at various concentrations with a CHO cell line constitutively expressing PD-1 or parent CHO cells that do not express PD-1. Binding was analyzed by flow cytometry. Figure 1 shows the median fluorescence intensity (MFI) of B7-DC-Ig-APC as a function of the concentration of probe (x-axis). B7-DC-Ig-APC binds to CHO.PD-1 cells (solid circle) but not untransfected CHO cells (gray triangle).

Example 2

15 **BT-DC-Ig competes with B7-H1 for binding to PD-1.**

[0221] B7-H1-Ig was first conjugated with allophycocyanin (APC). Unlabeled B7-DC-Ig at various concentrations was first incubated with a CHO cell line constitutively expressing PD-1 before adding B7-H1-Ig-APC to the probe and cell mixture. Figure 2 shows the median fluorescence intensity (MFI) of B7-H1-Fc-APC is shown as a function of the concentration of unlabeled B7-DC-Ig competitor (x-axis) added. As the concentration of unlabeled B7-DC-Ig is increased the amount of B7-H1-Ig-APC bound to CHO cells decreases, demonstrating that B7-DC-Ig competes with B7-H1 for binding to PD-1.

Example 3

25 **CT26 Tumor Model**

[0222] Mouse colorectal tumor cell line, CT26, was obtained from ATCC. A master cell bank at Passage 4 was generated following ATCC guidelines. Cells were tested and confirmed no mycoplasma and other pathogen contamination. One vial of tumor cells was thawed from the cryopreserved stocks and grown for two passages prior to inoculation.

[0223] CT26 cells were split at 1:5 dilution with 30 mL complete medium (RPMI + 10% FBS, 2 mM L-Glu, and 1x P/S) for two days culture or at 1:10 dilution with 30 ml complete medium for 3 days culture.

CT26 cells were harvested by aspirating medium, rinsing the flask with 5 mL PBS, adding 5 mL trypsin, incubating at 37 °C for 2 min, and then neutralizing with 10 mL complete medium. After centrifuge at 600 x g (~1000 rpm) for 5 min, media was sspirated and the cell pellet was resuspended by pipetting with 10 ml plain RPMI. This wash step was repeated for three times.

[0224] Cell number and viability of the inoculated cells were analyzed by trypan blue dye staining with proper dilution (e.g. 1:5 dilution, 10 μL cells + 40 μL trypan blue) and confirmed by NOVA cell count during the last wash step. Cell viability generally was greater than 95% for inoculation.

[0225] CT26 cells were diluted to 6.7x10⁵ cells/mL for initial inoculation with plain RPMI and stored on ice. Typically each mouse was inoculated with 150 μL (1x10⁵ cells).

[0226] On Day 9, all the tumor-bearing mice were first grouped into a rat cage and randomly divided the mice to experimental groups. CTX solution was reconstituted by 1x PBS to 4 mg/mL. Mice were intraperitoneally (IP) injected with 0.5 mL of CTX solution resulting in 2 mg for a 20 gram mouse, i.e. 100 mg/kg.

[0227] On Day 10, mice were IP injected with 0.5 mL of B7-DC-Ig (0.2 mg/mL) resulting in 0.1 mg for a 20 gram mouse, i.e. 5 mg/kg. The same dose was given 2 time a week for 4 weeks, total 8 doses. Tumor growth were monitored by measuring the tumor twice weekly, starting on the day when giving B7-DC-Ig via a digital caliper. Tumor volume was calculated as following:

50

$$\text{Tumor volume} = \frac{4}{3} \times (D_{\text{short}})^2 \times (D_{\text{long}}) / 6 = \sim 0.52 \times (D_{\text{short}})^2 \times (D_{\text{long}})$$

[0228] Mice were euthanized and taken off the study if the tumor volume reached 2000 mm³ or if there were skin ulcers and infections at the tumor inoculation site.

55

Example 4**Combination of cyclophosphamide and B7-DC-Ig can eradicate established tumors.**

5 [0229] Balb/C mice at age of 9 to 11 weeks were implanted subcutaneously with 1.0×10^5 CT26 colorectal tumor cells as described above. On day 10 post tumor implantation, mice received 100 mg/kg of cyclophosphamide. B7-DC-Ig treatment started 1 day later, on day 11. Mice were treated with 100 μ g of B7-DC-Ig, 2 doses per week, for 4 weeks and total 8 doses. 75% of the mice that received the CTX + B7-DC-Ig treatment regimen eradicated the established tumors by Day 44, whereas all mice in the control CTX alone group died as a result of tumor growth or were euthanized because
10 tumors exceeded the sizes approved by IACUC (results shown in Figure 3). These results demonstrate the effectiveness of the treatment regimen on established tumors and not mere prophylaxis.

Example 5

15 **Combination of cyclophosphamide and BT-DC-Ig can eradicate established tumors and protect against tumor re-challenge.**

[0230] Mice eradicated established CT26 colorectal tumors from the above described experiment were rechallenged with 1×10^5 CT26 cells on Day 44 and Day 70. No tumors grew out from the rechallenge suggesting they had developed long term anti-tumor immunity from the cyclophosphamide and B7-DC-Ig combination treatment. All mice in the vehicle control group developed tumors (results shown in Figure 4). These results show the effectiveness of the treatment regimen on established tumors and that the cyclophosphamide and B7-DC-Ig combination treatment resulted in memory responses to tumor antigens.

Example 6**Combination of cyclophosphamide and BT-DC-Ig can generate tumor specific, memory cytotoxic T lymphocytes**

30 [0231] Mice eradicated established CT26 colorectal tumors from the above described experiment were rechallenged with 2.5×10^5 CT26 cells on Day 44. Seven days later, mouse spleens were isolated. Mouse splenocytes were pulsed with 5 or 50 μ g/mL of ovalbumin (OVA) or AH1 peptides for 6 hours in the presence of a Golgi blocker (BD BioScience). Memory T effector cells were analyzed by assessing $CD8^+ / IFN\gamma^+$ T cells. Results in Figure 5 show that there were significant amount of CT26 specific T effector cells in the CT26 tumor-eradicated mice.

Example 7**Effect of BT-DC-Ig dose dependent on tumor eradication**

40 [0232] Balb/C mice at age of 9 to 11 weeks were implanted subcutaneously with 1.0×10^5 CT26 colorectal tumor cells. On day 9 post tumor implantation, mice received a single dose of cyclophosphamide (100 mg/kg) and started treatment on Day 10 with 30, 100 or 300 μ g of B7-DC-Ig, 2 doses per week for 4 weeks, total 8 doses. Figure 6 shows there were 70% of the mice eradicated the tumors at 300 μ g, 40% tumor eradication with 100 μ g, and 30 μ g dose gave rise to 10% tumor eradication.

Example 8**Combination of cyclophosphamide and anti-PD-1 can eradicate established tumors.**

[0233] This is a comparative example.

50 [0234] Balb/C mice at age of 9 to 11 weeks were challenged subcutaneously with 1.0×10^5 CT26 colorectal tumor cells. On day 11 post tumor challenge, mice received a single dose of cyclophosphamide (100 mg/kg) and started treatment with anti-PD-1 antibody (250 μ g, Clone G4, Hirano F. et al., 2005 Cancer Research) which was administered 3 times per week for four weeks. 70% of the mice that received the CTX + anti-PD-1 regimen eradicated established CT26 tumors at day 50 after tumor challenge, whereas all mice in the control and anti-PD-1 alone groups died as a result of tumor growth or were euthanized because tumors exceeded the sizes approved by IACUC. These results show
55 the effectiveness of the treatment regimen on established tumors and not mere prophylaxis. Results are shown in Figure 7.

Example 9**Combination of cyclophosphamide and anti-CTLA4 can eradicate established tumors.**

5 [0235] This is a comparative example.

[0236] Balb/C mice at age of 9 to 11 weeks were challenged subcutaneously with 1.0×10^5 CT26 colorectal tumor cells. On day 11 post tumor challenge, mice received 100 mg/kg of cyclophosphamide. Anti-CTLA4 (an anti-mouse CTLA4 from hamster hybridoma - ATCC deposit UC10-4F10-11) treatment was started 1 day later, on day 12. Mice were treated with 100 ug of anti-CTLA4, 2 doses per week, for 4 weeks. 56% of the mice that received the CTX + anti-CTLA4 regimen were tumor free at day 50 after tumor challenge, whereas all mice in the control group died as a result of tumor growth or were euthanized because tumors exceeded the sizes approved by IACUC. Results are shown in Figure 8. These results show the effectiveness of the treatment regimen on established tumors and not mere prophylaxis.

Example 10

15

Combination of cyclophosphamide and B7-DC-Ig Regimen Leads to Reduction of Tregs in the Tumor Microenvironment

[0237] Figure 9 shows the results of experiments wherein Balb/C mice at age of 9 to 11 weeks of age were implanted with 1×10^5 CT26 cells subcutaneously. On Day 9, mice were injected with 100 mg/kg of CTX, IP. Twenty four hours later, on Day 10, mice were treated with 100 ug of B7-DC-Ig. There were 5 groups: naive mice that did not receive any tumor cells, vehicle injected, CTX alone, CTX + B7-DC-Ig or B7-DC-Ig alone. Two naive mice and 4 mice from other groups were removed from the study on Day 11 (2 days post CTX) and Day 16 (7 days post CTX) for T cell analysis. Left panel shows on Day 11, 2 days post CTX injection, Treg in the spleen of the mice with CTX treatment was significantly lower than the one in the mice with tumor implantation and injected with vehicle. Right panel shows that on Day 16, 7 days post CTX and 6 days post B7-DC-Ig treatment, B7-DC-Ig significantly lowered the CD4+ T cells expressing high PD-1. This was observed in both the B7-DC-Ig treated and CTX + B7-DC-Ig treated mice. Mice implanted with tumor cells intended to have more PD-1+/CD4+ T cells in the draining LN compared with naive mice.

Example 11**Combination of cyclophosphamide and B7-DC-Ig can promote mouse survival in a metastatic prostate tumor model**

[0238] B10.D2 mice at age of 9 to 11 weeks were injected intravenously with 3.0×10^5 SP-1 cells, which were isolated from lung metastasis post parent TRAMP cell injection. The CTX mice received 3 doses of CTX, 50 mg/kg, on Day 5, 12 and 19. The B7-DC-Ig treated mice received 3 doses of B7-DC-Ig, 5 mg/kg, on Day 6, 13 and 20. On Day 100, 17% of mice in the control groups, no-treated, CTX alone, B7-DC-Ig alone survived while 43% of the mice received combination of CTX and B7-DC-Ig survived. Results are shown in Figure 10.

40

Example 12**Combination of Listeria cancer vaccine and B7-DC-Ig can enhance mouse survival post CT26 liver implantation**

45 [0239] This is a comparative example.

[0240] Balb/C mice at age of 11-13 weeks were implanted with CT26 cells using a hemispleen injection technique (Yoshimura K et al., 2007, Cancer Research). On Day 10, mice received 1 injection of CTX at 50 mg/kg, IP. Twenty four hours later, on Day 11, mice were treated with recombinant Listeria carrying AH1 peptide, an immunodominant epitope of CT26, at 0.1 LD₅₀ (1×10^7 CFU), then on Day 14 and 17. Mice were also treated with B7-DC-Ig on Day 11 and then on Day 18. Figure 11 shows mice without any treatment or treated with CTX and Listeria cancer vaccine all died before Day 45. There were 60% of the mice received triple combination, CTX + Listeria cancer vaccine and B7-DC-Ig survived.

50

1. Reference List

55 [0241]

1. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev.Immunol. 2008;28(2):109-26

2. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. *Cancer Immunol.Immunother.* 2009 Aug;58(8):1219-28
- 5
3. Taieb J, Chaput N, Scharzt N, Roux S, Novault S, Menard C, Ghiringhelli F, Terme M, Carpentier AF, Darrasse-Jeze G, et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. *J.Immunol.* 2006 Mar 1;176(5):2722-9
- 10
4. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. *Cancer Res.* 2001 May 1;61(9):3689-97
- 15
5. Bass KK, Mastrangelo MJ. Immunopotential with low-dose cyclophosphamide in the active specific immunotherapy of cancer. *Cancer Immunol.Immunother.* 1998 Sep;47(1):1-12
6. Hengst JC, Mokyr MB, Dray S. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. *Cancer Res.* 1981 Jun;41(6):2163-7
- 20
7. Hengst JC, Mokyr MB, Dray S. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. *Cancer Res.* 1980 Jul;40(7):2135-41
8. Tsung K, Meko JB, Tsung YL, Peplinski GR, Norton JA. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. *J.Immunol.* 1998 Feb 1;160(3):1369-77
- 25
9. Honeychurch J, Glennie MJ, Illidge TM. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. *Cancer Res.* 2005 Aug 15;65(16):7493-501
- 30
10. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. *Cancer Res.* 2009 May 15;69(10):4309-18.
- 35
11. Freeman,G.J. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. *Proc. Natl. Acad. Sci. U. S. A* 105, 10275-10276 (2008).
- 40
12. Brode,S. & Cooke,A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. *Crit Rev. Immunol.* 28, 109-126 (2008).
- 45
13. van der Most,R.G. et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. *Cancer Immunol. Immunother.* 58, 1219-1228 (2009).
- 50
14. Taieb,J. et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. *J. Immunol.* 176, 2722-2729 (2006).
- 55
15. Bass,K.K. & Mastrangelo,M.J. Immunopotential with low-dose cyclophosphamide in the active specific immunotherapy of cancer. *Cancer Immunol. Immunother.* 47, 1-12 (1998).
16. Machiels,J.P. et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. *Cancer Res.* 61, 3689-3697 (2001).
17. Hengst,J.C., Mokyr,M.B., & Dray,S. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. *Cancer Res.* 41, 2163-2167 (1981).
18. Hengst,J.C., Mokyr,M.B., & Dray,S. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. *Cancer Res.* 40, 2135-2141 (1980).

EP 2 350 129 B1

19. Tsung,K., Meko,J.B., Tsung,Y.L., Peplinski,G.R., & Norton,J.A. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. *J. Immunol.* 160, 1369-1377 (1998).

5 20. Honeychurch,J., Glennie,M.J., & Illidge,T.M. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. *Cancer Res.* 65, 7493-7501 (2005).

10 21. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. *Cancer Res.* 2009 May 15;69(10):4309-18.

SEQUENCE LISTING

[0242]

15 <110> Langermann, Solomon

<120> Compositions of PD-1 Antagonists and Methods of Use

20 <130> 21682-6

<140>

<141>

25 <150> 61/211,697 <151> 2009-04-02

<150> 61/091,692 <151> 2008-08-25

<150> 61/091,709 <151> 2008-08-25

30 <150> 61/091,705 <151> 2008-08-25

<160> 20

<170> PatentIn version 3.4

35

<210> 1

<211> 273

<212> PRT

<213> Homo sapiens

40

<400> 1

45

50

55

EP 2 350 129 B1

Met Ile Phe Leu Leu Leu Met Leu Ser Leu Glu Leu Gln Leu His Gln
 1 5 10 15
 5
 Ile Ala Ala Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr Ile Ile
 20 25 30
 10
 Glu His Gly Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser
 35 40 45
 His Val Asn Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn
 50 55 60
 15
 Asp Thr Ser Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu
 65 70 75 80
 20
 Pro Leu Gly Lys Ala Ser Phe His Ile Pro Gln Val Gln Val Arg Asp
 85 90 95
 25
 Glu Gly Gln Tyr Gln Cys Ile Ile Ile Tyr Gly Val Ala Trp Asp Tyr
 100 105 110
 30
 35
 40
 45
 50
 55

EP 2 350 129 B1

Lys Tyr Leu Thr Leu Lys Val Lys Ala Ser Tyr Arg Lys Ile Asn Thr
 115 120 125
 5 His Ile Leu Lys Val Pro Glu Thr Asp Glu Val Glu Leu Thr Cys Gln
 130 135 140
 10 Ala Thr Gly Tyr Pro Leu Ala Glu Val Ser Trp Pro Asn Val Ser Val
 145 150 155 160
 15 Pro Ala Asn Thr Ser His Ser Arg Thr Pro Glu Gly Leu Tyr Gln Val
 165 170 175
 20 Thr Ser Val Leu Arg Leu Lys Pro Pro Pro Gly Arg Asn Phe Ser Cys
 180 185 190
 25 Val Phe Trp Asn Thr His Val Arg Glu Leu Thr Leu Ala Ser Ile Asp
 195 200 205
 30 Leu Gln Ser Gln Met Glu Pro Arg Thr His Pro Thr Trp Leu Leu His
 210 215 220
 35 Ile Phe Ile Pro Phe Cys Ile Ile Ala Phe Ile Phe Ile Ala Thr Val
 225 230 235 240
 40 Ile Ala Leu Arg Lys Gln Leu Cys Gln Lys Leu Tyr Ser Ser Lys Asp
 245 250 255
 45 Thr Thr Lys Arg Pro Val Thr Thr Thr Lys Arg Glu Val Asn Ser Ala
 260 265 270
 Ile
 40 <210> 2
 <211> 254
 <212> PRT
 <213> Homo sapiens
 45 <400> 2
 50 Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr Ile Ile Glu His Gly
 1 5 10 15
 55 Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser His Val Asn
 20 25 30
 60 Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn Asp Thr Ser

EP 2 350 129 B1

1 Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr Ile Ile Glu His Gly
 5 Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser His Val Asn
 10 Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn Asp Thr Ser
 15 Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu Pro Leu Gly
 20 Lys Ala Ser Phe His Ile Pro Gln Val Gln Val Arg Asp Glu Gly Gln
 25 Tyr Gln Cys Ile Ile Ile Tyr Gly Val Ala Trp Asp Tyr Lys Tyr Leu
 30 Thr Leu Lys Val Lys Ala Ser Tyr Arg Lys Ile Asn Thr His Ile Leu
 35 Lys Val Pro Glu Thr Asp Glu Val Glu Leu Thr Cys Gln Ala Thr Gly
 40 Tyr Pro Leu Ala Glu Val Ser Trp Pro Asn Val Ser Val Pro Ala Asn
 45 Thr Ser His Ser Arg Thr Pro Glu Gly Leu Tyr Gln Val Thr Ser Val
 50 Leu Arg Leu Lys Pro Pro Pro Gly Arg Asn Phe Ser Cys Val Phe Trp
 55 Asn Thr His Val Arg Glu Leu Thr Leu Ala Ser Ile Asp Leu Gln Ser
 60 Gln Met Glu Pro Arg Thr His Pro Thr Trp
 <210> 4
 <211> 202
 <212> PRT
 <213> murine
 <400> 4
 55 Leu Phe Thr Val Thr Ala Pro Lys Glu Val Tyr Thr Val Asp Val Gly

EP 2 350 129 B1

Ile Ala Ala

5

<210> 6
 <211> 232
 <212> PRT
 <213> Homo sapiens

10

<400> 6

15 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 1 5 10 15

 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
 20 25 30

20 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
 35 40 45

 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
 50 55 60

 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
 65 70 75 80

30 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
 85 90 95

 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
 100 105 110

 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
 115 120 125

 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
 130 135 140

45 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
 145 150 155 160

 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
 165 170 175

 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
 180 185 190

55 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe

EP 2 350 129 B1

Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
 180 185 190

5

Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
 195 200 205

10

Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr
 210 215 220

Lys Ser Phe Ser Arg Thr Pro Gly Lys
 225 230

15

<210> 8

<211> 1365

<212> DNA

20

<213> artificial

<220>

<223> Murine B7-DC-Ig

25

<400> 8

atgctgctcc tgctgcegat actgaacctg agcttacaac ttcacccctgt agcagcttta 60
 ttcaccgtga cagcccctaa agaagtgtac accgtagacg tcggcagcag tgtgagcctg 120
 gagtgcgatt ttgaccgcag agaatgcact gaactggaag ggataagagc cagtttgcag 180
 aaggtagaaa atgatacgtc tctgcaaagt gaaagagcca ccctgctgga ggagcagctg 240
 cccctgggaa aggctttggt ccacatccct agtgtccaag tgagagattc cgggcagtac 300
 cgttgcctgg tcatctgcgg ggccgcctgg gactacaagt acctgacggt gaaagtcaaa 360
 gcttcttaca tgaggataga cactaggatc ctggaggttc caggtacagg ggaggtgcag 420
 cttacctgcc aggctagagg ttatccccta gcagaagtgt cctggcaaaa tgtcagtgtt 480
 cctgccaaca ccagccacat caggaccccc gaaggcctct accaggtcac cagtgttctg 540
 cgctcaagc ctcagcctag cagaaacttc agctgcatgt tctggaatgc tcacatgaag 600
 gagctgactt cagccatcat tgaccctctg agtcggatgg aaccctaaagt cccagaacg 660
 tgggagccaa gaggtcctac gatcaagccc tgcccgcctt gtaaatgccc agtcccaaat 720
 ttgctgggtg gaccgtcagt ctttatcttc ccgccaaga taaaggacgt cttgatgatt 780
 agtctgagcc ccatcgtgac atgcggtgtg gtggatgttt cagaggatga ccccgacgtg 840
 caaatcagtt ggttcgtaa caacgtggag gtgcataccg ctcaaacca gaccacaga 900
 gaggattata acagcacctt gcgggtagtg tccgccctgc cgatccagca tcaggattgg 960
 atgagcggga aagagttcaa gtgtaaggta aacaacaaag atctgccagc gccgattgaa 1020
 cgaaccatta gcaagccgaa agggagcgtg cgcgcacctc aggtttacgt ccttctctca 1080

55

EP 2 350 129 B1

ccagaagagg agatgacgaa aaagcaggtg accctgacat gcatggtaac tgactttatg 1140
 ccagaagata tttacgtgga atggactaat aacggaaaga cagagctcaa ttacaagaac 1200
 5 actgagcctg ttctggattc tgatggcagc tactttatgt actccaaatt gagggctcgag 1260
 aagaagaatt gggctgagag aaacagttat agttgctcag tggatgatga gggcctccat 1320
 10 aatcatcaca ccacaaagtc cttcagccga acgcccggga aatga 1365

<210> 9

<211> 454

<212> PRT

15 <213> artificial

<220>

<223> Murine B7-DC-Ig

20 <400> 9

Met Leu Leu Leu Leu Pro Ile Leu Asn Leu Ser Leu Gln Leu His Pro
 1 5 10 15
 25 Val Ala Ala Leu Phe Thr Val Thr Ala Pro Lys Glu Val Tyr Thr Val
 20 25 30
 30 Asp Val Gly Ser Ser Val Ser Leu Glu Cys Asp Phe Asp Arg Arg Glu
 35 40 45
 35 Cys Thr Glu Leu Glu Gly Ile Arg Ala Ser Leu Gln Lys Val Glu Asn
 50 55 60
 40 Asp Thr Ser Leu Gln Ser Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu
 65 70 75 80
 40 Pro Leu Gly Lys Ala Leu Phe His Ile Pro Ser Val Gln Val Arg Asp
 85 90 95
 45 Ser Gly Gln Tyr Arg Cys Leu Val Ile Cys Gly Ala Ala Trp Asp Tyr
 100 105 110
 50 Lys Tyr Leu Thr Val Lys Val Lys Ala Ser Tyr Met Arg Ile Asp Thr
 115 120 125
 50 Arg Ile Leu Glu Val Pro Gly Thr Gly Glu Val Gln Leu Thr Cys Gln
 130 135 140
 55 Ala Arg Gly Tyr Pro Leu Ala Glu Val Ser Trp Gln Asn Val Ser Val
 145 150 155 160

EP 2 350 129 B1

Pro Ala Asn Thr Ser His Ile Arg Thr Pro Glu Gly Leu Tyr Gln Val
 165 170 175

5 Thr Ser Val Leu Arg Leu Lys Pro Gln Pro Ser Arg Asn Phe Ser Cys
 180 185 190

10 Met Phe Trp Asn Ala His Met Lys Glu Leu Thr Ser Ala Ile Ile Asp
 195 200 205

15 Pro Leu Ser Arg Met Glu Pro Lys Val Pro Arg Thr Trp Glu Pro Arg
 210 215 220

20 Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn
 225 230 235 240

25 Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp
 245 250 255

30 Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp
 260 265 270

35 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn
 275 280 285

40 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn
 290 295 300

45 Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp
 305 310 315 320

50 Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro
 325 330 335

55 Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala
 340 345 350

60 Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys
 355 360 365

65 Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile
 370 375 380

70 Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn
 385 390 395 400

EP 2 350 129 B1

Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys
 405 410 415

5 Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys
 420 425 430

10 Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe
 435 440 445

Ser Arg Thr Pro Gly Lys
 450

15 <210> 10
 <211> 435
 <212> PRT
 <213> artificial

20 <220>
 <223> Murine B7-DC-Ig fusion protein without signal sequence

25 <400> 10

Leu Phe Thr Val Thr Ala Pro Lys Glu Val Tyr Thr Val Asp Val Gly
 1 5 10 15

30 Ser Ser Val Ser Leu Glu Cys Asp Phe Asp Arg Arg Glu Cys Thr Glu
 20 25 30

35 Leu Glu Gly Ile Arg Ala Ser Leu Gln Lys Val Glu Asn Asp Thr Ser
 35 40 45

Leu Gln Ser Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu Pro Leu Gly
 50 55 60

40 Lys Ala Leu Phe His Ile Pro Ser Val Gln Val Arg Asp Ser Gly Gln
 65 70 75 80

45 Tyr Arg Cys Leu Val Ile Cys Gly Ala Ala Trp Asp Tyr Lys Tyr Leu
 85 90 95

Thr Val Lys Val Lys Ala Ser Tyr Met Arg Ile Asp Thr Arg Ile Leu
 100 105 110

50 Glu Val Pro Gly Thr Gly Glu Val Gln Leu Thr Cys Gln Ala Arg Gly
 115 120 125

55 Tyr Pro Leu Ala Glu Val Ser Trp Gln Asn Val Ser Val Pro Ala Asn
 130 135 140

EP 2 350 129 B1

Thr Ser His Ile Arg Thr Pro Glu Gly Leu Tyr Gln Val Thr Ser Val
 145 150 155 160
 5
 Leu Arg Leu Lys Pro Gln Pro Ser Arg Asn Phe Ser Cys Met Phe Trp
 165 170 175
 10
 Asn Ala His Met Lys Glu Leu Thr Ser Ala Ile Ile Asp Pro Leu Ser
 180 185 190
 Arg Met Glu Pro Lys Val Pro Arg Thr Trp Glu Pro Arg Gly Pro Thr
 195 200 205
 15
 Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
 210 215 220
 20
 Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
 225 230 235 240
 Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
 245 250 255
 25
 Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
 260 265 270
 30
 His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
 275 280 285
 Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
 290 295 300
 35
 Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
 305 310 315 320
 40
 Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
 325 330 335
 45
 Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
 340 345 350
 Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
 355 360 365
 50
 Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
 370 375 380
 55

EP 2 350 129 B1

Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
 385 390 395 400

5 Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
 405 410 415

10 His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
 420 425 430

Pro Gly Lys
 435

15 <210> 11
 <211> 1362
 <212> DNA
 <213> artificial

20 <220>
 <223> Human B7-DC-Ig

25 <400> 11

atgatcttcc ttctcttgat gctgtctttg gaattgcaac ttcaccaaatt cgcggccttc 60
 ttactgtga ccggtccaaa agaactgtat atcattgagc acgggtccaa tgtgaccctc 120
 30 gaatgtaact ttgacaccgg cagccacggt aacctggggg ccatcactgc cagcttgcaa 180
 aaagttgaaa acgacacttc acctcaccgg gagagggcaa ccctcttgga ggagcaactg 240
 ccattgggga aggcctcctt tcatatccct caggtgcagg ttcgggatga gggacagtac 300
 35 cagtgcatca ttatctacgg cgtggcttgg gattacaagt atctgaccct gaaggtgaaa 360
 gcgtcctatc ggaaaattaa cactcacatt ctttaaggtgc cagagacgga cgaggtggaa 420
 ctgacatgcc aagccaccgg ctaccggttg gcagaggtca gctggcccaa cgtgagcgta 480
 40 cctgctaaca cttctcattc taggacaccg gagggcctct accaggttac atccgtgctc 540
 cgcctcaaac cgcctccagg ccggaatttt agttgcgtgt tttggaatac ccacgtgcga 600
 gagctgactc ttgcatctat tgatctgcag tcccagatgg agccacggac tcatccaact 660
 45 tgggaaccta aatcttgcca taaaactcat acctgtcccc cttgcccagc ccccagactt 720
 ctgggaggtc ccagtgtgtt tctgtttccc ccaaaaccta aggacacact tatgatattc 780
 cgaacgccgg aagtgacatg cgtgggttgg gacgtctcac acgaagaccg ggaggtgaaa 840
 50 ttcaactggt acgttgacgg agttgagggt cataacgcta agaccaagcc cagagaggag 900
 caatacaatt ccacctatcg agtgggttagt gtactgaccg ttttgacca agactggctg 960
 55 aatggaaaag aatacaagtg caaagtatca aacaaggctt tgccctgcacc catcgagaag 1020
 acaatttcta aagccaaagg gcagcccagg gaaccgcagg tgtacacact cccaccatcc 1080

EP 2 350 129 B1

cgcgacgagc tgacaaagaa tcaagtatcc ctgacctgcc tgggtgaaagg cttttaacca 1140
 tctgacattg ccggtggaatg ggaatcaaat ggacaacctg agaacaacta caaaaccact 1200
 5 ccacctgtgc ttgacagcga cgggtccttt ttctgtaca gtaagctcac tgtcgataag 1260
 tctcgctggc agcagggcaa cgtcttttca tgtagtgtga tgcacgaagc tctgcacaac 1320
 10 cattacaccc agaagtctct gtcactgagc ccaggtaaat ga 1362

<210> 12

<211> 453

<212> PRT

15 <213> Artificial

<220>

<223> Human B7-DC-Ig

20 <400> 12

Met Ile Phe Leu Leu Leu Met Leu Ser Leu Glu Leu Gln Leu His Gln
 1 5 10 15
 25 Ile Ala Ala Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr Ile Ile
 20 25 30
 30 Glu His Gly Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser
 35 40 45
 35 His Val Asn Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn
 50 55 60
 40 Asp Thr Ser Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu
 65 70 75 80
 45 Pro Leu Gly Lys Ala Ser Phe His Ile Pro Gln Val Gln Val Arg Asp
 85 90 95
 50 Glu Gly Gln Tyr Gln Cys Ile Ile Ile Tyr Gly Val Ala Trp Asp Tyr
 100 105 110
 55 Lys Tyr Leu Thr Leu Lys Val Lys Ala Ser Tyr Arg Lys Ile Asn Thr
 115 120 125
 60 His Ile Leu Lys Val Pro Glu Thr Asp Glu Val Glu Leu Thr Cys Gln
 130 135 140
 65 Ala Thr Gly Tyr Pro Leu Ala Glu Val Ser Trp Pro Asn Val Ser Val
 145 150 155 160

EP 2 350 129 B1

Pro Ala Asn Thr Ser His Ser Arg Thr Pro Glu Gly Leu Tyr Gln Val
 165 170 175
 5 Thr Ser Val Leu Arg Leu Lys Pro Pro Pro Gly Arg Asn Phe Ser Cys
 180 185 190
 10 Val Phe Trp Asn Thr His Val Arg Glu Leu Thr Leu Ala Ser Ile Asp
 195 200 205
 15 Leu Gln Ser Gln Met Glu Pro Arg Thr His Pro Thr Trp Glu Pro Lys
 210 215 220
 20 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
 225 230 235 240
 25 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 245 250 255
 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 260 265 270
 35 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 275 280 285
 40 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 290 295 300
 45 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 305 310 315 320
 50 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 325 330 335
 55 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 340 345 350
 60 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 355 360 365
 65 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 370 375 380
 70 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 385 390 395 400
 75 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu

EP 2 350 129 B1

				405					410					415			
5	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	
				420					425					430			
10	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	
				435				440					445				
15	Leu	Ser	Pro	Gly	Lys												
				450													
20	<210>	13															
	<211>	434															
	<212>	PRT															
	<213>	Artificial															
25	<220>																
	<223>	Human B7-DC-Ig without signal sequence															
	<400>	13															
30	Leu	Phe	Thr	Val	Thr	Val	Pro	Lys	Glu	Leu	Tyr	Ile	Ile	Glu	His	Gly	
	1				5					10					15		
35	Ser	Asn	Val	Thr	Leu	Glu	Cys	Asn	Phe	Asp	Thr	Gly	Ser	His	Val	Asn	
				20					25					30			
40	Leu	Gly	Ala	Ile	Thr	Ala	Ser	Leu	Gln	Lys	Val	Glu	Asn	Asp	Thr	Ser	
			35					40					45				
45	Pro	His	Arg	Glu	Arg	Ala	Thr	Leu	Leu	Glu	Glu	Gln	Leu	Pro	Leu	Gly	
		50					55					60					
50	Lys	Ala	Ser	Phe	His	Ile	Pro	Gln	Val	Gln	Val	Arg	Asp	Glu	Gly	Gln	
	65					70					75					80	
55	Tyr	Gln	Cys	Ile	Ile	Ile	Tyr	Gly	Val	Ala	Trp	Asp	Tyr	Lys	Tyr	Leu	
				85						90					95		
60	Thr	Leu	Lys	Val	Lys	Ala	Ser	Tyr	Arg	Lys	Ile	Asn	Thr	His	Ile	Leu	
				100					105					110			
65	Lys	Val	Pro	Glu	Thr	Asp	Glu	Val	Glu	Leu	Thr	Cys	Gln	Ala	Thr	Gly	
			115					120					125				
70	Tyr	Pro	Leu	Ala	Glu	Val	Ser	Trp	Pro	Asn	Val	Ser	Val	Pro	Ala	Asn	
	130						135					140					

EP 2 350 129 B1

Thr Ser His Ser Arg Thr Pro Glu Gly Leu Tyr Gln Val Thr Ser Val
 145 150 155 160
 5
 Leu Arg Leu Lys Pro Pro Pro Gly Arg Asn Phe Ser Cys Val Phe Trp
 165 170 175
 10
 Asn Thr His Val Arg Glu Leu Thr Leu Ala Ser Ile Asp Leu Gln Ser
 180 185 190
 15
 Gln Met Glu Pro Arg Thr His Pro Thr Trp Glu Pro Lys Ser Cys Asp
 195 200 205
 20
 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
 210 215 220
 25
 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 225 230 235 240
 30
 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 245 250 255
 35
 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 260 265 270
 40
 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 275 280 285
 45
 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 290 295 300
 50
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
 305 310 315 320
 55
 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 325 330 335
 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 340 345 350
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 355 360 365
 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 370 375 380
 60
 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp

EP 2 350 129 B1

Lys Val Pro Glu Thr Asp Glu Val Glu Leu Thr Cys Gln Ala Thr Gly
 115 120 125
 5 Tyr Pro Leu Ala Glu Val Ser Trp Pro Asn Val Ser Val Pro Ala Asn
 130 135 140
 10 Thr Ser His Ser Arg Thr Pro Glu Gly Leu Tyr Gln Val Thr Ser Val
 145 150 155 160
 15 Leu Arg Leu Lys Pro Pro Pro Gly Arg Asn Phe Ser Cys Val Phe Trp
 165 170 175
 20 Asn Thr His Val Arg Glu Leu Thr Leu Ala Ser Ile Asp Leu Gln Ser
 180 185 190
 25 Gln Met Glu Pro Arg Thr His Pro Thr Trp
 195 200
 <210> 16
 <211> 290
 <212> PRT
 <213> Homo sapiens
 <400> 16
 30 Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu
 1 5 10 15
 35 Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr
 20 25 30
 40 Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu
 35 40 45
 45 Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile
 50 55 60
 50 Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser
 65 70 75 80
 55 Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn
 85 90 95
 60 Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr
 100 105 110
 65 Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val
 115 120 125

EP 2 350 129 B1

Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val
 130 135 140
 5
 Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr
 145 150 155 160
 10
 Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser
 165 170 175
 15
 Gly Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn
 180 185 190
 20
 Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr
 195 200 205
 25
 Cys Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu
 210 215 220
 30
 Val Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His
 225 230 235 240
 35
 Leu Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr
 245 250 255
 40
 Phe Ile Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys
 260 265 270
 45
 Gly Ile Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu
 275 280 285
 50
 Glu Thr
 290

<210> 17
 <211> 290
 <212> PRT
 <213> Mus musculus

<400> 17.

Met Arg Ile Phe Ala Gly Ile Ile Phe Thr Ala Cys Cys His Leu Leu
 1 5 10 15
 50
 Arg Ala Phe Thr Ile Thr Ala Pro Lys Asp Leu Tyr Val Val Glu Tyr
 20 25 30
 55

EP 2 350 129 B1

Gly Ser Asn Val Thr Met Glu Cys Arg Phe Pro Val Glu Arg Glu Leu
 35 40 45
 5 Asp Leu Leu Ala Leu Val Val Tyr Trp Glu Lys Glu Asp Glu Gln Val
 50 55 60
 10 Ile Gln Phe Val Ala Gly Glu Glu Asp Leu Lys Pro Gln His Ser Asn
 65 70 75 80
 15 Phe Arg Gly Arg Ala Ser Leu Pro Lys Asp Gln Leu Leu Lys Gly Asn
 85 90 95
 20 Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr
 100 105 110
 25 Cys Cys Ile Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Leu
 115 120 125
 30 Lys Val Asn Ala Pro Tyr Arg Lys Ile Asn Gln Arg Ile Ser Val Asp
 130 135 140
 35 Pro Ala Thr Ser Glu His Glu Leu Ile Cys Gln Ala Glu Gly Tyr Pro
 145 150 155 160
 40 Glu Ala Glu Val Ile Trp Thr Asn Ser Asp His Gln Pro Val Ser Gly
 165 170 175
 45 Lys Arg Ser Val Thr Thr Ser Arg Thr Glu Gly Met Leu Leu Asn Val
 180 185 190
 50 Thr Ser Ser Leu Arg Val Asn Ala Thr Ala Asn Asp Val Phe Tyr Cys
 195 200 205
 55 Thr Phe Trp Arg Ser Gln Pro Gly Gln Asn His Thr Ala Glu Leu Ile
 210 215 220
 60 Ile Pro Glu Leu Pro Ala Thr His Pro Pro Gln Asn Arg Thr His Trp
 225 230 235 240
 65 Val Leu Leu Gly Ser Ile Leu Leu Phe Leu Ile Val Val Ser Thr Val
 245 250 255
 70 Leu Leu Phe Leu Arg Lys Gln Val Arg Met Leu Asp Val Glu Lys Cys
 260 265 270
 75 Gly Val Glu Asp Thr Ser Ser Lys Asn Arg Asn Asp Thr Gln Phe Glu

EP 2 350 129 B1

275

280

285

Glu Thr
290

5

<210> 18

<211> 290

<212> PRT

10

<213> Macaca mulatta

<400> 18

15

Met Arg Ile Phe Ala Val Phe Ile Phe Thr Ile Tyr Trp His Leu Leu
1 5 10 15

20

Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr
20 25 30

25

Gly Ser Asn Met Thr Ile Glu Cys Arg Phe Pro Val Glu Lys Gln Leu
35 40 45

30

Gly Leu Thr Ser Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile
50 55 60

Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Asn
65 70 75 80

35

Tyr Arg Gln Arg Ala Gln Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn
85 90 95

Ala Ala Leu Arg Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr
100 105 110

40

Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val
115 120 125

45

Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val
130 135 140

Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr
145 150 155 160

50

Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser
165 170 175

55

Gly Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Leu Asn
180 185 190

EP 2 350 129 B1

5 Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Ala Asn Glu Ile Phe Tyr
 195 200 205

10 Cys Ile Phe Arg Arg Leu Gly Pro Glu Glu Asn His Thr Ala Glu Leu
 210 215 220

15 Val Ile Pro Glu Leu Pro Leu Ala Leu Pro Pro Asn Glu Arg Thr His
 225 230 235 240

20 Leu Val Ile Leu Gly Ala Ile Phe Leu Leu Leu Gly Val Ala Leu Thr
 245 250 255

25 Phe Ile Phe Tyr Leu Arg Lys Gly Arg Met Met Asp Met Lys Lys Ser
 260 265 270

30 Gly Ile Arg Val Thr Asn Ser Lys Lys Gln Arg Asp Thr Gln Leu Glu
 275 280 285

35 Glu Thr
 290

<210> 19
 <211> 288
 <212> PRT
 <213> Homo sapiens

<400> 19

35 Met Gln Ile Pro Gln Ala Pro Trp Pro Val Val Trp Ala Val Leu Gln
 1 5 10 15

40 Leu Gly Trp Arg Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp
 20 25 30

45 Asn Pro Pro Thr Phe Phe Pro Ala Leu Leu Val Val Thr Glu Gly Asp
 35 40 45

50 Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val
 50 55 60

55 Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala
 65 70 75 80

60 Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg
 85 90 95

65 Val Thr Gln Leu Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg

EP 2 350 129 B1

	100		105		110											
5	Ala	Arg	Arg	Asn	Asp	Ser	Gly	Thr	Tyr	Leu	Cys	Gly	Ala	Ile	Ser	Leu
			115					120					125			
10	Ala	Pro	Lys	Ala	Gln	Ile	Lys	Glu	Ser	Leu	Arg	Ala	Glu	Leu	Arg	Val
		130					135					140				
15	Thr	Glu	Arg	Arg	Ala	Glu	Val	Pro	Thr	Ala	His	Pro	Ser	Pro	Ser	Pro
	145					150					155					160
20	Arg	Pro	Ala	Gly	Gln	Phe	Gln	Thr	Leu	Val	Val	Gly	Val	Val	Gly	Gly
				165						170					175	
25	Leu	Leu	Gly	Ser	Leu	Val	Leu	Leu	Val	Trp	Val	Leu	Ala	Val	Ile	Cys
			180						185					190		
30	Ser	Arg	Ala	Ala	Arg	Gly	Thr	Ile	Gly	Ala	Arg	Arg	Thr	Gly	Gln	Pro
		195						200					205			
35	Leu	Lys	Glu	Asp	Pro	Ser	Ala	Val	Pro	Val	Phe	Ser	Val	Asp	Tyr	Gly
		210					215					220				
40	Glu	Leu	Asp	Phe	Gln	Trp	Arg	Glu	Lys	Thr	Pro	Glu	Pro	Pro	Val	Pro
	225					230					235					240
45	Cys	Val	Pro	Glu	Gln	Thr	Glu	Tyr	Ala	Thr	Ile	Val	Phe	Pro	Ser	Gly
				245						250					255	
50	Met	Gly	Thr	Ser	Ser	Pro	Ala	Arg	Arg	Gly	Ser	Ala	Asp	Gly	Pro	Arg
			260					265						270		
55	Ser	Ala	Gln	Pro	Leu	Arg	Pro	Glu	Asp	Gly	His	Cys	Ser	Trp	Pro	Leu
		275						280					285			

<210> 20

<211> 288

45 <212> PRT

<213> Macaca fascicularis

<400> 20

50	Met	Gln	Ile	Pro	Gln	Ala	Pro	Trp	Pro	Val	Val	Trp	Ala	Val	Leu	Gln
	1				5					10					15	
55	Leu	Gly	Trp	Arg	Pro	Gly	Trp	Phe	Leu	Glu	Ser	Pro	Asp	Arg	Pro	Trp
			20						25					30		

EP 2 350 129 B1

Asn Ala Pro Thr Phe Ser Pro Ala Leu Leu Leu Val Thr Glu Gly Asp
 35 40 45

5 Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Ala Ser Glu Ser Phe Val
 50 55 60

10 Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala
 65 70 75 80

Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg
 85 90 95

15 Val Thr Arg Leu Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg
 100 105 110

20 Ala Arg Arg Asn Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu
 115 120 125

25 Ala Pro Lys Ala Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val
 130 135 140

Thr Glu Arg Arg Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro
 145 150 155 160

30 Arg Pro Ala Gly Gln Phe Gln Thr Leu Val Val Gly Val Val Gly Gly
 165 170 175

35 Leu Leu Gly Ser Leu Val Leu Leu Val Trp Val Leu Ala Val Ile Cys
 180 185 190

Ser Arg Ala Ala Arg Gly Thr Ile Gly Ala Arg Arg Thr Gly Gln Pro
 195 200 205

40 Leu Lys Glu Asp Pro Ser Ala Val Pro Val Phe Ser Val Asp Tyr Gly
 210 215 220

45 Glu Leu Asp Phe Gln Trp Arg Glu Lys Thr Pro Glu Pro Pro Val Pro
 225 230 235 240

Cys Val Pro Glu Gln Thr Glu Tyr Ala Thr Ile Val Phe Pro Ser Gly
 245 250 255

50 Met Gly Thr Ser Ser Pro Ala Arg Arg Gly Ser Ala Asp Gly Pro Arg
 260 265 270

55 Ser Ala Gln Pro Leu Arg Pro Glu Asp Gly His Cys Ser Trp Pro Leu
 275 280 285

Claims

1. A composition comprising:

5 a fusion protein comprising first and second peptide portions wherein said first peptide portion consists of an amino acid sequence selected from: wild type B7-DC, an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1 and which competes in vitro with wild-type B7-DC for binding to PD-1, a fragment of B7-DC which competes in vitro with wild-type B7-DC for binding to PD-1, and an extra-cellular domain of B7-DC and said second peptide portion comprises a portion of an immunoglobulin (Ig);
 10 for use in a method of increasing a T cell response in a human;
 wherein the human is one to whom a composition comprising a potentiating agent selected from the group consisting of: cyclophosphamide, an analog of cyclophosphamide, sunitinib, anti-TGF β , imatinib, anthracyclines, oxaliplatin and doxorubicin, and wherein the dosage of the potentiating agent is not effective to have direct anti-tumor activity, has previously been administered;
 15 and wherein the T cell response achieved following the administration of fusion protein is greater than the T cell response achieved by administering either the fusion protein alone or the potentiating agent alone.

2. A composition comprising

20 a potentiating agent selected from the group consisting of: cyclophosphamide, an analog of cyclophosphamide, sunitinib, anti-TGF β , imatinib, anthracyclines, oxaliplatin and doxorubicin,
 for use in a method of increasing a T cell response in a human;
 wherein the dosage of the potentiating agent is not effective to have direct anti-tumor activity;
 wherein the human is one to whom a composition comprising a fusion protein comprising first and second peptide portions wherein said first peptide portion consists of an amino acid sequence selected from: wild type B7-DC, an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1 and which competes in vitro with wild-type B7-DC for binding to PD-1, a fragment of B7-DC which competes in vitro with wild-type B7-DC for binding to PD-1, and an extracellular domain of B7-DC and said second peptide portion comprises a portion of an immunoglobulin (Ig), is subsequently to be administered;
 25 and wherein the T cell response achieved following the administration of fusion protein is greater than the T cell response achieved by administering either the fusion protein alone or the potentiating agent alone.
 30

3. A composition for use according to claim 1 or 2 wherein said first peptide portion consists of a wild type B7-DC polypeptide.

35 4. A composition for use according to claim 3 wherein said B7-DC is a human B7-DC.

5. A composition for use according to claim 1 or 2 wherein said first peptide portion consists of a fragment of B7-DC which does not comprise any portion of the transmembrane portion of said B7-DC polypeptide.

40 6. A composition for use according to claim 5 wherein said first peptide portion consists of the soluble portion of said B7-DC polypeptide and said second peptide portion comprises the Fc region of an antibody but does not comprise any of the variable region of said antibody.

45 7. A composition for use according to claim 5 or 6 wherein said first peptide portion consists of the amino acid sequence of SEQ ID NO: 3 and said second polypeptide portion comprises the Fc region of an antibody but does not comprise any of the variable region of said antibody.

8. A composition for use according to claim 1 or 2 wherein said first peptide portion consists of an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1.

50 9. A composition for use according to claim 8 wherein said first peptide portion consists of the amino acid sequence of amino acids 20-221 or 20-121 of SEQ ID NO: 1.

55 10. A composition for use according to claim 1 or 2 wherein said fusion protein comprises an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 9, 10, 12 or 13.

11. A composition for use according to claim 10 wherein said fusion protein comprises the amino acid sequence of SEQ ID NO: 9, 10, 12, or 13.

12. A composition for use according to any preceding claim wherein said fusion protein is a monomer.
13. A composition for use according to any of claims 1 to 11 wherein said fusion protein forms a dimer.
- 5 14. A composition for use according to claim 13 wherein said fusion protein forms a homodimer.
15. A composition for use according to claim 13 wherein said fusion protein forms a heterodimer.
- 10 16. A composition for use according to any preceding claim wherein said potentiating agent is cyclophosphamide or an analog of cyclophosphamide.
- 15 17. A composition for use according to any preceding claim for use in a method of any preceding claim wherein said potentiating agent is administered at least X hours before administering said fusion protein, wherein X is selected from 1, 2, 3, 5, 10, 15, 20, 24 and 30.
18. A composition for use according to any preceding claim wherein said fusion protein comprises a fragment of wild-type B7-DC which competes in vitro with wild-type B7-DC for binding to PD-1.
- 20 19. A composition for use according to claim 18 wherein said fragment of wild-type B7-DC does not comprise any portion of the transmembrane portion of such polypeptide.
- 25 20. A composition for use according to claim 18 wherein said B7-DC polypeptide is human B7-DC polypeptide.
- 30 21. A composition for use according to claim 1 or 2 wherein said first peptide portion consists of the extracellular domain of B7-DC or a polypeptide differing therefrom by only conservative amino acid substitutions.
- 35 22. A composition for use according to any preceding claim wherein said fusion protein is used in an amount sufficient to treat cancer or infection by an increased T cell mediated immune response.
- 40 23. A composition for use according to claim 1 or 2 wherein said method comprises the treatment of cancer.
- 45 24. A composition for use according to claim 1 or 2 wherein said method comprises the treatment of an infectious disease.
25. A composition for use according to claim 23 wherein said cancer is bladder cancer, brain cancer, breast cancer, cervical cancer, colo-rectal cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, uterine cancer, ovarian cancer, testicular cancer, or hematologic cancer.
- 40 26. A composition for use according to claim 23 for use in said method wherein said method further comprises administering at least one additional agent selected from the group consisting of an anti-PD-1 antibody, an anti-CTLA4 antibody, a mitosis inhibitor, an aromatase inhibitor, an A2AR antagonist, and an angiogenesis inhibitor with said fusion protein.
- 45 27. A kit-of-parts comprising:
a fusion protein comprising a first and second peptide portions wherein said first peptide portion consists of amino acids 20-221 of SEQ ID NO: 1, and said second peptide portion comprises a portion of an immunoglobulin (Ig);
and cyclophosphamide;
50 for use in a method of treating cancer;
wherein said cyclophosphamide is administered before said fusion protein and said fusion protein is administered without cyclophosphamide following administration of cyclophosphamide;
wherein the dosage of cyclophosphamide is not effective to have direct anti-tumor activity.
- 55 28. The composition for use according to claim 27 wherein said second peptide portion comprises amino acids 245-476 of human IgG1.
29. The composition for use according to claim 27 for use in the method of claim 27 wherein said cyclophosphamide is

administered to said patient at least 24 hours prior to the administration of the fusion protein.

30. A kit of parts comprising:

5 a fusion protein comprising first and second peptide portions wherein said first peptide portion consists of an amino acid sequence selected from: wild type B7-DC, an amino acid sequence having at least 98% identity to amino acids 20-221 or 20-121 of SEQ ID NO: 1 and which competes in vitro with wild-type B7-DC for binding to PD-1, a fragment of B7-DC which competes in vitro with wild-type B7-DC for binding to PD-1, and an extra-cellular domain of B7-DC and said second peptide portion comprises a portion of an immunoglobulin (Ig);
10 and a potentiating agent selected from the group consisting of: cyclophosphamide, an analog of cyclophosphamide, sunitinib, anti-TGF β , imatinib, anthracyclines, oxaliplatin and doxorubicin;
for use in a method of increasing a T cell response in a human;
wherein said potentiating agent is to be administered before said fusion protein and said fusion protein is to be administered without said potentiating agent following administration of said potentiating agent;
15 wherein the dosage of the potentiating agent is not effective to have direct anti-tumor activity;
and wherein the T cell response achieved following the administration of fusion protein is greater than the T cell response achieved by administering either the fusion protein alone or the potentiating agent alone.

20 **Patentansprüche**

1. Zusammensetzung, die Folgendes beinhaltet:

25 ein Fusionsprotein, das einen ersten und zweiten Peptidanteil beinhaltet, wobei der erste Peptidanteil aus einer Aminosäuresequenz besteht, ausgewählt aus: Wildtyp-B7-DC, einer Aminosäuresequenz mit mindestens 98%iger Identität mit Aminosäuren 20-221 oder 20-121 von SEQ ID NO: 1 und die in vitro mit Wildtyp B7-DC um Bindung an PD-1 konkurriert,
einem Fragment von B7-DC, das in vitro mit Wildtyp B7-DC um Bindung an PD-1 konkurriert, und einer extrazellulären Domäne von B7-DC, und der zweite Peptidanteil einen Anteil eines Immunglobulins (Ig) beinhaltet;
30 zur Verwendung in einem Verfahren zum Steigern einer T-Zell-Antwort bei einem Menschen; wobei der Mensch ein Mensch ist, dem zuvor eine Zusammensetzung verabreicht wurde, die ein Potenzierungsmittel beinhaltet, ausgewählt aus der Gruppe, bestehend aus:

35 Cyclophosphamid, einem Cyclophosphamidanalogon, Sunitinib, Anti-TGF β , Imatinib, Anthracyclinen, Oxaliplatin und Doxorubicin, und wobei die Dosierung des Potenzierungsmittels nicht wirksam ist, um direkte Anti-Tumor-Aktivität aufzuweisen;
und wobei die T-Zell-Antwort, die nach der Verabreichung des Fusionsproteins erzielt wird, größer als die T-Zell-Antwort ist, die durch Verabreichen entweder des Fusionsproteins alleine oder des Potenzierungsmittels alleine erzielt wird.

40 2. Zusammensetzung, die Folgendes beinhaltet

ein Potenzierungsmittel, ausgewählt aus der Gruppe, bestehend aus: Cyclophosphamid, einem Cyclophosphamidanalogon, Sunitinib, Anti-TGF β , Imatinib, Anthracyclinen, Oxaliplatin und Doxorubicin,
zur Verwendung in einem Verfahren zum Steigern einer T-Zell-Antwort bei einem Menschen; wobei die Dosierung
45 des Potenzierungsmittels nicht wirksam ist, um direkte Anti-Tumor-Aktivität aufzuweisen;
wobei der Mensch ein Mensch ist, dem anschließend eine Zusammensetzung verabreicht werden soll, die ein Fusionsprotein beinhaltet, das einen ersten und zweiten Peptidanteil beinhaltet, wobei der erste Peptidanteil aus einer Aminosäuresequenz besteht, ausgewählt aus: Wildtyp-B7-DC, einer Aminosäuresequenz mit mindestens 98%iger Identität mit Aminosäuren 20-221 oder 20-121 von SEQ ID NO: 1 und die in vitro mit Wildtyp B7-DC um Bindung an PD-1 konkurriert, einem Fragment von B7-DC, das in vitro mit Wildtyp B7-DC um Bindung an PD-1 konkurriert, und einer extrazellulären Domäne von B7-DC, und der zweite Peptidanteil einen Anteil eines Immunglobulins (Ig) beinhaltet;
50 und wobei die T-Zell-Antwort, die nach der Verabreichung des Fusionsproteins erzielt wird, größer als die durch Verabreichen entweder des Fusionsproteins alleine oder des Potenzierungsmittels alleine erzielte T-Zell-Antwort ist.

55 3. Zusammensetzung zur Verwendung gemäß Anspruch 1 oder 2, wobei der erste Peptidanteil aus einem Wildtyp-B7-DC-Polypeptid besteht.

EP 2 350 129 B1

4. Zusammensetzung zur Verwendung gemäß Anspruch 3, wobei das B7-DC ein menschliches B7-DC ist.
5. Zusammensetzung zur Verwendung gemäß Anspruch 1 oder 2, wobei der erste Peptidanteil aus einem Fragment von B7-DC besteht, das keinen Anteil des Transmembrananteils des B7-DC-Polypeptids beinhaltet.
- 5 6. Zusammensetzung zur Verwendung gemäß Anspruch 5, wobei der erste Peptidanteil aus dem löslichen Anteil des B7-DC-Polypeptids besteht und der zweite Peptidanteil die Fc-Region eines Antikörpers beinhaltet, aber keinen Teil der variablen Region des Antikörpers beinhaltet.
- 10 7. Zusammensetzung zur Verwendung gemäß Anspruch 5 oder 6, wobei der erste Peptidanteil aus der Aminosäuresequenz von SEQ ID No: 3 besteht und der zweite Polypeptidanteil die Fc-Region eines Antikörpers beinhaltet, aber keinen Teil der variablen Region des Antikörpers beinhaltet.
- 15 8. Zusammensetzung zur Verwendung gemäß Anspruch 1 oder 2, wobei der erste Peptidanteil aus einer Aminosäuresequenz mit mindestens 98%iger Identität mit Aminosäuren 20-221 oder 20-121 von SEQ ID NO: 1 besteht.
9. Zusammensetzung zur Verwendung gemäß Anspruch 8, wobei der erste Peptidanteil aus der Aminosäuresequenz von Aminosäuren 20-221 oder 20-121 von SEQ ID NO: 1 besteht.
- 20 10. Zusammensetzung zur Verwendung gemäß Anspruch 1 oder 2, wobei das Fusionsprotein eine Aminosäuresequenz mit mindestens 95%iger Identität mit der Sequenz von SEQ ID NO: 9, 10, 12 oder 13 beinhaltet.
11. Zusammensetzung zur Verwendung gemäß Anspruch 10, wobei das Fusionsprotein die Aminosäuresequenz von SEQ ID NO: 9, 10, 12 oder 13 beinhaltet.
- 25 12. Zusammensetzung zur Verwendung gemäß einem der vorherigen Ansprüche, wobei das Fusionsprotein ein Monomer ist.
13. Zusammensetzung zur Verwendung gemäß einem der Ansprüche 1 bis 11, wobei das Fusionsprotein ein Dimer bildet.
- 30 14. Zusammensetzung zur Verwendung gemäß Anspruch 13, wobei das Fusionsprotein ein Homodimer bildet.
15. Zusammensetzung zur Verwendung gemäß Anspruch 13, wobei das Fusionsprotein ein Heterodimer bildet.
- 35 16. Zusammensetzung zur Verwendung gemäß einem der vorherigen Ansprüche, wobei das Potenzierungsmittel Cyclophosphamid oder ein Cyclophosphamidanalogon ist.
- 40 17. Zusammensetzung zur Verwendung gemäß einem der vorherigen Ansprüche zur Verwendung in einem Verfahren gemäß einem der vorherigen Ansprüche, wobei das Potenzierungsmittel mindestens X Stunden vor dem Verabreichen des Fusionsproteins verabreicht wird, wobei X aus 1, 2, 3, 5, 10, 15, 20, 24 und 30 ausgewählt ist.
18. Zusammensetzung zur Verwendung gemäß einem der vorherigen Ansprüche, wobei das Fusionsprotein ein Fragment von Wildtyp-B7-DC beinhaltet, das in vitro mit Wildtyp-B7-DC um Bindung an PD-1 konkurriert.
- 45 19. Zusammensetzung zur Verwendung gemäß Anspruch 18, wobei das Fragment von Wildtyp-B7-DC keinen Anteil des Transmembrananteils eines solchen Polypeptids beinhaltet.
20. Zusammensetzung zur Verwendung gemäß Anspruch 18, wobei das B7-DC-Polypeptid ein menschliches B7-DC-Polypeptid ist.
- 50 21. Zusammensetzung zur Verwendung gemäß Anspruch 1 oder 2, wobei der erste Peptidanteil aus der extrazellulären Domäne von B7-DC oder einem Polypeptid besteht, das sich nur durch konservative Aminosäuresubstitutionen von dieser unterscheidet.
- 55 22. Zusammensetzung zur Verwendung gemäß einem der vorherigen Ansprüche, wobei das Fusionsprotein in einer Menge verwendet wird, die ausreicht, um Krebs oder Infektion durch eine gesteigerte T-Zell-vermittelte Immunantwort zu behandeln.

EP 2 350 129 B1

23. Zusammensetzung zur Verwendung gemäß Anspruch 1 oder 2, wobei das Verfahren die Behandlung von Krebs beinhaltet.

5 24. Zusammensetzung zur Verwendung gemäß Anspruch 1 oder 2, wobei das Verfahren die Behandlung einer Infektionskrankheit beinhaltet.

10 25. Zusammensetzung zur Verwendung gemäß Anspruch 23, wobei der Krebs Blasenkrebs, Hirnkrebs, Brustkrebs, Gebärmuttermundkrebs, Kolorektalkrebs, Speiseröhrenkrebs, Nierenkrebs, Leberkrebs, Lungenkrebs, Nasenrachenkrebs, Bauchspeicheldrüsenkrebs, Prostatakrebs, Hautkrebs, Magenkrebs, Gebärmutterkrebs, Eierstockkrebs, Hodenkrebs oder Blutkrebs ist.

15 26. Zusammensetzung zur Verwendung gemäß Anspruch 23 zur Verwendung in dem Verfahren, wobei das Verfahren ferner das Verabreichen von mindestens einem zusätzlichen Mittel, ausgewählt aus der Gruppe, bestehend aus einem Anti-PD-1-Antikörper, einem Anti-CTLA4-Antikörper, einem Mitosehemmer, einem Aromatasehemmer, einem A2AR-Antagonisten und einem Angiogenesehemmer, mit dem Fusionsprotein beinhaltet.

27. Ein aus Teilen bestehender Kit, der Folgendes beinhaltet:

20 ein Fusionsprotein, das einen ersten und zweiten Peptidanteil beinhaltet, wobei der erste Peptidanteil aus Aminosäuren 20-221 von SEQ ID NO: 1 besteht, und der zweite Peptidanteil einen Anteil eines Immunglobulins (Ig) beinhaltet:

und Cyclophosphamid;

25 zur Verwendung in einem Verfahren zum Behandeln von Krebs;

wobei das Cyclophosphamid vor dem Fusionsprotein verabreicht wird und das Fusionsprotein ohne Cyclophosphamid nach Verabreichung des Cyclophosphamids verabreicht wird;

wobei die Dosierung des Cyclophosphamids nicht wirksam ist, um direkte Anti-Tumor-Aktivität aufzuweisen.

30 28. Zusammensetzung zur Verwendung gemäß Anspruch 27, wobei der zweite Peptidanteil Aminosäuren 245-476 von menschlichem 1gG1 beinhaltet.

35 29. Zusammensetzung zur Verwendung gemäß Anspruch 27 zur Verwendung in dem Verfahren nach Anspruch 27, wobei das Cyclophosphamid dem Patienten mindestens 24 Stunden vor der Verabreichung des Fusionsproteins verabreicht wird.

30. Ein aus Teilen bestehender Kit, der Folgendes beinhaltet:

40 ein Fusionsprotein, das einen ersten und zweiten Peptidanteil beinhaltet, wobei der erste Peptidanteil aus einer Aminosäuresequenz besteht, ausgewählt aus: Wildtyp-B7-DC, einer Aminosäuresequenz mit mindestens 98%iger Identität mit Aminosäuren 20-221 oder 20-121 von SEQ ID NO: 1 und die in vitro mit Wildtyp B7-DC um Bindung an PD-1 konkurriert,

einem Fragment von B7-DC, das in vitro mit Wildtyp B7-DC um Bindung an PD-1 konkurriert, und einer extrazellulären Domäne von B7-DC, und der zweite Peptidanteil einen Anteil eines Immunglobulins (Ig) beinhaltet; und ein Potenzierungsmittel, ausgewählt aus der Gruppe, bestehend aus:

45 Cyclophosphamid, einem Cyclophosphamidanalogon, Sunitinib, Anti-TGF β , Imatinib, Anthracyclinen, Oxaliplatin und Doxorubicin;

zur Verwendung in einem Verfahren zum Steigern einer T-Zell-Antwort bei einem Menschen;

50 wobei das Potenzierungsmittel vor dem Fusionsprotein verabreicht werden soll und das Fusionsprotein ohne das Potenzierungsmittel nach Verabreichung des Potenzierungsmittels verabreicht werden soll;

wobei die Dosierung des Potenzierungsmittels nicht wirksam ist, um direkte Anti-Tumor-Aktivität aufzuweisen;

55 und wobei die T-Zell-Antwort, die nach der Verabreichung des Fusionsproteins erzielt wird, größer als die T-Zell-Antwort ist, die durch Verabreichen entweder des Fusionsproteins alleine oder des Potenzierungsmittels alleine erzielt wird.

Revendications

1. Composition comprenant :

5 une protéine de fusion comprenant des première et deuxième parties peptidiques, dans laquelle ladite première partie peptidique est constituée d'une séquence d'acides aminés choisie parmi : B7-DC de type sauvage, une séquence d'acides aminés ayant au moins 98 % de similitude avec les acides aminés 20 à 221 ou 20 à 121 de SEQ ID n° : 1 et qui exerce une concurrence *in vitro* avec B7-DC de type sauvage pour la liaison à PD-1, un fragment de B7-DC qui exerce une concurrence *in vitro* avec B7-DC de type sauvage pour la liaison à PD-1, et un domaine extracellulaire de B7-DC et ladite deuxième partie peptidique comprend une partie d'une immunoglobuline (Ig) ;

10 pour une utilisation dans un procédé d'augmentation de la réponse d'un lymphocyte T chez un humain ; dans laquelle l'humain est un individu auquel une composition comprenant un agent de potentialisation choisi dans le groupe constitué par : le cyclophosphamide, un analogue du cyclophosphamide, le sunitinib, l'anti-TGF β , l'imatinib, les anthracyclines, l'oxaliplatine et la doxorubicine, et dans laquelle le dosage de l'agent de potentialisation n'est pas efficace pour exercer une activité antitumorale directe, a été préalablement administrée ;

15 et dans laquelle la réponse du lymphocyte T obtenue après l'administration de la protéine de fusion est plus élevée que la réponse du lymphocyte T obtenue en administrant soit la protéine de fusion seule soit l'agent de potentialisation seul.

20

2. Composition comprenant :

25 un agent de potentialisation choisi dans le groupe constitué par : le cyclophosphamide, un analogue du cyclophosphamide, le sunitinib, l'anti-TGF β , l'imatinib, les anthracyclines, l'oxaliplatine et la doxorubicine, pour une utilisation dans un procédé d'augmentation de la réponse d'un lymphocyte T chez un humain ; dans laquelle le dosage de l'agent de potentialisation n'est pas efficace pour exercer une activité antitumorale directe,

30 dans laquelle l'humain est un individu auquel une composition comprenant une protéine de fusion comprenant des première et deuxième parties peptidiques, dans laquelle ladite première partie peptidique est constituée d'une séquence d'acides aminés choisie parmi :

B7-DC de type sauvage, une séquence d'acides aminés ayant au moins 98 % de similitude avec les acides aminés 20 à 221 ou 20 à 121 de SEQ ID n° : 1 et qui exerce une concurrence *in vitro* avec B7-DC de type sauvage pour la liaison à PD-1, un fragment de B7-DC qui exerce une concurrence *in vitro* avec B7-DC de type sauvage pour la liaison à PD-1, et un domaine extracellulaire de B7-DC et ladite deuxième partie peptidique comprend une partie d'une immunoglobuline (Ig), doit être administrée ultérieurement ;

35 et dans laquelle la réponse du lymphocyte T obtenue après l'administration de la protéine de fusion est plus élevée que la réponse du lymphocyte T obtenue en administrant soit la protéine de fusion seule soit l'agent de potentialisation seul.

40

3. Composition pour une utilisation selon la revendication 1 ou 2, dans laquelle ladite première partie peptidique est constituée d'un polypeptide B7-DC de type sauvage.

45 4. Composition pour une utilisation selon la revendication 3, dans laquelle ledit B7-DC est un B7-DC humain.

5. Composition pour une utilisation selon la revendication 1 ou 2, dans laquelle ladite première partie peptidique est constituée d'un fragment de B7-DC qui ne comprend aucune partie de la partie transmembranaire dudit polypeptide B7-DC.

50 6. Composition pour une utilisation selon la revendication 5, dans laquelle ladite première partie peptidique est constituée de la partie soluble dudit polypeptide B7-DC et ladite deuxième partie peptidique comprend la région Fc d'un anticorps mais ne comprend aucune région variable dudit anticorps.

55 7. Composition pour une utilisation selon la revendication 5 ou 6, dans laquelle ladite première partie peptidique est constituée de la séquence d'acides aminés de SEQ ID n° : 3 et ladite deuxième partie polypeptidique comprend la région Fc d'un anticorps mais ne comprend aucune région variable dudit anticorps.

EP 2 350 129 B1

8. Composition pour une utilisation selon la revendication 1 ou 2, dans laquelle ladite première partie peptidique est constituée d'une séquence d'acides aminés ayant au moins 98 % de similitude avec les acides aminés 20 à 221 ou 20 à 121 de SEQ ID n° : 1.
- 5 9. Composition pour une utilisation selon la revendication 8, dans laquelle ladite première partie peptidique est constituée de la séquence d'acides aminés des acides aminés 20 à 221 ou 20 à 121 de SEQ ID n° : 1.
10. Composition pour une utilisation selon la revendication 1 ou 2, dans laquelle ladite protéine de fusion comprend une séquence d'acides aminés ayant au moins 95 % de similitude avec la séquence de SEQ ID n° : 9, 10, 12 ou 13.
- 10 11. Composition pour une utilisation selon la revendication 10, dans laquelle ladite protéine de fusion comprend une séquence d'acides aminés de SEQ ID n° : 9, 10, 12 ou 13.
12. Composition pour une utilisation selon l'une quelconque des revendications précédentes, dans laquelle ladite protéine de fusion est un monomère.
- 15 13. Composition pour une utilisation selon l'une quelconque des revendications 1 à 11, dans laquelle ladite protéine de fusion forme un dimère.
- 20 14. Composition pour une utilisation selon la revendication 13, dans laquelle ladite protéine de fusion forme un homodimère.
15. Composition pour une utilisation selon la revendication 13, dans laquelle ladite protéine de fusion forme un hétérodimère.
- 25 16. Composition pour une utilisation selon l'une quelconque des revendications précédentes, dans laquelle ledit agent de potentialisation est le cyclophosphamide ou un analogue du cyclophosphamide.
- 30 17. Composition pour une utilisation selon l'une quelconque des revendications précédentes, pour une utilisation dans un procédé selon l'une quelconque des revendications précédentes, dans laquelle ledit agent de potentialisation est administré au moins X heures avant l'administration de ladite protéine de fusion, X étant choisi parmi 1, 2, 3, 5, 10, 15, 20, 24 et 30.
- 35 18. Composition pour une utilisation selon l'une quelconque des revendications précédentes, dans laquelle ladite protéine de fusion comprend un fragment de B7-DC de type sauvage qui exerce une concurrence *in vitro* avec B7-DC de type sauvage pour la liaison à PD-1.
- 40 19. Composition pour une utilisation selon la revendication 18, dans laquelle ledit fragment de B7-DC de type sauvage ne comprend aucune partie de la partie transmembranaire de ce polypeptide.
20. Composition pour une utilisation selon la revendication 18, dans laquelle ledit polypeptide B7-DC est un polypeptide B7-DC humain.
- 45 21. Composition pour une utilisation selon la revendication 1 ou 2, dans laquelle ladite première partie peptidique est constituée du domaine extracellulaire de B7-DC ou d'un polypeptide différant de celui-ci uniquement au niveau des substitutions conservatives d'acides aminés.
22. Composition pour une utilisation selon l'une quelconque des revendications précédentes, dans laquelle ladite protéine de fusion est utilisée dans une quantité suffisante pour traiter le cancer ou l'infection par une réponse immunitaire augmentée médiée par les lymphocytes T.
- 50 23. Composition pour une utilisation selon la revendication 1 ou 2, dans laquelle ledit procédé comprend le traitement du cancer.
- 55 24. Composition pour une utilisation selon la revendication 1 ou 2, dans laquelle ledit procédé comprend le traitement d'une maladie infectieuse.
25. Composition pour une utilisation selon la revendication 23, dans laquelle ledit cancer est le cancer de la vessie, le

EP 2 350 129 B1

cancer du cerveau, le cancer du sein, le cancer du col de l'utérus, le cancer colorectal, le cancer de l'oesophage, le cancer du rein, le cancer du foie, le cancer du poumon, le cancer du rhinopharynx, le cancer du pancréas, le cancer de la prostate, le cancer de la peau, le cancer de l'estomac, le cancer de l'utérus, le cancer des ovaires, le cancer des testicules ou le cancer hématologique.

5

26. Composition pour une utilisation selon la revendication 23, pour une utilisation dans ledit procédé, dans laquelle ledit procédé comprend en outre l'administration d'au moins un agent supplémentaire choisi dans le groupe constitué par un anticorps anti-PD-1, un anticorps anti-CTLA4, un inhibiteur de la mitose, un inhibiteur de l'aromatase, un antagoniste des A2AR et un inhibiteur de l'angiogenèse avec ladite protéine de fusion.

10

27. Ensemble de composants comprenant :

une protéine de fusion comprenant des première et deuxième parties peptidiques, dans laquelle ladite première partie peptidique est constituée des acides aminés 20 à 221 de SEQ ID n° : 1, et ladite deuxième partie peptidique comprend une partie d'une immunoglobuline (Ig) ;
et du cyclophosphamide ;
pour une utilisation dans un procédé de traitement du cancer ;
dans lequel ledit cyclophosphamide est administré avant ladite protéine de fusion et ladite protéine de fusion est administré sans cyclophosphamide après l'administration de cyclophosphamide ;
dans lequel le dosage de cyclophosphamide n'est pas efficace pour exercer une activité antitumorale directe.

15

20

28. Composition pour une utilisation selon la revendication 27, dans laquelle ladite deuxième partie peptidique comprend les acides aminés 245 à 476 de l'IgG1 humaine.

25

29. Composition pour une utilisation selon la revendication 27, pour une utilisation dans le procédé selon la revendication 27, dans lequel ledit cyclophosphamide est administré audit patient au moins 24 heures avant l'administration de la protéine de fusion.

30

30. Ensemble de composants comprenant :

une protéine de fusion comprenant des première et deuxième parties peptidiques, dans laquelle ladite première partie peptidique est constituée d'une séquence d'acides aminés choisie parmi : B7-DC de type sauvage, une séquence d'acides aminés ayant au moins 98 % de similitude avec les acides aminés 20 à 221 ou 20 à 121 de SEQ ID n° : 1 et qui exerce une concurrence *in vitro* avec B7-DC de type sauvage pour la liaison à PD-1, un fragment de B7-DC qui exerce une concurrence *in vitro* avec B7-DC de type sauvage pour la liaison à PD-1, et un domaine extracellulaire de B7-DC et ladite deuxième partie peptidique comprend une partie d'une immunoglobuline (Ig) ;
et un agent de potentialisation choisi dans le groupe constitué par : le cyclophosphamide, un analogue du cyclophosphamide, le sunitinib, l'anti-TGF, l'imatinib, les anthracyclines, l'oxaliplatine et la doxorubicine ;
pour une utilisation dans un procédé d'augmentation de la réponse d'un lymphocyte T chez un humain ;
dans lequel ledit agent de potentialisation doit être administré avant ladite protéine de fusion et ladite protéine de fusion doit être administrée sans ledit agent de potentialisation après l'administration dudit agent de potentialisation ;
dans lequel le dosage de l'agent de potentialisation n'est pas efficace pour exercer une activité antitumorale directe ;
et dans lequel la réponse du lymphocyte T obtenue après l'administration de la protéine de fusion est plus élevée que la réponse du lymphocyte T obtenue en administrant soit la protéine de fusion seule soit l'agent de potentialisation seul.

35

40

45

50

55

Figure 1. B7-DC-Ig binding to PD-1 expressing CHO cells




Figure 2. B7-DC-Ig competes with B7-H1 for binding to PD-1





Figure 3-1. CTX combined with B7-DC-Ig



* CTX, 100 mg/kg on day 10

↑ B7-DC-Ig, 5 mg/kg, day 11, 2x/wk

N=8

Figure 3-2. CTX combined with B7-DC-Ig




Figure 4. CTX + B7-DC-Ig Eradicates Tumors and Protects Against Re-Challenge with CT26






Figure 5. CTX + B7-DC-Ig treatment results in tumor specific, memory cytotoxic T lymphocytes



- CTX + B7-DC-Ig treatment eradicates tumor in up to 75% of Mice
- Results in an effective and specific immune response
- 100% reject CT26 tumor cells in re-challenge
- Significant increase in functional T effector cells (CD8⁺ / IFNγ⁺) that react with AH1, the dominant CT26 antigen

Figure 6. Correlation of B7-DC-Ig Dose with Tumor Eradication:
CT26 Model






Figure 7. CTX combined with anti-PD-1



* CTX, 100 mg/kg on day 11
↑ αPD-1, 12.5 mg/kg, day 12, 2x/wk
N=9-10

Figure 8. CTX combined with anti-CTLA4



* CTX, 100 mg/kg on day 11

↑ αCTLA-4, 5 mg/kg, day 12, 2x/wk

N= 9 - 10

Figure 9. Inclusion of CTX in B7-DC-Ig Regimen Leads to Reduction of Tregs in the Spleen 2 Days Later. B7-DC-Ig Significantly Reduced PD-1^{high} CD4⁺ T Cells in the Draining Lymph Node.




Figure 10. B7-DC-Ig Synergized with CTX in a Lung Met Model





Figure 11. B7-DC-Ig Synergized with CTX and Listeria vaccine in a Liver Met Model



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2006012232 A [0005]
- US 6803192 B [0018]
- WO 2001014557 A [0101]
- WO 2002079499 A [0101]
- IL 0300425 W [0149]
- WO 2003099196 A, Hardy [0149]
- JP 2006309606 W [0149]
- WO 2006121168 A, Korman [0149]
- US 2008008925 W [0149]
- WO 2009014708 A, Li [0149]
- JP 3008420 W [0149]
- WO 2004004771 A, Honjo [0149]
- JP 4000549 W [0149]
- WO 2004072286 A, Honjo [0149]
- WO IB2003006304 W [0149]
- WO 2004056875 A, Collins [0149]
- US 2007088851 W [0149]
- WO 2008083174 A, Ahmed [0149] [0152]
- US 2006026046 W [0149]
- WO 2007005874 A, Korman [0149] [0153]
- US 2008084923 W [0149]
- WO 2009073533 A, Terrett [0149]
- US 20070166281 A, Kosak [0150]
- US 06022423 W [0152]
- WO 2006133396 A [0152]
- US 07088851 W [0152]
- US 20060110383 A [0152]
- US 7411051 B [0153]
- US 7052694 B [0153]
- US 7390888 B [0153]
- US 20060099203 A [0153]
- US 2006043690 W [0155]
- WO 2007056539 A, Fischkoff [0155]
- US 20070202077 A [0161]
- US 5190929 A [0161]
- US 20080274490 A [0216]
- US 7105328 B [0216]
- US 61211697 B [0242]
- US 61091692 B [0242]
- US 61091709 B [0242]
- US 61091705 B [0242]

Non-patent literature cited in the description

- LENSLOW et al. *Annu. Rev. Immunol.*, 1996, vol. 14, 233-258 [0005]
- CHAMBERS ; ALLISON. *Curr. Opin. Immunol.*, 1997, vol. 9, 396-404 [0005]
- RATHMELL ; THOMPSON. *Annu. Rev. Immunol.*, 1999, vol. 17, 781-828 [0005]
- KRUMMEL ; ALLISON. *J. Exp. Med.*, 1996, vol. 183, 2533-2540 [0005]
- WALUNAS et al. *J. Exp. Med.*, 1996, vol. 183, 2541-2550 [0005]
- DONG et al. *Nature Med.*, 1999, vol. 5, 1365-1369 [0005] [0007]
- FREEMAN et al. *J. Exp. Med.*, 2000, vol. 192, 1-9 [0005]
- TSENG et al. *J. Exp. Med.*, 2001, vol. 193, 839-846 [0005] [0097]
- LATCHMAN et al. *Nature Immunol.*, 2001, vol. 2, 261-268 [0005] [0007]
- WANG et al. *Blood*, 2000, vol. 96, 2808-2813 [0005]
- SWALLOW et al. *Immunity*, 1999, vol. 11, 423-432 [0005]
- YOSHINAGA et al. *Nature*, 1999, vol. 402, 827-832 [0005]
- CHAPOVAL et al. *Nature Immunol.*, 2001, vol. 2, 269-274 [0005]
- CHOI et al. *J. Immunol.*, 2003, vol. 171, 4650-4654 [0005]
- SICA et al. *Immunity*, 2003, vol. 18, 849-861 [0005]
- PRASAD et al. *Immunity*, 2003, vol. 18, 863-873 [0005]
- ZANG et al. *Proc. Natl. Acad. Sci. U.S.A.*, 2003, vol. 100, 10388-10392 [0005]
- SCHWARTZ et al. *Nature Immunol.*, 2002, vol. 3, 427-434 [0006]
- WILLIAMS ; BARCLAY. *Annu. Rev. Immunol.*, 1988, vol. 6, 381-405 [0006]
- OSTROV et al. *Science*, 2000, vol. 290, 816-819 [0006]
- SCHWARTZ et al. *Nature*, 2001, vol. 410, 604-608 [0006]
- STAMPER et al. *Nature*, 2001, vol. 410, 608-611 [0006]
- IKEMIZU et al. *Immunity*, 2000, vol. 12, 51-60 [0006]
- BAJORATH et al. *J. Mol. Graph. Model.*, 1997, vol. 15, 135-139 [0006]
- WAND et al. *J. Exp. Med.*, 2002, vol. 195, 1033-1041 [0006]

- **TAMURA.** *Blood*, 2001, vol. 97, 1809-1816 [0007]
- **FREEMAN et al.** *J. Exp. Med.*, 2000, vol. 192, 1027-1034 [0008]
- **ISHIDA et al.** *EMBO J.*, 1992, vol. 11, 3887-3895 [0008]
- **KEIR et al.** *Curr. Opin. Immunol.*, 2007, vol. 19, 309-314 [0008]
- **WAHL et al.** *J. Nuc. Med.*, 1983, vol. 24, 316-325 [0043]
- **HOCHMAN, J. et al.** *Biochemistry*, 1973, vol. 12, 1130-1135 [0043]
- **SHARON, J. et al.** *Biochemistry*, 1976, vol. 15, 1591-1594 [0043]
- **ROUSSEAU et al.** *Meth. Enzymol.*, 1986, vol. 121, 663-69 [0043]
- **KABAT et al.** *J. Biol. Chem.*, 1977, vol. 252, 6609-6616 [0059]
- **FREEMAN.** *Proc. Natl. Acad. Sci. U. S. A*, 2008, vol. 105, 10275-10276 [0065] [0073]
- **MOLNAR et al.** Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. *PNAS*, 29 July 2008, vol. 105, 10483-10488 [0069] [0102]
- **ONLAMOON et al.** *Immunology*, 2008, vol. 124, 277-293 [0076]
- **PERTOVAS et al.** *J. Exp. Med.*, 2006, vol. 203, 2281 [0080] [0146]
- **NISHIMURA et al.** *Immunity*, 1999, vol. 11, 141-151 [0097]
- **NISHIMURA et al.** *Science*, 2001, vol. 291, 319-322 [0097]
- **BUTTE et al.** *Immunity*, 2007, vol. 27, 111-122 [0102]
- **LAZAR MOLNAR et al.** *PNAS*, 2008, vol. 105, 10483-10488 [0118]
- **BERGER et al.** *Clin. Cancer Res.*, 2008, vol. 14, 30443051 [0149]
- **ERBE et al.** *J. Biol. Chem.*, 2002, vol. 277, 7363-7368 [0158]
- **CUBILLOS-RUIZ et al.** *J. Clin. Invest.*, 2009, vol. 119 (8), 2231-2244 [0159]
- **LIANG J ; HUANG M ; DUAN W ; YU XQ ; ZHOU S.** Design of new oxazaphosphorine anticancer drugs. *Curr Pharm Des.*, 2007, vol. 13 (9), 963-78 [0161]
- **LI et al.** Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. *Clin Cancer Res.*, 15 November 2006, vol. 12 (22), 6808-16 [0163]
- **BRODE ; COOKE.** *Crit Rev. Immunol.*, 2008, vol. 28, 109-126 [0184]
- **VAN DER MOST et al.** *Cancer Immunol. Immunother.*, 2009, vol. 58, 1219-1228 [0185]
- **TAIEB, J.** *J. Immunol.*, 2006, vol. 176, 2722-2729 [0185]
- **BAS ; MASTRANGELO.** *Cancer Immunol. Immunother.*, 1998, vol. 47, 1-12 [0186]
- **MACHIELS et al.** *Cancer Res.*, 2001, vol. 61, 3689-3697 [0187] [0188]
- **HENGST et al.** *Cancer Res.*, 1981, vol. 41, 2163-2167 [0188]
- **HENGST.** *Cancer Res.*, 1980, vol. 40, 2135-2141 [0188]
- REMINGTON'S PHARMACEUTICAL SCIENCES. Mack Pub. Co, [0193]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor, 1989 [0197]
- **WU et al.** *Methods in Gene Biotechnology.* CRC Press, 1997 [0197]
- *Recombinant Gene Expression Protocols. Methods in Molecular Biology.* Humana Press, 1997, vol. 62 [0197]
- **HIRANO F. et al.** *Cancer Research*, 2005 [0234]
- **YOSHIMURA K et al.** *Cancer Research*, 2007 [0240]
- **BRODE S ; COOKE A.** Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. *Crit Rev. Immunol.*, 2008, vol. 28 (2), 109-26 [0241]
- **VAN DER MOST RG ; CURRIE AJ ; MAHENDRAN S ; PROSSER A ; DARABI A ; ROBINSON BW ; NOWAK AK ; LAKE RA.** Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. *Cancer Immunol. Immunother.*, August 2009, vol. 58 (8), 1219-28 [0241]
- **TAIEB J ; CHAPUT N ; SCHARTZ N ; ROUX S ; NO-VAULT S ; MENARD C ; GHIRINGHELLI F ; TERME M ; CARPENTIER AF ; DARRASSE-JEZE G et al.** Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. *J. Immunol.*, 01 March 2006, vol. 176 (5), 2722-9 [0241]
- **MACHIELS JP ; REILLY RT ; EMENS LA ; ERCOLINI AM ; LEI RY ; WEINTRAUB D ; OKOYE FI ; JAFFEE EM.** Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. *Cancer Res.*, 01 May 2001, vol. 61 (9), 3689-97 [0241]
- **BASS KK ; MASTRANGELO MJ.** Immunopotential with low-dose cyclophosphamide in the active specific immunotherapy of cancer. *Cancer Immunol. Immunother.*, September 1998, vol. 47 (1), 1-12 [0241]
- **HENGST JC ; MOKYR MB ; DRAY S.** Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. *Cancer Res.*, June 1981, vol. 41 (6), 2163-7 [0241]
- **HENGST JC ; MOKYR MB ; DRAY S.** Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. *Cancer Res.*, July 1980, vol. 40 (7), 2135-41 [0241]

- **TSUNG K ; MEKO JB ; TSUNG YL ; PEPLINSKI GR ; NORTON JA.** Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. *J.Immunol.*, 01 February 1998, vol. 160 (3), 1369-77 [0241]
- **HONEYCHURCH J ; GLENNIE MJ ; ILLIDGE TM.** Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. *Cancer Res.*, 15 August 2005, vol. 65 (16), 7493-501 [0241]
- **WADA S ; YOSHIMURA K ; HIPKISS EL ; HARRIS TJ ; YEN HR ; GOLDBERG MV ; GROSSO JF ; GETNET D ; DEMARZO AM ; NETTO GJ.** Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. *Cancer Res.*, 15 May 2009, vol. 69 (10), 4309-18 [0241]
- **FREEMAN,G.J.** Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. *Proc. Natl. Acad. Sci. U. S. A.*, 2008, vol. 105, 10275-10276 [0241]
- **BRODE,S. ; COOKE,A.** Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. *Crit Rev. Immunol.*, 2008, vol. 28, 109-126 [0241]
- **VAN DER MOST,R.G. et al.** Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. *Cancer Immunol. Immunother.*, 2009, vol. 58, 1219-1228 [0241]
- **TAIEB,J. et al.** Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. *J. Immunol.*, 2006, vol. 176, 2722-2729 [0241]
- **BASS,K.K. ; MASTRANGELO,M.J.** Immunopotential with low-dose cyclophosphamide in the active specific immunotherapy of cancer. *Cancer Immunol. Immunother.*, 1998, vol. 47, 1-12 [0241]
- **MACHIELS,J.P. et al.** Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. *Cancer Res.*, 2001, vol. 61, 3689-3697 [0241]
- **HENGST,J.C. ; MOKYR,M.B. ; DRAY,S.** Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. *Cancer Res.*, 1981, vol. 41, 2163-2167 [0241]
- **HENGST,J.C. ; MOKYR,M.B. ; DRAY,S.** Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. *Cancer Res.*, 1980, vol. 40, 2135-2141 [0241]
- **TSUNG,K. ; MEKO,J.B. ; TSUNG,Y.L. ; PEPLINSKI,G.R. ; NORTON,J.A.** Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. *J. Immunol.*, 1998, vol. 160, 1369-1377 [0241]
- **HONEYCHURCH,J. ; GLENNIE,M.J. ; ILLIDGE,T.M.** Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. *Cancer Res.*, 2005, vol. 65, 7493-7501 [0241]
- **WADA S ; YOSHIMURA K ; HIPKISS EL ; HARRIS TJ ; YEN HR ; GOLDBERG MV ; GROSSO JF ; GETNET D ; DEMARZO AM ; NETTO GJ.** Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. *Cancer Res.*, 15 May 2009, vol. 69 (10), 4309-18 [0241]

PD-1-ANTAGONISTA KÉSZÍTMÉNYEK ÉS ALKALMAZÁSUK

Szabadalmi igénypontok

1. Készítmény, amely tartalmaz

első és második peptidrészt tartalmazó fúziós fehérjét, ahol az első peptidrészt a következők közül választott aminosav-szekvencia alkotja: vad típusú B7-DC, SEQ ID NO: 1 szerinti szekvencia 20-221. aminosavaival vagy 20-121. aminosavaival legalább 98%-ban azonos aminosav-szekvencia, amely *in vitro* verseng a vad típusú B7-DC-vel a PD-1-hez kötődésért, B7-DC fragmense, amely *in vitro* verseng a vad típusú B7-DC-vel a PD-1-hez kötődésért, és B7-DC extracelluláris doménje; és ahol a második peptidréz immunoglobulin részét (Ig) tartalmazza,

emberben T-sejt-válasz fokozására szolgáló eljárásban történő alkalmazásra,

ahol az embernek korábban a következők alkotta csoportból választott, hatást fokozó szert adtak be: ciklofoszfamid, ciklofoszfamid-analóg, szunitinib, anti-TGF β , imatinib, antraciklinek, oxaliplatin és doxorubicin, és ahol a hatást fokozó szer adagja közvetlen tumorelleses aktivitás kifejtésében nem hatékony,

és ahol a fúziós fehérje beadását követően elért T-sejt-válasz nagyobb, mint a fúziós fehérje egyedüli beadásával elért T-sejt-válasz vagy a hatást fokozó szer egyedüli beadásával elért T-sejt-válasz.

2. Készítmény, amely tartalmaz

a következők alkotta csoportból választott hatást fokozó szert: ciklofoszfamid, ciklofoszfamid-analóg, szunitinib, anti-TGF β , imatinib, antraciklinek, oxaliplatin és doxorubicin,

emberben T-sejt-válasz fokozására szolgáló eljárásban történő alkalmazásra,

ahol a hatást fokozó szer adagja közvetlen tumorelleses aktivitás kifejtésében nem hatékony,

ahol az ember olyan ember, akinek ezt követően a következőt tartalmazó készítményt adnak be: első és második peptidrészt tartalmazó fúziós fehérje, ahol az első peptidrészt a következők közül választott aminosav-szekvencia alkotja: vad típusú B7-DC, SEQ ID NO: 1 szerinti szekvencia 20-221. aminosavaival vagy 20-121. aminosavaival legalább 98%-ban azonos aminosav-szekvencia, amely *in vitro* verseng a vad típusú B7-DC-vel a PD-1-hez kötődésért, B7-DC fragmense, amely *in vitro* verseng a vad típusú B7-DC-vel a PD-1-hez kötődésért, és B7-DC extracelluláris doménje; és ahol a második peptidréz immunoglobulin részét (Ig) tartalmazza,

és ahol a fúziós fehérje beadását követően elért T-sejt-válasz nagyobb, mint a fúziós fehérje egyedüli beadásával elért T-sejt-válasz vagy a hatást fokozó szer egyedüli beadásával elért T-sejt-válasz.

3. Az 1. vagy 2. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol az első peptidrészt vad típusú B7-DC polipeptid alkotja.

4. A 3. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol a B7-DC humán B7-DC.

5. Az 1. vagy 2. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol az első peptidrészt a B7-DC polipeptid transzmembrán részének egyetlen részét sem tartalmazó B7-DC-fragmens alkotja.

6. Az 5. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol az első peptidrészt a B7-DC polipeptid oldható része alkotja, és a második peptidréz ellenanyag Fc-régióját tartalmazza, de nem tartalmazza az ellenanyag variábilis régiójának semmilyen részét sem.

7. Az 5. vagy 6. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol az első peptidrészt a SEQ ID NO: 3 szerinti aminosav-szekvencia alkotja, és a második peptidréz ellenanyag Fc-régióját tartalmazza, de nem tartalmazza az ellenanyag variábilis régiójának semmilyen részét sem.

8. Az 1. vagy 2. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol az első peptidrészt a SEQ ID NO: 1 szerinti szekvencia 20-221. aminosavaival vagy 20-121. aminosavaival legalább 98%-ban azonos aminosav-szekvencia alkotja.

9. A 8. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol az első peptidrészt a SEQ ID NO: 1 szerinti szekvencia 20-221. aminosavaiból álló vagy 20-121. aminosavaiból álló aminosav-szekvencia alkotja.

10. Az 1. vagy 2. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol a fúziós fehérje SEQ ID NO: 9, 10, 12 vagy 13 szerinti szekvenciával legalább 95%-ban azonos aminosav-szekvenciát tartalmaz.

11. A 10. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol a fúziós fehérje SEQ ID NO: 9, 10, 12 vagy 13 szerinti aminosav-szekvenciát tartalmaz.

12. Az előző igénypontok bármelyike szerinti készítmény az ott meghatározott alkalmazásra, ahol a fúziós fehérje monomer.

13. Az 1-11. igénypontok bármelyike szerinti készítmény az ott meghatározott alkalmazásra, ahol a fúziós fehérje dimert képez.

14. A 13. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol a fúziós fehérje homodimert képez.

15. A 13. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol a fúziós fehérje heterodimert képez.

16. Az előző igénypontok bármelyike szerinti készítmény az ott meghatározott alkalmazásra, ahol a hatást fokozó szer ciklofoszfamid vagy ciklofoszfamid analógja.

17. Az előző igénypontok bármelyike szerinti készítmény az ott meghatározott alkalmazásra, az előző igénypontok bármelyike szerinti eljárásban történő alkalmazásra, ahol a hatást fokozó szert a fúziós fehérje beadását legalább X órával megelőzően adjuk be, ahol X értéke a következők közül választott: 1, 2, 3, 5, 10, 15, 20, 24 és 30.

18. Az előző igénypontok bármelyike szerinti készítmény az ott meghatározott alkalmazásra, ahol a fúziós fehérje PD-1-hez kötődésért a vad típusú B7-DC-vel *in vitro* versengő, vad típusú B7-DC-fragmenst tartalmaz.

19. A 18. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol a vad típusú B7-DC-fragmens a B7-DC polipeptid transzmembrán részének egyetlen részét sem tartalmazza.

20. A 18. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol a B7-DC polipeptid human B7-DC polipeptid.

21. Az 1. vagy 2. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol az első peptidrészt B7-DC extracelluláris doménje vagy attól csupán konzervatív aminosav-szubsztitúciókban különböző polipeptid alkotja.

22. Az előző igénypontok bármelyike szerinti készítmény az ott meghatározott alkalmazásra, ahol a fúziós fehérjét olyan mennyiségben alkalmazzák, amely fokozott T-sejt-mediált immunválasz révén elegendő rák vagy fertőzés kezelésére.

23. Az 1. vagy 2. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol az eljárás magában foglalja rák kezelését.

24. Az 1. vagy 2. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol az eljárás magában foglalja fertőző betegség kezelését.

25. A 23. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol a rák húgyhólyagrák, agyrák, mellrák, méhnyakrák, kolorektális rák, nyelőcsőrák, veserák, májrák, tüdőrák, nazofaringeális rák, hasnyálmirigyrák, prosztatarák, bőrrák, gyomorrák, méhrák, petefészekrák, hererák vagy hematológiai rák.

26. A 23. igénypont szerinti készítmény az ott meghatározott alkalmazásra, az eljárásban történő alkalmazásra, ahol az eljárás magában foglalja legalább egy, a következők alkotta csoportból választott további hatóanyag beadását a fúziós fehérjével együtt: anti-PD-1 ellenanyag, anti-CTLA4 ellenanyag, mitózisinhibitor, aromataz-inhibitor, AZAR-antagonista és angiogenezis-inhibitor.

27. Készlet, amely tartalmaz:

fúziós fehérjét, amely első és második peptidrészt tartalmaz, ahol az első peptidrészt SEQ ID NO: 1 szerinti szekvencia 20-221. aminosavai alkotják, és a második peptidrész immunoglobulin részét (Ig) tartalmazza,

és ciklofoszfamidot,

rák kezelésére szolgáló eljárásban történő alkalmazásra,

ahol a ciklofoszfamidot a fúziós fehérje előtt adjuk be, és a fúziós fehérjét ciklofoszfamid beadását követően, ciklofoszfamid nélkül adjuk be;

ahol a ciklofoszfamid adagja közvetlen tumorelles aktivitás kifejtésében nem hatékony.

28. A 27. igénypont szerinti készítmény az ott meghatározott alkalmazásra, ahol a második peptidrész humán IgG1 245-476. aminosavait tartalmazza.

29. A 27. igénypont szerinti készítmény az ott meghatározott alkalmazásra, a 27. igénypont szerinti eljárásban történő alkalmazásra, ahol a ciklofoszfamidot a fúziós fehérje beadását legalább 24 órával megelőzően adjuk be a betegnek.

30. Készlet, amely tartalmaz:

fúziós fehérjét, amely első és második peptidrészt tartalmaz, ahol az első peptidrészt a következők közül választott aminosav-szekvencia alkotja: vad típusú B7-DC, SEQ ID NO: 1 szerinti szekvencia 20-221. aminosavaival vagy 20-121. aminosavaival legalább 98%-ban azonos aminosav, amely in vitro verseng a vad típusú B7-DC-vel a PD-1-hez kötődésért, B7-DC fragmentum, amely in vitro verseng a vad típusú B7-DC-vel a PD-1-hez kötődésért, és B7-DC extracelluláris doménje; és ahol a második peptidrész immunoglobulin részét (Ig) tartalmaz,

és a következők alkotta csoportból választott, hatást fokozó szert: ciklofoszfamid, ciklofoszfamid-analóg, szunitinib, anti-TGF β , imatinib, antraciklinek, oxaliplatin és doxorubicin,

emberben T-sejt-válasz fokozására szolgáló eljárásban történő alkalmazásra,

ahol a hatást fokozó szer a fúziós fehérje előtt adandó be, és a fúziós fehérje a hatást fokozó szer beadását követően, a hatást fokozó szer nélkül adandó be,

ahol a hatást fokozó szer adagja közvetlen tumorelles aktivitás kifejtésében nem hatékony,

és ahol a fúziós fehérje beadását követően elért T-sejt-válasz nagyobb, mint a fúziós fehérje egyedüli beadásával elért T-sejt-válasz vagy a hatást fokozó szer egyedüli beadásával elért T-sejt-válasz.